UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION
PERIOD FROM TO
COMMISSION
FILE NUMBER 001-40957
PYROPHYTE
ACQUISITION CORP.
(Exact name of registrant as specified in its charter)
Cayman Islands | | N/A |
(State or other jurisdiction of incorporation or organization) | | (I.R.S. Employer
Identification Number) |
Houston, Texas | | |
3262 Westheimer Road | | |
Suite 706 | | |
Houston, Texas | | 77098 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s
telephone number, including area code: (281) 701-4234
Securities
registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbols | | Name of each exchange on which registered |
Units, each consisting of one Class A ordinary share, $0.0001 par value, and one-half of one redeemable warrant | | PHYT.U | | The New York Stock Exchange |
Class A ordinary shares, par value $0.0001 per share | | PHYT | | The New York Stock Exchange |
Redeemable warrants, each warrant exercisable for one Class A ordinary share, each at an exercise price of $11.50 per share | | PHYT WS | | The New York Stock Exchange |
Securities
registered pursuant to Section 12(g) of the Act: None
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒
Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements
for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
(1) has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports) and has been subject to such filing
requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. ☐
If securities are registered pursuant to Section
12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction
of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error
corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s
executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Act). Yes ☒
No ☐
The aggregate market value of the registrant’s
ordinary shares outstanding, other than shares held by persons who may be deemed affiliates of the registrant, at June 30, 2023, computed
by reference to the closing price for the ordinary shares on such date, as reported on the New York Stock Exchange, was $95,661,102.
As of May 23, 2024, the Registrant had 11,321,961
Class A ordinary shares, $0.0001 par value per share outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
None.
Table of Contents
CAUTIONARY NOTE REGARDING FORWARD-LOOKING
STATEMENTS
Some of the statements contained in this report
may constitute “forward looking statements” for purposes of the federal securities laws. Our forward looking statements include,
but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies
regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are forward looking statements. The words “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,”
“plan,” “possible,” “potential,” “predict,” “project,” “should,”
“would” and similar expressions may identify forward looking statements, but the absence of these words does not mean that
a statement is not forward looking. The forward-looking statements contained in this report are based on our current expectations and
beliefs concerning future developments and their potential effects on us. There can be no assurance that future developments affecting
us will be those that we have anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are
beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed
or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described
under the heading “Risk Factors” in this Annual Report on Form 10-K (this “Annual Report”). Forward looking statements
in this Annual Report may include, for example, statements about:
|
● |
our ability to complete our initial Business Combination with Sio (as
defined herein), or any other initial Business Combination; |
| ● | our expectations around the performance of the prospective
target business of businesses; |
| ● | our success in retaining or recruiting, or changes required in, our
officers, key employees or directors following our initial Business Combination; |
| ● | our officers and directors allocating their time to other businesses
and potentially having conflicts of interest with our business or in approving our initial Business Combination; |
| ● | our potential ability to obtain additional financing to complete our
initial Business Combination; |
| ● | our pool of prospective target businesses; |
| ● | the adverse impacts that events outside of our control, such as increased
geopolitical unrest, significant outbreaks of infectious diseases (such as COVID-19) and increased volatility in the debt and equity markets,
may have on our ability to consummate an initial Business Combination; |
| ● | the ability of our officers and directors to generate a number of potential
Business Combination opportunities; |
| ● | our public securities’ potential liquidity and trading; |
| ● | the lack of a market for our securities; |
| ● | the use of proceeds not held in the Trust Account (as described
herein) or available to us from interest income on the Trust Account balance; |
| ● | the Trust Account not being subject to claims of third parties;
or |
| ● | our financial performance. |
Should one or more of these risks or uncertainties
materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these
forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise, except as may be required under applicable securities laws.
Summary of Risk Factors
An investment in our securities involves a high
degree of risk. You should consider carefully all of the risks described below, together with the other information contained in this
Annual Report, before making a decision to invest in our securities. If any of the following events occur, our business, financial condition
and operating results may be materially adversely affected. In that event, the trading price of our securities could decline, and you
could lose all or part of your investment. Unless otherwise stated, the Risk Factors described below do not assume the closing the Sio
Business Combination (as defined below). References to the term “initial
business combination” in this section include the Sio Business Combination where context requires.
Such
risks include, but are not limited to:
| ● | We
are a blank check company with no operating history and no revenues, and you have no basis
on which to evaluate our ability to achieve our business objective. |
| ● | None
of the Sponsor, officers or directors has any experience with a blank check company or special
purpose acquisition company in the past. |
|
● |
Our public
shareholders may not be afforded an opportunity to vote on our proposed initial business combination, and even if we hold a vote,
holders of our Founder Shares will participate in such vote, which means we may complete our initial business combination even though
a majority of our shareholders do not support such a combination. |
|
● |
Your only
opportunity to affect the investment decision regarding a potential business combination may be limited to the exercise of your right
to redeem your shares from us for cash. |
|
● |
If we
seek shareholder approval of our initial business combination, our Sponsor and members of our management team have agreed to vote
in favor of such initial business combination, regardless of how our public shareholders vote. |
|
● |
The ability
of our public shareholders to redeem their shares for cash may make our financial condition unattractive to potential business combination
targets, which may make it difficult for us to enter into a business combination with a target. |
|
● |
The ability
of our public shareholders to exercise redemption rights with respect to a large number of our shares could increase the probability
that our initial business combination would be unsuccessful and that you would have to wait for liquidation in order to redeem your
shares. |
| ● | The
ability of our public shareholders to exercise redemption rights with respect to a large
number of our shares may not allow us to complete the most desirable business combination
or optimize our capital structure. |
| ● | The requirement that we consummate an initial business combination
by the Extended Date may give potential target businesses leverage over us in negotiating a business combination and may limit the time
we have in which to conduct due diligence on potential business combination targets, in particular as we approach our dissolution deadline,
which could undermine our ability to complete our initial business combination on terms that would produce value for our shareholders. |
| ● | Our
search for a business combination, and any target business with which we ultimately consummate a business combination, may be materially
adversely affected by events that are outside of our control, such as increased geopolitical unrest, pandemic outbreaks (such as COVID-19),
and volatility in the debt and equity markets. |
|
● |
We may not be able to consummate an initial business combination within the Combination Period, in which case we would cease all operations except for the purpose of winding up and we would redeem our public shares and liquidate. |
|
● |
If we seek shareholder approval of our initial business combination, the Sponsor, directors, officers and their affiliates may elect to purchase shares or public warrants from public shareholders, which may influence a vote on a proposed business combination and reduce the public “float” of our Class A ordinary shares or public warrants. |
|
● |
If a shareholder fails to receive notice of our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for submitting or tendering its shares, such shares may not be redeemed. |
|
● |
You will not have any rights or interests in funds from the Trust Account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss. |
|
● |
The NYSE may delist our securities from trading on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading restrictions. |
|
● |
Our independent registered public accounting firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going concern.” |
|
● |
The other risks and uncertainties discussed in “Risk Factors” and elsewhere in this Annual Report. |
PART I
References in this report to “we,”
“us,” “Pyrophyte” or the “Company” refer to Pyrophyte Acquisition Corp. References to our “management”
or our “management team” refer to our officers and directors, and references to the “Sponsor” refer to Pyrophyte
Acquisition LLC, a Delaware limited liability company.
ITEM 1. BUSINESS.
Introduction
We are a blank check company incorporated on February
12, 2021 as a Cayman Islands exempted company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
reorganization or similar business combination with one or more businesses or entities. Based on our business activities, the Company
is a “shell company” as defined under the Exchange Act of 1934 (the “Exchange Act”) because we have no operations
and nominal assets consisting almost entirely of cash. We have neither engaged in any operations nor generated any revenue to date.
On February 24, 2021, the Sponsor paid an aggregate
of $25,000 for certain expenses on our behalf in exchange for the issuance of an aggregate of 5,750,000 Class B ordinary shares, par value
$0.0001 per share (the “Class B ordinary shares”), each of which was later converted, on a one-for-one basis, into Class A
ordinary shares (as defined below) as described in more detail below (such shares, the “Founder Shares”), or approximately
$0.004 per share. On September 29, 2021, the Sponsor surrendered 718,750 Founder Shares to us for cancellation for no consideration, resulting
an aggregate of 5,031,250 Founder Shares outstanding. The Founder Shares included up to 656,250 Class B ordinary shares of which were
subject to forfeiture depending on the extent to which the underwriter’s over-allotment option, as discussed in further detail below,
was exercised.
On October 29, 2021, we consummated our initial
public offering (the “Public Offering” or the “Initial Public Offering”) of 20,125,000 units (the “Units”),
including the issuance of 2,625,000 Units as a result of the underwriter’s exercise of its over-allotment option in full. Following
the exercise of the underwriter’s over-allotment option no Founder Shares remain subject to forfeiture. Each Unit consists of one
Class A ordinary share, par value $0.0001 per share (the “Class A ordinary share” or “public shares”) and one-half
of one redeemable warrant (the “public warrants”). Each public warrant entitles the holder thereof to purchase one Class A
ordinary share at a price of $11.50 per share. The Units were sold at an offering price of $10.00 per unit, generating gross proceeds,
before expenses, of $201,250,000.
Simultaneously with the consummation of the Public
Offering, we consummated the private sale of an aggregate of 10,156,250 warrants, each exercisable to purchase one Class A ordinary share
at $11.50 per share, to the Sponsor at a price of $1.00 per warrant, generating gross proceeds, before expenses, of approximately $10,156,250
(the “Private Placement”). The warrants sold in the Private Placement, or the “Private Placement Warrants”, are
identical to the warrants included in the Units sold in the Public Offering, except that, so long as they are held by their initial purchasers
or their permitted transferees, (i) they will not be redeemable by the Company (except in certain circumstances as described further below),
(ii) they (including the Class A ordinary shares issuable upon exercise of these warrants) may not, subject to certain limited exceptions,
be transferred, assigned or sold until 30 days after the Company completes its initial business combination, (iii) they may be exercised
by the holders on a cashless basis and (iv) they will be entitled to registration rights.
Upon the closing of the Public Offering and
the Private Placement, $206,281,250 (or $10.25 per Unit) was placed in the Trust Account. Except with respect to interest earned on
the funds held in the Trust Account that may be released to the Company to pay its taxes and up to $100,000 of interest to pay
dissolution expenses, if any, the funds held in the Trust Account would not be released from the Trust Account until the earliest of
(i) the completion of the Company’s initial business combination, (ii) the redemption of our public shares if we are unable to
complete our initial business combination by April 29, 2025 (or such further extended date, the “Extended Date”),
subject to applicable law, (iii) the redemption of the Company’s public shares properly submitted in connection with a
shareholder vote to approve an amendment to our amended and restated memorandum and articles of association (as amended, the
“Articles”) (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem 100% of our public shares if we have not consummated our initial business combination by the
Extended Date or (B) with respect to any other provisions relating to shareholders’ rights or pre-initial business combination
activity. The proceeds held in the Trust Account have been and may only be held as cash, in an interest-bearing demand deposit
account, or invested only in U.S. government treasury obligations with a maturity of 185 days or less or in money market funds
meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury
obligations until April 2024. On April 24, 2024, the Company amended the investment management trust agreement, dated as of October
26, 2021, by and between the Company and Continental Stock Transfer and Trust Company, as trustee (as amended, the “Trust
Agreement”), to permit Continental Stock Transfer & Trust Company (the “Trustee”), to hold the assets in the
Trust Account in an interest-bearing demand deposit account or cash until the earlier of the consummation of an initial business
combination or the Company’s liquidation. On the same day, the Company instructed the Trustee to liquidate the investments
held in the Trust Account and move the funds to an interest-bearing demand deposit account, with Continental continuing to act as
trustee. As a result, following the liquidation of investments in the Trust Account, the remaining proceeds from the initial public
offering and the sale of the private placement warrants are no longer invested in U.S. government securities or money market funds.
The proceeds deposited in the Trust Account could become subject to the claims of the Company’s creditors, if any, which could
have priority over the claims of its public shareholders.
After the payment of underwriting discounts and commissions (excluding
the deferred portion of up to $8,443,750 in underwriting discounts and commissions, which amount, as modified as described in the section
entitled “Modifications to the Initial Public Offering Underwriter’s Deferred Discount”, is payable upon consummation
of our initial business combination if consummated) and approximately $1,500,000 in expenses relating to the Public Offering, approximately
$1,000,000 of the net proceeds of the Public Offering and Private Placement was not deposited into the Trust Account and was retained
by us for working capital purposes. The net proceeds deposited into the Trust Account remains on deposit in the Trust Account earning
interest. As of December 31, 2023, there was $98,870,109 in investments held in the Trust Account and $1,253 of cash held outside the
Trust Account available for working capital purposes. As of December 31, 2023 and 2022, none of the funds had been withdrawn from the
Trust Account to fund the Company’s working capital expenses.
On April 24, 2023, we held an extraordinary general
meeting of shareholders (the “First Extension Meeting”), pursuant to which our shareholders approved an amendment to the Articles
to extend the date by which the Company must complete initial business combination from April 29, 2023 to April 29, 2024 (or such earlier
date as determined by our board of directors and included in a public announcement) (the “Extension”). In connection therewith,
the Sponsor agreed to loan us $160,000 for each calendar month beginning on April 30, 2023 and ending on the earlier of the completion
of a business combination or the date of the our liquidation in accordance with the terms of the Extension, up to a maximum aggregate
amount of $1.92 million (the “Extension Contribution”). On May 4, 2023, we issued a convertible promissory note (the “Extension
Note”) to the Sponsor with a principal amount up to $1.92 million. The Sponsor deposited the first Extension Contribution on April
30, 2023. As of December 31, 2023, $960,000 has been drawn on the Extension Note and there were Trust Account deposits in connection with
the Extension Note, totaling $960,000. As of December 31, 2023, there was a $480,000 deposit into the Trust Account due from Sponsor representing
Extension Contributions for three months. Pursuant to the Extension Note, the Sponsor may convert the principal outstanding into warrants
at $1.00 per warrant. Such warrants will be identical to the terms of the Private Placement Warrants. In connection with the vote to approve
the Extension, the holders of 11,151,163 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption
price of approximately $10.56 per share, for an aggregate redemption amount of approximately $118 million, resulting in 8,973,837 public
shares remaining.
At the First Extension Meeting, the shareholders also approved a proposal
to provide the holders of the Class B ordinary shares with the right to convert such shares into Class A ordinary shares on a one-for-one
basis prior to the closing of an initial business combination at the election of such holder. On April 28, 2023, the Sponsor elected to
convert 5,031,250 Class B ordinary shares held by it, which represented all of the Class B ordinary shares outstanding into Class A ordinary
shares on a one-for-one basis for no consideration.
Proposed Business Combination with Sio Silica
Corporation
On November 13, 2023, we entered into a business
combination agreement (the “Sio Business Combination Agreement” and the transactions contemplated thereby, the “Sio
Business Combination”) with Sio Silica Corporation, an Alberta corporation (“Sio”), Sio Silica Incorporated, a newly-formed
Alberta corporation that is wholly owned by Feisal Somji, a nominee (“Nominee”) of Sio (“Sio Newco”), and Snowbank
NewCo Alberta ULC, an Alberta unlimited liability corporation and wholly-owned subsidiary of Pyrophyte (“Pyrophyte Newco”),
pursuant to which, among other things and subject to the terms and conditions contained therein, (i) we will transfer by way of continuation
from the Cayman Islands to Alberta in accordance with the Cayman Islands Companies Act (as revised) (the “Companies Act”)
and continue as an Alberta corporation in accordance with the applicable provisions of the Business Corporations Act (Alberta) (the “ABCA”)
(such continuation, the “Domestication”), (ii) following the Domestication, we will amalgamate with Sio Newco (the “SPAC
Amalgamation”), with Sio Newco surviving the SPAC Amalgamation (“Pubco”) in accordance with the terms of a Plan of Arrangement
(the “Plan of Arrangement”), and (iii) Sio and Pyrophyte Newco will amalgamate (the “Sio Amalgamation” and together
with the SPAC Amalgamation, the “Amalgamations”), with Sio surviving the Sio Amalgamation as a wholly-owned subsidiary of
Pubco and such entity will continue the business operations currently undertaken by Sio. Our board of directors has unanimously approved
and declared advisable the Sio Business Combination and all the transaction documents therein and resolved to recommend approval of the
Sio Business Combination Agreement and related matters by our shareholders.
Conversion of Securities
Domestication
Pursuant to the Domestication, we will transfer
by way of continuation from the Cayman Islands to Alberta in accordance with the Companies Act and continue as an Alberta corporation
in accordance with the applicable provisions of the ABCA. In connection with the Domestication, each then-issued and outstanding Class
A ordinary share will convert automatically, on a one-for-one basis, into one Class A common share of Pyrophyte (after the Domestication)
(the “SPAC Class A Common Shares”) and each of the then-issued and outstanding warrants of Pyrophyte will automatically become
a warrant to acquire one SPAC Class A Common Share.
SPAC Amalgamation
Pursuant to the SPAC Amalgamation,
which will take place not later than one business day prior to the closing (the “Closing”) of the Sio Business Combination
(the “Closing Date”), but after the Domestication, (i) each then-issued and outstanding SPAC Class A Common Share will be
exchanged, on a one-for-one basis, for a Class A common share in the authorized share capital of Pubco (the “Pubco Class A Common
Shares”), (ii) each then-issued and outstanding warrant of the Company will become a warrant to acquire one Pubco Class A Common
Share (the “Pubco Warrants”), (iii) each then-issued and outstanding unit of the Company will be exchanged for a unit of Pubco
representing one Pubco Class A Common Share and one-half of one Pubco Warrant (the “Pubco Units”) (each of which will be separated
into its component parts in connection with the Closing), (iv) each common share of Sio Newco will be exchanged for one Pubco Class A
Common Share, and (v) immediately thereafter, the Pubco Class A Common Share will be purchased by Sio Newco for cash at the price initially
paid by such shareholder and immediately cancelled, in each case upon and subject to the terms and conditions set forth in the Sio Business
Combination Agreement, the Plan of Arrangement and in accordance with the provisions of applicable law.
As a result of the SPAC Amalgamation,
all holders of then-issued and outstanding SPAC Class A Common Shares will become holders of Pubco Class A Common Shares.
Sio Amalgamation
Pursuant to the Sio Amalgamation,
on the Closing Date and following the exercise on a cashless basis of all then-issued and outstanding warrants (the “Sio Warrants”)
and options of Sio for common shares in the authorized share capital of Sio (the “Sio Common Shares”) in accordance with the
Plan of Arrangement (the “Sio Warrant and Option Settlement”), (i) each then-issued and outstanding Sio Common Share (other
than any Sio Common Shares issued by Sio to certain investors during the interim period (the “Sio Interim Common Shares”))
will be exchanged for (x) a number of Pubco Class A Common Shares equal to the Sio Common Share Exchange Ratio (as defined below) and
(y) a number of Sio Earnout Shares (as defined below) equal to the Sio Earnout Exchange Ratio (as defined below), (ii) each then-issued
and outstanding share award to purchase Sio Common Shares (each, a “Sio RSU”) will become exercisable for a number of Pubco
Class A Common Shares (rounded down to the nearest whole share) equal to (a) the number of Sio Common Shares subject to the applicable
Sio RSU multiplied by (b) the Sio Common Share Exchange Ratio, (iii) any Sio Warrant that is not exercised pursuant to the Sio Warrant
and Option Settlement will remain outstanding and will automatically in accordance with its terms become a warrant to acquire Pubco Class
A Common Shares, and (iv) each then-issued and outstanding Sio Interim Common Share will be exchanged for a number of Pubco Class A Common
Shares equal to (a) the number of then-issued and outstanding Sio Interim Common Shares multiplied by (b) the Sio Common Share Exchange
Ratio, in each case upon and subject to the other terms and conditions set forth in the Sio Business Combination Agreement, the Plan of
Arrangement and in accordance with the provisions of applicable law.
As a result of the Amalgamations,
Sio will become a wholly-owned subsidiary of Pubco and will continue the business operations currently undertaken by it. Upon the Closing,
the Pubco Class A Common Shares and the Pubco Warrants are expected to trade on the New York Stock Exchange under the symbols “SIOS”
and “SIOS WS,” respectively.
“Sio Common Share Exchange
Ratio” means the quotient obtained by (A) dividing (i) Sio’s valuation of $675,000,000 by (ii) $10.25, and then (B) by further
dividing the resulting number of Pubco Class A Common Shares established in (A) above by the sum of (x) the number of Sio Common Shares
that are issuable upon the exercise of Sio RSUs that are unexpired, issued and outstanding as of immediately prior to the effective of
the Sio Amalgamation (the “Sio Amalgamation Effective Time”), (y) the number of Sio Common Shares issued and outstanding immediately
prior to the Sio Amalgamation Effective Time, which shall (1) include any Sio Common Shares issued in connection with the Sio Warrant
and Option Settlement and (2) exclude any Sio Interim Common Shares, and (z) the number of Sio Common Shares that are issuable upon the
exercise of any issued and outstanding warrants to purchase Sio Common Shares that is not exercised pursuant to the Company Warrant and
Option Settlement (“Unexercised Company Warrants”) issued and outstanding as of immediately prior to the Sio Amalgamation
Effective Time minus a number of Sio Common Shares with a fair market value equal to the aggregate exercise price (determined with reference
to the US dollar to the Canadian dollar exchange rate reported by the Bank of Canada at the close of business on the date that is two
(2) business days prior to the Closing) of all such Unexercised Company Warrants if they were so exercised (such sum, the “Fully-Diluted
Sio Common Shares”).
“Sio Earnout Exchange
Ratio” means the quotient obtained by dividing (i) 6,585,366 by (ii) the Fully-Diluted Sio Common Shares.
“Sio Earnout Shares”
means the pro rata portion of an aggregate of 6,585,366 Pubco Class A Common Shares (without duplication) issued to each shareholder of
Sio (other than holders of any Sio Interim Common Shares) pursuant to the Sio Amalgamation and the Sio Business Combination Agreement
(the “Earnout”), valued at the deemed issue price of the Pubco Class A Common Shares in connection with the Earnout, which
is $10.25 per Pubco Class A Common Share, which Sio Earnout shares are subject to forfeiture in accordance with the terms of the Sio Business
Combination Agreement.
Subscription Agreements
Concurrently with the execution of the Sio Business
Combination Agreement, Pyrophyte, Sio and Sio Newco entered into subscription agreements with (i) a certain accredited investor (the “Non-Insider
PIPE Investor”) and (ii) certain other accredited investors who are existing shareholders of Sio or the Company (the “Insider
PIPE Investors” and, together with the Non-Insider PIPE Investor, the “PIPE Investors”), pursuant to which, among other
things, Sio Newco agreed to issue and sell, in a private placement to close concurrently with and conditioned upon the effectiveness of
the consummation of the Sio Business Combination, an aggregate of 3,114,258 Pubco Class A Common Shares (the “PIPE Investment”)
to the PIPE Investors for an aggregate purchase price equal to $20,122,474.
Non-Redemption Agreement
Concurrently with the execution of the Sio Business
Combination Agreement, Pyrophyte and Sio Newco entered into a non-redemption agreement (the “Non-Redemption Agreement”) with
a Pyrophyte shareholder with respect to 100,000 SPAC Class A ordinary shares held by such shareholder (the “Non-Redemption SPAC
Shares”), pursuant to which, among other things, Pyrophyte agreed to issue 58,570 Class A ordinary shares to such shareholder in
consideration of such shareholder’s commitment not to redeem the Non-Redemption SPAC Shares held by it in connection with the approval
of the Sio Business Combination by Pyrophyte’s shareholders (the “Non-Redemption Transaction”).
Sponsor Support Agreement
Concurrently with the execution of the Sio Business
Combination Agreement, the Sponsor entered into a letter agreement (the “Sponsor Support Agreement”) with Sio, Sio Newco,
Pyrophyte and the directors and officers (or otherwise a part of the management team) of Pyrophyte, solely for purposes of amending certain
of the terms of the letter agreement signed by them in connection with the Initial Public Offering, pursuant to which, among other things,
the Sponsor agreed to among other things, vote all Class A ordinary shares, or any securities convertible into, exercisable or exchangeable
for Class A ordinary shares, held by it or acquired after the date of the Sponsor Support Agreement (the “Covered Shares”)
at the meeting of Pyrophyte shareholders to be held in connection with the Sio Business Combination in favor of the adoption and approval
of the Sio Business Combination and each other proposal related to the Sio and not transfer any Covered Shares (other than Pubco Class
A Common Shares issued upon exercise of any Private Placement Warrants held by the Sponsor) until the earlier of (A) one year after the
Closing, (B) the first day the last sale price of Pubco Class A Common Shares equals or exceeds $12.00 per share for any 20 trading days
within a 30-day trading period commencing at least 150 days after the Closing or (C) after the Closing, the date on which Pubco completes
a liquidation, amalgamation, share exchange or similar transaction resulting in the shareholders of Pubco having the right to exchange
their shares for consideration.
In addition, under the terms of the Sponsor Support
Agreement, the Pyrophyte Sponsor agreed to subject up to 4,025,000 Pyrophyte Class A ordinary shares (“Restricted Owned Shares”)
to certain earn out restrictions, if and only to the extent such shares are used to obtain any additional PIPE Financing or other financing
arrangements in connection with the consummation of the Sio Business Combination; provided that in no event shall the aggregate number
of Restricted Owned Shares equal more than 4,025,000 Class A ordinary shares (the “Maximum Restricted Owned Shares”). If,
prior to the Closing, the SPAC Proceeds (as defined in the Sio Business Combination Agreement) are less than $70,000,000, then the number
of Restricted Owned Shares will be adjusted pursuant to the terms of the Sponsor Support Agreement.
In connection with the Closing, each Restricted
Owned Share will be exchanged on a one-for-one basis for Pubco Class A Common Shares pursuant to the Sio Business Combination and the
Plan of Arrangement and such shares will be subject to forfeiture or release as follows: (i) half of the Restricted Owned Shares will
be released to the Sponsor on the first day that the Trading Price (as defined in the Sio Business Combination Agreement) is at least
$12.50, (ii) the other half of the Restricted Owned Shares will be released from forfeiture on the first day that the Trading Price is
at least $15.00, in each case during the period commencing on the Closing Date and ending on the date that is three (3) years after the
Closing Date (the “End Date”), and (iii) after the End Date, any Restricted Owned Shares that have not been released to the
Sponsor pursuant to clauses (i) or (ii) above will be automatically forfeited for no consideration. If a change of control of Pubco occurs
at any time between the Closing Date and the End Date and the price achieved per Restricted Owned Shares is at least $12.50 or $15.00,
then the vesting conditions outlined will be considered to be met.
Sio Securityholder Support Agreements
In connection with the execution of the Sio Business
Combination Agreement, on November 13, 2023, the Company, Sio, and certain securityholders of Sio entered into support agreements (the
“Sio Securityholder Support Agreements”), pursuant to which, among other things, such shareholders agreed to vote (or cause
to be voted) all of their Sio shares and other voting securities of Sio (“Subject Securities”) in favor of the special resolution
of Sio shareholders in respect of the Plan of Arrangement, to be considered at Sio’s shareholders meeting to approve the Sio Business
Combination. Additionally, such shareholders have agreed, among other things, not to, prior to the Closing, (a) transfer any of their
Subject Securities (or enter into any agreement, arrangement or understanding in connection therewith other than pursuant to the Plan
of Arrangement), subject to certain customary exceptions, or (b) enter into any voting arrangement that is inconsistent with the Sio Securityholder
Support Agreements. Sio agreed in the Sio Business Combination Agreement to use its commercially reasonable efforts to obtain Sio Securityholder
Support Agreements from at least 66⅔% of its shareholders as promptly as possible, but in any event, within five days of the execution
date of the Sio Business Combination Agreement.
Modifications to the Initial Public Offering
Underwriters’ Deferred Discount
On June 8, 2023, we entered into an engagement
letter with UBS Securities LLC (“UBS”), the sole underwriter of the Company’s Initial Public Offering, which was subsequently
amended on October 26, 2023, pursuant to which the Company engaged UBS to act as its exclusive capital markets advisor with respect to
the Sio Business Combination. Pursuant to such engagement letter, if the Sio Business Combination has closed UBS agreed to waive the $8,443,750
of deferred underwriting commission owed to it in connection with the Initial Public Offering in exchange for the right to receive a transaction
fee of $5,000,000, plus an incentive fee of up to $3,443,750, each of which is payable upon the closing of the Sio Business Combination.
In addition, members of our management team have agreed to offset a certain amount of the fees that may be due to UBS under this engagement
letter.
Effecting Our Initial Business Combination
General
As described above, we have entered into a definitive
agreement for the Sio Business Combination. Unless otherwise stated, this Annual Report does not assume the closing of the Sio Business
Combination. References to the term “initial business combination” in this section include the Sio Business Combination where
context requires.
We are not presently engaged in, and we will not
engage in, any operations for an indefinite period of time. We intend to effectuate our initial business combination using cash held in
the Trust Account, our equity, debt or a combination of these as the consideration to be paid in our initial business combination. If
the Sio Business Combination does not close, we may seek to complete our initial business combination with another company or business,
including a company or business that may be financially unstable or in its early stages of development or growth, which would subject
us to the numerous risks inherent in such companies and businesses.
If our initial business combination is paid for
using equity or debt securities, or not all of the funds released from the Trust Account are used for payment of the consideration in
connection with our initial business combination or used for redemptions of our Class A ordinary shares, we may apply the balance of the
cash released to us from the Trust Account for general corporate purposes, including for maintenance or expansion of operations of the
post-transaction company, the payment of principal or interest due on indebtedness incurred in completing our initial business combination,
to fund the purchase of other companies or for working capital.
Selection of Target Businesses
While we may pursue an initial business combination
target in any industry, we intend to focus our search on businesses that serve the growing segments in the energy transition ecosystem.
Specifically, we seek to focus on differentiated targets that provide products, services, equipment, and technologies that support a variety
of energy transition solutions. Although our management will assess the risks inherent in a particular target business with which we may
combine, we cannot assure you that this assessment will result in our identifying all risks that a target business may encounter. Furthermore,
some of those risks may be outside of our control, meaning that we can do nothing to control or reduce the chances that those risks will
adversely affect a target business.
The New York Stock Exchange (“NYSE”)
rules require that we must consummate an initial business combination with one or more operating businesses or assets with a fair market
value equal to at least 80% of the net assets held in the Trust Account (excluding the amount of any deferred underwriting discount held
in Trust Account) at the time of our signing a definitive agreement in connection with our initial business combination. Our board of
directors will make the determination as to the fair market value of our initial business combination upon standards generally accepted
by the financial community. If our board of directors is not able to independently determine the fair market value of our initial business
combination (including with the assistance of financial advisors), we will obtain an opinion from an independent investment banking firm
which is a member of FINRA or a valuation or appraisal firm with respect to the satisfaction of such criteria. While we consider it unlikely
that our board of directors will not be able to make an independent determination of the fair market value of our initial business combination,
it may be unable to do so if it is less familiar or experienced with the business of a particular target or if there is a significant
amount of uncertainty as to the value of the target’s assets or prospects.
We anticipate structuring our initial business
combination so that the post transaction company in which our public shareholders own shares will own or acquire 100% of the equity interests
or assets of the target business or businesses. We may, however, structure our initial business combination such that the post transaction
company owns or acquires less than 100% of such interests or assets of the target business in order to meet certain objectives of the
target management team or shareholders or for other reasons, but we will only complete such business combination if the post transaction
company owns or acquires 50% or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in
the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended,
or the Investment Company Act. Even if the post transaction company owns or acquires 50% or more of the voting securities of the target,
our shareholders prior to the business combination may collectively own a minority interest in the post transaction company, depending
on valuations ascribed to the target and us in the business combination. For example, we could pursue a transaction in which we issue
a substantial number of new shares in exchange for all of the outstanding capital stock, shares or other equity interest of a target.
In this case, we would acquire a 100% controlling interest in the target. However, as a result of the issuance of a substantial number
of new shares, our shareholders immediately prior to our initial business combination could own less than a majority of our issued and
outstanding shares subsequent to our initial business combination. If less than 100% of the equity interests or assets of a target business
or businesses are owned or acquired by the post transaction company, the portion of such business or businesses that is owned or acquired
is what will be taken into account for purposes of NYSE’s 80% of net assets test. If the business combination involves more than
one target business, the 80% of net assets test will be based on the aggregate value of all of the target businesses.
In evaluating a prospective target business, we
expect to conduct a thorough due diligence review which may encompass, among other things, meetings with incumbent management and employees,
document reviews and, inspection of facilities, as applicable, as well as a review of financial and other information which will be made
available to us. If we determine to move forward with a particular target, we will proceed to structure and negotiate the terms of the
business combination transaction.
The time required to select and evaluate a target
business and to structure and complete our initial business combination, and the costs associated with this process, are not currently
ascertainable with any degree of certainty. Any costs incurred with respect to the identification and evaluation of, and negotiation with,
a prospective target business with which our initial business combination is not ultimately completed will result in our incurring losses
and will reduce the funds we can use to complete another business combination. The company will not pay any consulting fees to members
of our management team, or any of their respective affiliates, for services rendered to or in connection with our initial business combination.
Redemption Rights for Public Shareholders
upon Completion of Our Initial Business Combination
We will provide our public shareholders with the
opportunity to redeem all or a portion of their Class A ordinary shares upon the completion of our initial business combination at a per-share
price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account calculated as of two business days prior to
the consummation of the initial business combination, including interest earned on the funds held in the Trust Account and not previously
released to us to pay our taxes, divided by the number of then issued and outstanding public shares, subject to certain limitations. Our
Sponsor, officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to waive their redemption
rights with respect to their Founder Shares and any public shares they may hold in connection with the completion of our initial business
combination.
Conduct of Redemptions Pursuant to
Tender Offer Rules
If we conduct redemptions pursuant to the tender
offer rules of the U.S. Securities and Exchange Commission (the “SEC”), we will, pursuant to our Articles: (a) conduct the
redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers; and (b) file tender offer
documents with the SEC prior to completing our initial business combination which contain substantially the same financial and other information
about the initial business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates
the solicitation of proxies.
Submission of Our Initial Business
Combination to a Shareholder Vote
In the event that we seek shareholder approval
of our initial business combination, we will distribute proxy materials and, in connection therewith, provide our public shareholders
with the redemption rights described above upon completion of the initial business combination.
If we seek shareholder approval, we will complete
our initial business combination only if we receive an ordinary resolution under Cayman Islands law, which requires the affirmative vote
of a majority of the shareholders who attend and vote at a general meeting of the company. In accordance with our Articles, shareholders
representing at least one-third of our issued and outstanding ordinary shares, present in person or by proxy, will constitute a quorum
for such meeting. Our Sponsor, officers and directors will count toward this quorum and, pursuant to that certain letter agreement, the
Sponsor, officers and directors have agreed to vote their Founder Shares, private placement shares and any public shares purchased during
or after the Public Offering (including in open market and privately-negotiated transactions) in favor of our initial business combination.
For purposes of seeking approval of an ordinary resolution, non-votes will have no effect on the approval of our initial business combination
once a quorum is obtained. Each public shareholder may elect to redeem their public shares irrespective of whether they vote for or against
the proposed transaction or whether they were a public shareholder on the record date for the shareholder meeting held to approve the
proposed transaction. Our Articles requires that at least five days’ notice will be given of any such shareholder meeting.
If
we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our initial
business combination pursuant to the tender offer rules, the Sponsor, our directors, officers, advisors or their affiliates may
purchase shares or public warrants in privately negotiated transactions or in the open market either prior to or following the
completion of our initial business combination. There is no limit on the number of shares our Sponsor, directors, officers, advisors
or their affiliates may purchase in such transactions, subject to compliance with applicable law and NYSE rules. However, other than
as described elsewhere in this Annual Report, they have no current commitments, plans or intentions to engage in such transactions
and have not formulated any terms or conditions for any such transactions. None of the funds in the Trust Account will be used to
purchase shares or public warrants in such transactions. If they engage in such transactions, they will not make any such purchases
when they are in possession of any material non-public information not disclosed to the seller or if such purchases are prohibited
by Regulation M under the Exchange Act. To the extent any such shares or public warrants are purchased by our Sponsor, directors,
officers, advisors or their affiliates, such securities would be (a) purchased at a price no higher than the redemption price for
the public shares, which as of December 31, 2023 was estimated to be $11.06 per share and (b) would not be (i) voted by the Sponsor,
directors, officers, advisors or their respective affiliates or (ii) redeemable by the Sponsor, directors, officers, advisors or
their respective affiliates. See the risk factor entitled “If we seek shareholder approval of our initial business
combination, the Sponsor, directors, officers and their affiliates may elect to purchase shares or public warrants from public
shareholders, which may influence a vote on a proposed business combination and reduce the public “float” of our Class A
ordinary shares or public warrants” in Item 1A. Risk Factors for additional information.
In the event that the Sponsor, directors, officers,
advisors or their affiliates purchase shares in privately negotiated transactions from public shareholders who have already elected to
exercise their redemption rights, such selling shareholders would be required to revoke their prior elections to redeem their shares.
We do not currently anticipate that such purchases, if any, would constitute a tender offer subject to the tender offer rules under the
Exchange Act or a going-private transaction subject to the going-private rules under the Exchange Act; however, if the purchasers determine
at the time of any such purchases that the purchases are subject to such rules, the purchasers will comply with such rules.
The purpose of any such purchases of shares could
be to satisfy a closing condition in an agreement with a target that requires us to have a minimum net worth or a certain amount of cash
at the closing of our initial business combination, where it appears that such requirement would otherwise not be met. The purpose of
any such purchases of public warrants could be to reduce the number of public warrants outstanding or to vote such warrants on any matters
submitted to the warrant holders for approval in connection with our initial business combination. Any such purchases of our securities
may result in the completion of our initial business combination that may not otherwise have been possible. In addition, if such purchases
are made, the public “float” of our Class A ordinary shares or public warrants may be reduced and the number of beneficial
holders of our securities may be reduced, which may make it difficult to maintain or obtain the quotation, listing or trading of our securities
on a national securities exchange.
Limitation on Redemption Rights Upon
Completion of Our Initial Business Combination If We Seek Shareholder Approval
Notwithstanding the foregoing redemption rights,
if we seek shareholder approval of our initial business combination and we do not conduct redemptions in connection with our business
combination pursuant to the tender offer rules, our Articles provide that a public shareholder, together with any affiliate of such shareholder
or any other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange
Act), will be restricted from redeeming its shares with respect to more than an aggregate of 15% of the shares sold in the Public Offering.
We believe the restriction described above will discourage shareholders from accumulating large blocks of shares, and subsequent attempts
by such holders to use their ability to redeem their shares as a means to force us or our management to purchase their shares at a significant
premium to the then-current market price or on other undesirable terms. Absent this provision, a public shareholder holding more than
an aggregate of 15% of the shares sold in the Public Offering could threaten to exercise its redemption rights against a business combination
if such holder’s shares are not purchased by us or our management at a premium to the then-current market price or on other undesirable
terms. By limiting our shareholders’ ability to redeem to no more than 15% of the shares sold in the Public Offering, we believe
we will limit the ability of a small group of shareholders to unreasonably attempt to block our ability to complete our business combination,
particularly in connection with a business combination with a target that requires as a closing condition that we have a minimum net worth
or a certain amount of cash. However, we would not be restricting our shareholders’ ability to vote all of their shares (including
all shares held by those shareholders that hold more than 15% of the shares sold in the Public Offering) for or against our initial business
combination.
Redemption of Public Shares and Liquidation
If No Initial Business Combination
Our Articles provide that we will have the Extended
Date to complete our initial business combination. If we are unable to complete our initial business combination within such period, we
will: (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business
days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the
Trust Account, including interest earned on the funds held in the Trust Account and not previously released to us (less taxes payable
and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public shares, which redemption
will completely extinguish public shareholders’ rights as shareholders (including the right to receive further liquidation distributions,
if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders
and our board of directors, liquidate and dissolve, subject in each case to our obligations under Cayman Islands law to provide for claims
of creditors and in all cases subject to the other requirements of applicable law. There will be no redemption rights or liquidating distributions
with respect to our warrants, which will expire worthless if we fail to complete our initial business combination by the Extended Date.
Competition
In identifying, evaluating and selecting a target
business for our initial business combination, we may encounter competition from other entities having a business objective similar to
ours, including other special purpose acquisition companies, private equity groups and leveraged buyout funds, public companies and operating
businesses seeking strategic acquisitions. Many of these entities are well established and have extensive experience identifying and effecting
business combinations directly or through affiliates. Moreover, many of these competitors possess similar or greater financial, technical,
human and other resources than us. Additionally, the number of blank check companies looking for business combination targets has increased
compared to recent years and many of these blank check companies are sponsored by entities or persons that have significant experience
with completing business combinations. Our ability to acquire larger target businesses will be limited by our available financial resources.
This inherent limitation gives others an advantage in pursuing the acquisition of a target business. Furthermore, our obligation to pay
cash in connection with our public shareholders who exercise their redemption rights may reduce the resources available to us for our
initial business combination and our issued and outstanding warrants, and the future dilution they potentially represent, may not be viewed
favorably by certain target businesses. Either of these factors may place us at a competitive disadvantage in successfully negotiating
an initial business combination.
Employees
We currently have two officers: Sten L. Gustafson
and Bernard J. Duroc-Danner. These individuals are not obligated to devote any specific number of hours to our matters but they intend
to devote as much of their time as they deem necessary to our affairs until we have completed our initial business combination. The amount
of time they will devote in any time period will vary based on whether a target business has been selected for our initial business combination
and the stage of the business combination process we are in. Aside from our chief executive officer and chief financial officer, we do
not intend to have any full time employees prior to the completion of our initial business combination.
Available Information
We are required to file Annual Reports on Form
10-K and Quarterly Reports on Form 10-Q with the SEC on a regular basis, and are required to disclose certain material events (e.g., changes
in corporate control, acquisitions or dispositions of a significant amount of assets other than in the ordinary course of business and
bankruptcy) in a Current Report on Form 8-K. The SEC maintains an Internet website that contains reports, proxy and information statements
and other information regarding issuers that file electronically with the SEC. The SEC’s Internet website is located at http://www.sec.gov.
In addition, the Company will provide copies of these documents without charge upon request from us in writing at 3262 Westheimer Road,
Suite 706, Houston, TX, 77098 or on our website https://pyrophytespac.com.
ITEM 1A. RISK FACTORS.
An investment in our securities involves a
high degree of risk. You should consider carefully all of the risks described below, together with the other information contained in
this Annual Report on Form 10-K, the prospectus associated with our Initial Public Offering and the Registration Statement, before making
a decision to invest in our securities. If any of the following events occur, our business, financial condition and operating results
may be materially adversely affected. In that event, the trading price of our securities could decline, and you could lose all or part
of your investment.
Unless otherwise stated, the Risk Factors described
below do not assume the closing the Sio Business Combination. References to the term “initial business combination” in this
section include the Sio Business Combination where context requires.
Risks Relating to our Search for, and Consummation
of or Inability to Consummate, a Business Combination
We are a blank check company with no operating
history and no revenues, and you have no basis on which to evaluate our ability to achieve our business objective.
We are a blank check company incorporated under
the laws of the Cayman Islands with no operating results. Because we lack an operating history, you have no basis upon which to evaluate
our ability to achieve our business objective of completing our initial business combination. We have no plans, arrangements or understandings
with any prospective target business concerning a business combination and may be unable to complete our initial business combination.
If we fail to complete our initial business combination, we will never generate any operating revenues.
Our public shareholders may not be afforded
an opportunity to vote on our proposed initial business combination, and even if we hold a vote, holders of our Founder Shares will participate
in such vote, which means we may complete our initial business combination even though a majority of our public shareholders do not support
such a combination.
While we plan to hold a meeting of our shareholders
to approve the Sio Business Combination, we may choose not to hold a shareholder vote to approve an alternative business combination unless
the business combination would require shareholder approval under applicable law or stock exchange listing requirements. In such case,
the decision as to whether we will seek shareholder approval of a proposed business combination or will allow shareholders to sell their
shares to us in a tender offer will be made by us, solely in our discretion, and will be based on a variety of factors, such as the timing
of the transaction and whether the terms of the transaction would otherwise require us to seek shareholder approval. Even if we seek shareholder
approval, the holders of our Founder Shares will participate in the vote on such approval. Accordingly, we may complete our initial business
combination even if holders of a majority of our ordinary shares do not approve of the business combination we complete.
Your only opportunity to effect your investment
decision regarding a potential business combination may be limited to the exercise of your right to redeem your shares from us for cash.
At the time of your investment in us, you were
not provided with an opportunity to evaluate the specific merits or risks of our initial business combination. If we do not complete the
Sio Business Combination, our board of directors may complete an initial business combination without seeking shareholder approval, in
which case, public shareholders may not have the right or opportunity to vote on the business combination, unless we seek such shareholder
vote. Accordingly, your only opportunity to effect your investment decision regarding our initial business combination may be limited
to exercising your redemption rights within the period of time (which will be at least 20 business days) set forth in our tender offer
documents mailed to our public shareholders in which we describe our initial business combination.
If we seek shareholder approval of our initial
business combination, our Sponsor and management team have agreed to vote in favor of such initial business combination, regardless of
how our public shareholders vote.
Our Sponsor currently owns approximately 36% of
our issued and outstanding ordinary shares. Our Sponsor and management team also may from time to time purchase Class A ordinary shares
prior to our initial business combination. Our Articles provide that, if we seek shareholder approval of an initial business combination,
such initial business combination will be approved if we receive an ordinary resolution under Cayman Islands law, which requires the affirmative
vote of a majority of the shareholders who attend and vote at a general meeting of the Company, including the Founder Shares. As a result,
in addition to our Sponsor’s Founder Shares, we would need 1,971,294 or 22.0% of the 8,973,837 outstanding public shares sold in
the Public Offering to be voted in favor of an initial business combination in order to have our initial business combination approved
(assuming all outstanding shares are voted). Accordingly, if we seek shareholder approval of our initial business combination, the agreement
by our Sponsor and management team to vote in favor of our initial business combination will increase the likelihood that we will receive
an ordinary resolution, being the requisite shareholder approval for such initial business combination.
The ability of our public shareholders to redeem
their shares for cash may make our financial condition unattractive to potential business combination targets, which may make it difficult
for us to enter into a business combination with a target.
The definitive agreement for our initial business
combination transaction, including the Sio Business Combination Agreement, may contain minimum cash requirement for (i) cash consideration
to be paid to the target or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash
to satisfy other conditions. If too many public shareholders exercise their redemption rights, we would not be able to meet such closing
condition and, as a result, would not be able to proceed with the business combination, unless such condition was modified or waived.
Prospective targets will be aware of these risks and, thus, may be reluctant to enter into a business combination transaction with us.
The ability of our public shareholders to exercise
redemption rights with respect to a large number of our shares may not allow us to complete the most desirable business combination or
optimize our capital structure.
At the time we enter into an agreement for our
initial business combination, including the Sio Business Combination Agreement, we will not know how many shareholders may exercise their
redemption rights, and therefore will need to structure the transaction based on our expectations as to the number of shares that will
be submitted for redemption. If our initial business combination agreement requires us to use a portion of the cash in the Trust Account
to pay the purchase price, or requires us to have a minimum amount of cash at closing, we will need to reserve a portion of the cash in
the Trust Account to meet such requirements, or arrange for third party financing. In addition, if a larger number of shares are submitted
for redemption than we initially expected, we may need to restructure the transaction to reserve a greater portion of the cash in the
Trust Account or arrange for third party financing. Raising additional third party financing may involve dilutive equity issuances or
the incurrence of indebtedness at higher than desirable levels. The above considerations may limit our ability to complete the most desirable
business combination available to us or optimize our capital structure.
The ability of our public shareholders to exercise
redemption rights with respect to a large number of our shares could increase the probability that our initial business combination would
be unsuccessful and that you would have to wait for liquidation in order to redeem your shares.
If our initial business combination agreement
requires us to use a portion of the cash in the Trust Account to pay the purchase price, or requires us to have a minimum amount of cash
at closing, the probability that our initial business combination would be unsuccessful is increased. If our initial business combination
is unsuccessful, you would not receive your pro rata portion of the Trust Account until we liquidate the Trust Account. If you are in
need of immediate liquidity, you could attempt to sell your shares in the open market; however, at such time our shares may trade at a
discount to the pro rata amount per share in the Trust Account. In either situation, you may suffer a material loss on your investment
or lose the benefit of funds expected in connection with your exercise of redemption rights until we liquidate or you are able to sell
your shares in the open market.
The requirement that we complete our initial
business combination by the Extended Date may give potential target businesses leverage over us in negotiating a business combination
and may limit the time we have in which to conduct due diligence on potential business combination targets, in particular as we approach
our dissolution deadline, which could undermine our ability to complete our initial business combination on terms that would produce
value for our shareholders.
Any potential target business with which we enter into negotiations
concerning a business combination, including Sio, will be aware that we must complete our initial business combination by the Extended
Date. Consequently, such target business may obtain leverage over us in negotiating a business combination, knowing that if we do not
complete our initial business combination with that particular target business, we may be unable to complete our initial business combination
with any target business. This risk will increase as we get closer to the timeframe described above. In addition, we may have limited
time to conduct due diligence and may enter into our initial business combination on terms that we would have rejected upon a more comprehensive
investigation.
Our search for a business combination, and
any target business with which we ultimately consummate a business combination, may be materially adversely affected by events that are
outside of our control, such as increased geopolitical unrest, pandemic outbreaks (such as COVID-19), and volatility in the debt and equity
markets.
Our ability to find a potential target business
and the business of any potential target business with which we may consummate a business combination could be materially and adversely
affected by events that are outside of our control. For example, geopolitical unrest, including war, terrorist activity and acts of civil
or international hostility are increasing. Similarly, other events outside of our control, including natural disasters, climate-related
events, pandemics or health crises (such as the COVID-19 pandemic) may arise from time to time. Any such events may cause significant
volatility and declines in the global markets, disproportionate impacts to certain industries or sectors, disruptions to commerce (including
to economic activity, travel and supply chains), loss of life and property damage, and may adversely affect the global economy or capital
markets, and the business of any potential target business with which we may consummate a business combination could be materially and
adversely affected. In addition, our ability to consummate a transaction may be dependent on the ability to raise equity and debt financing
which may be impacted by these and other events, including as a result of increased market volatility, decreased market liquidity in third-party
financing being unavailable on terms acceptable to us or at all.
We may not be able to complete our initial
business combination by the Extended Date, in which case we would cease all operations except for the purpose of winding up and we would
redeem our public shares and liquidate.
We may not be able to find a suitable target business and complete
our initial business combination by the Extended Date. Our ability to complete our initial business combination may be negatively impacted
by general market conditions, volatility in the capital and debt markets and the other risks described herein, including, without limitation,
as a result of terrorist attacks, natural disasters or a significant outbreak of other infection diseases. If we have not completed our
initial business combination within such time period, we will: (i) cease all operations except for the purpose of winding up, (ii) as
promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable
in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust
Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding public
shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive
further liquidation distributions, if any) and (iii) as promptly as reasonably possible following such redemption, subject to the approval
of our remaining shareholders and our board of directors, liquidate and dissolve, subject in each case to our obligations under Cayman
Islands law to provide for claims of creditors and in all cases subject to the other requirements of applicable law.
If we seek shareholder approval of our initial
business combination, the Sponsor, directors, officers and their affiliates may elect to purchase shares or public warrants from public
shareholders, which may influence a vote on a proposed business combination and reduce the public “float” of our Class A
ordinary shares or public warrants.
If we seek shareholder approval of our initial
business combination and we do not conduct redemptions in connection with our initial business combination pursuant to the tender offer
rules, our Sponsor, directors, officers, advisors or their affiliates may purchase shares or public warrants in privately negotiated transactions
or in the open market either prior to or following the closing of our initial business combination. There is no limit on the number of
public shares and/or public warrants our Sponsor, directors, officers, advisors or their affiliates may purchase in such transactions,
subject to compliance with applicable law and the rules of the NYSE. However, other than as previously disclosed, they have no current
commitments, plans or intentions to engage in such transactions and have not formulated any terms or conditions for any such transactions.
In the event our Sponsor, directors, officers, advisors and their affiliates were to purchase public shares from public shareholders,
such purchases would be structured in compliance with the requirements of Rule 14e-5 under the Exchange Act including, in pertinent part,
through adherence to the following:
| ● | Our registration statement/proxy statement filed for our business combination
transaction would disclose the possibility that our Sponsor, directors, officers, advisors and their affiliates may purchase public shares
from public shareholders outside the redemption process, along with the purpose of such purchases; |
| ● | if our Sponsor, directors, officers, advisors and their affiliates
were to purchase public shares from public shareholders, they would do so at a price no higher than the price offered through our redemption
process; |
| ● | our registration statement/proxy statement filed for our business combination
transaction would include a representation that any of our securities purchased by our Sponsor, directors, officers, advisors and their
affiliates would not be voted in favor of approving the business combination transaction; |
| ● | our Sponsor, directors, officers, advisors and their affiliates would
not possess any redemption rights with respect to our securities or, if they do acquire and possess redemption rights, they would waive
such rights; and |
| ● | we would disclose in a Form 8-K, before our security holder
meeting to approve the business combination transaction, the following material items: |
| o | the amount of our securities purchased outside of the redemption offer
by our Sponsor, directors, officers, advisors and their affiliates, along with the purchase price; |
| o | the purpose of the purchases by our Sponsor, directors, officers, advisors
and their affiliates; |
| o | the impact, if any, of the purchases by our Sponsor, directors, officers,
advisors and their affiliates on the likelihood that the business combination transaction will be approved; |
| o | the identities of our security holders who sold to our Sponsor, directors,
officers, advisors and their affiliates (if not purchased on the open market) or the nature of our security holders (e.g., 5% security
holders) who sold to our Sponsor, directors, officers, advisors and their affiliates; and |
| o | the number of our securities for which we have received redemption
requests pursuant to our redemption offer. |
Any such purchases
will be reported pursuant to Section 13 and Section 16 of the Exchange Act to the extent such purchasers are subject to such
reporting requirements and may include a contractual acknowledgment that such shareholder, although still the record holder of our shares
is no longer the beneficial owner thereof and therefore agrees not to exercise its redemption rights. None of the funds held in the Trust
Account will be used to purchase shares or public warrants in such transactions. If such purchases are made, the public “float”
of our securities may be reduced and the number of beneficial holders of our securities may be reduced, which may make it difficult to
maintain or obtain the quotation, listing or trading of our securities on a national securities exchange.
Additionally, at any
time at or prior to our initial business combination, subject to applicable securities laws (including with respect to material non-public information),
our Sponsor, directors, officers, advisors and their affiliates may enter into transactions with investors and others to provide them
with incentives to acquire public shares, vote their public shares in favor of our initial business combination or not redeem their public
shares. However, they have no current commitments, plans or intentions to engage in such transactions and have not formulated any terms
or conditions for any such transactions.
The purpose of any such
transactions could be to increase the likelihood of obtaining shareholder approval of the business combination, or satisfy a closing condition
in an agreement with a target, including the Business Combination Agreement, that requires us to have a minimum net worth or a certain
amount of cash at the closing of our initial business combination where it appears that such requirement would otherwise not be met. Any
such transactions may result in the completion of our initial business combination that may not otherwise have been possible.
If a shareholder fails to receive notice of
our offer to redeem our public shares in connection with our initial business combination, or fails to comply with the procedures for
submitting or tendering its shares, such shares may not be redeemed.
We will comply with the proxy rules or tender
offer rules, as applicable, when conducting redemptions in connection with our initial business combination. Despite our compliance with
these rules, if a shareholder fails to receive our proxy materials or tender offer documents, as applicable, such shareholder may not
become aware of the opportunity to redeem its shares. In addition, proxy materials or tender offer documents, as applicable, that we will
furnish to holders of our public shares in connection with our initial business combination will describe the various procedures that
must be complied with in order to validly tender or submit public shares for redemption. For example, we intend to require our public
shareholders seeking to exercise their redemption rights, whether they are record holders or hold their shares in “street name,”
to, at the holder’s option, either deliver their share certificates to our transfer agent, or to deliver their shares to our transfer
agent electronically prior to the date set forth in the proxy materials or tender offer documents, as applicable. In the case of proxy
materials, this date may be up to two business days prior to the scheduled vote on the proposal to approve the initial business combination.
In addition, if we conduct redemptions in connection with a shareholder vote, we intend to require a public shareholder seeking redemption
of its public shares to also submit a written request for redemption to our transfer agent two business days prior to the scheduled vote
in which the name of the beneficial owner of such shares is included. In the event that a shareholder fails to comply with these or any
other procedures disclosed in the proxy or tender offer materials, as applicable, its shares may not be redeemed.
If we seek shareholder approval of our initial
business combination and we do not conduct redemptions pursuant to the tender offer rules, and if you or a “group” of shareholders
are deemed to hold in excess of 15% of our Class A ordinary shares, you will lose the ability to redeem all such shares in excess of 15%
of our Class A ordinary shares.
If we seek shareholder approval of our initial business combination,
including the Sio Business Combination, and we do not conduct redemptions in connection with our initial business combination pursuant
to the tender offer rules, our Articles provide that a public shareholder, together with any affiliate of such shareholder or any other
person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange Act),
will be restricted from seeking redemption rights with respect to more than an aggregate of 15% of the shares sold in the Public Offering,
which we refer to as the “Excess Shares.” However, we would not be restricting our shareholders’ ability to vote all
of their shares (including Excess Shares) for or against our initial business combination. Your inability to redeem the Excess Shares
will reduce your influence over our ability to complete our initial business combination and you could suffer a material loss on your
investment in us if you sell Excess Shares in open market transactions. Additionally, you will not receive redemption distributions with
respect to the Excess Shares if we complete our initial business combination. And as a result, you will continue to hold that number of
shares exceeding 15% and, in order to dispose of such shares, would be required to sell your shares in open market transactions, potentially
at a loss.
Because of our limited resources and the significant
competition for business combination opportunities, it may be more difficult for us to complete our initial business combination. If have
not completed our initial business combination, our public shareholders may receive only their pro rata portion of the funds in the Trust
Account that are available for distribution to public shareholders, and our warrants will expire worthless.
We expect to encounter competition from other
entities having a business objective similar to ours, including private investors (which may be individuals or investment partnerships),
other blank check companies and other entities, domestic and international, competing for the types of businesses we intend to acquire.
Many of these individuals and entities are well-established and have extensive experience in identifying and effecting, directly or indirectly,
acquisitions of companies operating in or providing services to various industries. Many of these competitors possess similar or greater
technical, human and other resources to ours or more local industry knowledge than we do and our financial resources will be relatively
limited when contrasted with those of many of these competitors. Additionally, the number of blank check companies looking for business
combination targets has increased compared to recent years and many of these blank check companies are sponsored by entities or persons
that have significant experience with completing business combinations. While we believe there are numerous other target businesses we
could potentially acquire with the net proceeds of the Public Offering and the sale of the Private Placement Warrants, if the Sio Business
Combination does not close, our ability to compete with respect to the acquisition of certain target businesses that are sizable will
be limited by our available financial resources. This inherent competitive limitation gives others an advantage in pursuing the acquisition
of certain other target businesses. Furthermore, we are obligated to offer holders of our public shares the right to redeem their shares
for cash at the time of our initial business combination in conjunction with a shareholder vote or via a tender offer. Potential target
companies will be aware that this may reduce the resources available to us for our initial business combination, if needed. Any of these
obligations may place us at a competitive disadvantage in successfully negotiating a business combination. If we have not completed our
initial business combination, our public shareholders may receive only their pro rata portion of the funds in the Trust Account that are
available for distribution to public shareholders, and our warrants will expire worthless.
As the number of special purpose acquisition
companies evaluating targets increases, attractive targets may become scarcer and there may be more competition for attractive targets.
This could increase the cost of our initial business combination and could even result in our inability to find a target or to consummate
an initial business combination.
In recent years, the number of special purpose
acquisition companies that have been formed has increased substantially. Many potential targets for special purpose acquisition companies
have already entered into an initial business combination, and there are still many special purpose acquisition companies seeking targets
for their initial business combination, as well as many such companies currently in registration. As a result, at times, fewer attractive
targets may be available, and it may require more time, more effort and more resources to identify a suitable target and to consummate
an initial business combination.
In addition, because there are more special purpose
acquisition companies seeking to enter into an initial business combination with available targets, the competition for available targets
with attractive fundamentals or business models may increase, which could cause target companies to demand improved financial terms. Attractive
deals could also become scarcer for other reasons, such as economic or industry sector downturns, geopolitical tensions, or increases
in the cost of additional capital needed to close business combinations or operate targets post-business combination.
This could increase the cost of, delay or otherwise
complicate or frustrate our ability to find and consummate an initial business combination, and may result in our inability to consummate
an initial business combination on terms favorable to our investors altogether.
If the net proceeds of the Public Offering
and the sale of the Private Placement Warrants not being held in the Trust Account are insufficient to allow us to operate at least until
the Extended Date, it could limit the amount available to fund our search for a target business or businesses and complete our initial
business combination, and we will depend on loans from the Sponsor or management team to fund our search and to complete our initial
business combination.
Of the net proceeds of the Public Offering and the Private Placement,
only approximately $1,000,000 was made available to us initially outside Trust Account to fund our working capital requirements, together
with up to $1,500,000 in IPO Working Capital Loans (as defined herein) committed by the Sponsor. While we believe that the funds available
to us outside of the Trust Account will be sufficient to allow us to operate at least until the Extended Date, we cannot assure you that
our estimate is accurate. Of the funds available to us, we could use a portion of the funds available to us to pay fees to consultants
to assist us with our search for a target business. We could also use a portion of the funds as a down payment or to fund a “no-shop”
provision (a provision in letters of intent or merger agreements designed to keep target businesses from “shopping” around
for transactions with other companies or investors on terms more favorable to such target businesses) with respect to an alternative target
business, although we do not have any current intention to do so. If we enter into a letter of intent or merger agreement for an alternative
transaction where we pay for the right to receive exclusivity from a target business and were subsequently required to forfeit such funds
(whether as a result of our breach or otherwise), we might not have sufficient funds to continue searching for, or conduct due diligence
with respect to, a target business.
If we are required to seek additional capital,
we would need to borrow funds from the Sponsor, management team or other third parties to operate or may be forced to liquidate. Except
for the committed Sponsor loans, neither the Sponsor, members of our management team nor any of their affiliates is under any obligation
to advance funds to us in such circumstances. Any such advances would be repaid only from funds held outside the Trust Account or from
funds released to us upon completion of our initial business combination. Up to $1,500,000 of such loans (which amount includes the committed
Sponsor loans) may be convertible into Private Placement Warrants of the post-business combination entity at a price of $1.00 per warrant
at the option of the lender. Such warrants would be identical to the Private Placement Warrants. Prior to the completion of our initial
business combination, we do not expect to seek loans from parties other than the Sponsor or an affiliate of the Sponsor as we do not believe
third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds in our Trust
Account. If we have not completed our initial business combination because we do not have sufficient funds available to us, we will be
forced to cease operations and liquidate the Trust Account. Consequently, our public shareholders may only receive an estimated $10.25
per share, or possibly less, on our redemption of our public shares, and our warrants will expire worthless.
If third parties bring claims against us, the
proceeds held in the Trust Account could be reduced and the per-share redemption amount received by shareholders may be less than $10.25
per share.
Our placing of funds in the Trust Account may
not protect those funds from third party claims against us. Although we will seek to have all vendors, service providers, prospective
target businesses and other entities with which we do business execute agreements with us waiving any right, title, interest or claim
of any kind in or to any monies held in the Trust Account for the benefit of our public shareholders, such parties may not execute such
agreements, or even if they execute such agreements they may not be prevented from bringing claims against the Trust Account, including,
but not limited to, fraudulent inducement, breach of fiduciary responsibility or other similar claims, as well as claims challenging the
enforceability of the waiver, in each case in order to gain advantage with respect to a claim against our assets, including the funds
held in the Trust Account. If any third party refuses to execute an agreement waiving such claims to the monies held in the Trust Account,
our management will consider whether competitive alternatives are reasonably available to us and will only enter into an agreement with
such third party if management believes that such third party’s engagement would be in the best interests of the Company under the
circumstances. The underwriter of the Public Offering will not execute agreements with us waiving such claims to the monies held in the
Trust Account.
Examples of possible instances where we may
engage a third party that refuses to execute a waiver include the engagement of a third party consultant whose particular expertise
or skills are believed by management to be significantly superior to those of other consultants that would agree to execute a waiver
or in cases where management is unable to find a service provider willing to execute a waiver. In addition, there is no guarantee
that such entities will agree to waive any claims they may have in the future as a result of, or arising out of, any negotiations,
contracts or agreements with us and will not seek recourse against the Trust Account for any reason. Upon redemption of our public
shares, if we have not completed our initial business combination within the prescribed timeframe, or upon the exercise of a
redemption right in connection with our initial business combination, we will be required to provide for payment of claims of
creditors that were not waived that may be brought against us within the 10 years following redemption. Accordingly, the per-share
redemption amount received by public shareholders could be less than the $10.25 per public share initially held in the Trust
Account, due to claims of such creditors. Pursuant to the letter agreement the form of which is filed as an exhibit to this Annual
Report, the Sponsor has agreed that it will be liable to us if and to the extent any claims by a third party for services rendered
or products sold to us, or a prospective target business with which we have entered into a written letter of intent, confidentiality
or other similar agreement or business combination agreement, reduce the amount of funds in the Trust Account to below the lesser of
(i) $10.25 per public share and (ii) the actual amount per public share held in the Trust Account as of the date of the ontaidation
of the Trust Account, if less than $10.25 per share due to reductions in the value of the trust assets, less taxes payable, provided
that such liability will not apply to any claims by a third party or prospective target business who executed a waiver of any and
all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under
our indemnity of the underwriter of the Public Offering against certain liabilities, including liabilities under the Securities Act.
However, we have not asked the Sponsor to reserve for such indemnification obligations, nor have we independently verified whether
the Sponsor has sufficient funds to satisfy its indemnity obligations and we believe that the Sponsor’s only assets are
securities of our Company. Therefore, we cannot assure you that the Sponsor would be able to satisfy those obligations.
As a result, if any such claims were successfully
made against the Trust Account, the funds available for our initial business combination and redemptions could be reduced to less than
$10.25 per public share. In such event, we may not be able to complete our initial business combination, and you would receive such lesser
amount per share in connection with any redemption of your public shares. None of our officers or directors will indemnify us for claims
by third parties including, without limitation, claims by vendors and prospective target businesses.
Our directors may decide not to enforce the
indemnification obligations of the Sponsor, resulting in a reduction in the amount of funds in the Trust Account available for distribution
to our public shareholders.
In the event that the proceeds in the Trust Account
are reduced below the lesser of (i) $10.25 per share and (ii) the actual amount per public share held in the Trust Account as of the date
of the liquidation of the Trust Account if less than $10.25 per share due to reductions in the value of the trust assets, in each case
less taxes payable, and the Sponsor asserts that it is unable to satisfy his obligations or that it has no indemnification obligations
related to a particular claim, our independent directors would determine whether to take legal action against the Sponsor to enforce its
indemnification obligations. While we currently expect that our independent directors would take legal action on our behalf against the
Sponsor to enforce its indemnification obligations to us, it is possible that our independent directors in exercising their business judgment
and subject to their fiduciary duties may choose not to do so in any particular instance if, for example, the cost of such legal action
is deemed by the independent directors to be too high relative to the amount recoverable or if the independent directors determine that
a favorable outcome is not likely. If our independent directors choose not to enforce these indemnification obligations, the amount of
funds in the Trust Account available for distribution to our public shareholders may be reduced below $10.25 per share.
If, after we distribute the proceeds in the
Trust Account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition
is filed against us that is not dismissed, a bankruptcy or insolvency court may seek to recover such proceeds, and the members of our
board of directors may be viewed as having breached their fiduciary duties to our creditors, thereby exposing the members of our board
of directors and us to claims of punitive damages.
If, after we distribute the proceeds in the Trust
Account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is
filed against us that is not dismissed, any distributions received by shareholders could be viewed under applicable debtor/creditor and/or
bankruptcy or insolvency laws as either a “preferential transfer” or a “fraudulent conveyance.” As a result, a
bankruptcy or insolvency court could seek to recover some or all amounts received by our shareholders. In addition, our board of directors
may be viewed as having breached its fiduciary duty to our creditors and/or having acted in bad faith, thereby exposing itself and us
to claims of punitive damages, by paying public shareholders from the Trust Account prior to addressing the claims of creditors.
If, before distributing the proceeds in the
Trust Account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition
is filed against us that is not dismissed, the claims of creditors in such proceeding may have priority over the claims of our shareholders
and the per-share amount that would otherwise be received by our shareholders in connection with our liquidation may be reduced.
If, before distributing the proceeds in the Trust
Account to our public shareholders, we file a bankruptcy or winding-up petition or an involuntary bankruptcy or winding-up petition is
filed against us that is not dismissed, the proceeds held in Trust Account could be subject to applicable bankruptcy or insolvency law,
and may be included in our bankruptcy estate and subject to the claims of third parties with priority over the claims of our shareholders.
To the extent any bankruptcy claims deplete the Trust Account, the per-share amount that would otherwise be received by our shareholders
in connection with our liquidation may be reduced.
If we are deemed to be an investment company
under the Investment Company Act, we may be required to institute burdensome compliance requirements and our activities may be restricted,
which may make it difficult for us to complete our initial business combination or force us to abandon our efforts to complete an initial
business combination, including the Sio Business Combination.
If we are deemed to be an investment company under
the Investment Company Act of 1940, as amended (the “Investment Company Act”), our activities may be restricted, including:
| ● | restrictions on the nature of our investments; and |
| ● | restrictions on the issuance of securities, each of which
may make it difficult for us to complete our initial business combination, including the Sio Business Combination. In addition, we may
have imposed on us burdensome requirements, including: |
| o | registration as an investment company; |
| o | adoption of a specific form of corporate structure; and |
| o | reporting, record keeping, voting, proxy and disclosure requirements
and other rules and regulations. |
In order not to be regulated as an investment
company under the Investment Company Act, unless it can qualify for an exclusion, a company must ensure that it is engaged primarily
in a business other than investing, reinvesting or trading of securities and that its activities do not include investing, reinvesting,
owning, holding or trading “investment securities” constituting more than 40% of our assets (exclusive of
U.S. government securities and cash items) on an unconsolidated basis.
The SEC recently provided guidance that the determination of whether
a special purpose acquisition company, like us, is an “investment company” under the Investment Company Act is a facts and
circumstances determination requiring individualized analysis and depends on a variety of factors, including a SPAC’s duration,
asset composition, business purpose and activities, and “is a question of facts and circumstances” requiring individualized
analysis. When applying these factors to us, we do not believe that our principal activities will subject us to the Investment Company
Act. To this end, the Company was formed for the purpose of completing an initial business combination with one or more businesses. Since
our inception, our business has been and will continue to be focused on identifying and completing an initial business combination, and
thereafter, operating the post-transaction business or assets for the long term. Further, we do not plan to buy businesses or assets with
a view to resale or profit from their resale and we do not plan to buy unrelated businesses or assets or be a passive investor. In addition,
the proceeds held in the Trust Account were invested in United States “government securities” within the meaning of Section
2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under
Rule 2a-7 promulgated under the Investment Company Act which invest only in direct U.S. government treasury obligations until April 2024, when, to mitigate the potential risk that we might be deemed to be an investment company for purposes of the Investment Company
Act, the trustee liquidated such investments and moved the proceeds to an interest-bearing demand deposit account. Pursuant to the Trust Agreement, the trustee is not permitted to invest in other securities or assets.
By restricting the investment of the proceeds in this manner, and by focusing our directors’ and officers’ time toward, and
operating our business for the purpose of, acquiring and growing businesses for the long term (rather than buying and selling businesses
in the manner of a merchant bank or private equity fund or investing in assets for the purpose of achieving investment returns on such
assets), we intend to avoid being deemed an “investment company” within the meaning of the Investment Company Act. Further,
investing in our securities is not intended for persons who are seeking a return on investments in government securities or investment
securities. Instead, the Trust Account is intended as a holding place for funds pending the earliest to occur of either: (i) the completion
of our initial business combination; (ii) the redemption of any public shares properly submitted in connection with a shareholder
vote to amend our Articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem 100% of our public shares if we do not complete its initial business combination by the Extended Date
or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity;
or (iii) absent an initial business combination by the Extended Date, our return of the funds held in the Trust Account to our public
shareholders as part of our redemption of the public shares. If we do not invest the proceeds as described above, we may be deemed to
be subject to the Investment Company Act.
If we were deemed to be an investment company for purposes of the
Investment Company Act, we would need to register as such under the Investment Company Act and compliance with these additional
regulatory burdens would require additional expenses for which we have not allotted funds and may hinder our ability to complete a
business combination. We may also be forced to abandon our efforts to complete an initial
business combination, including the Sio Business Combination, and instead be required to liquidate the Trust Account. In which case,
our investors would not be able to realize the benefits of owning shares in a successor operating business, including the potential
appreciation in the value of our securities following such a transaction, and our warrants would expire worthless. For illustrative
purposes, in connection with the liquidation of our Trust Account, our public shareholders may receive only approximately $11.06 per
public share, which is based on estimates as of December 31, 2023, or less in certain circumstances, and our warrants would expire worthless.
Changes in laws or regulations, or a failure
to comply with any laws and regulations, may adversely affect our business, including our ability to negotiate and complete our initial
business combination, and results of operations, including the Sio Business Combination.
We are subject to rules and regulations by various
national, regional and local governing bodies, including, for example, the SEC, and to new and evolving regulatory measures under applicable
law. Compliance with, and monitoring of, applicable laws and regulations may be difficult, time consuming and costly and our efforts to
comply with such new and evolving laws and regulations have resulted in and are likely to continue to result in, increased general and
administrative expenses and a diversion of management time and attention. In addition, these changes could have a material adverse effect
on our business, investments and results of operations.
Moreover, because these laws, regulations and
standards are subject to varying interpretations, their application in practice may evolve over time as new guidance becomes available.
For example, on January 24, 2024, the SEC issued final rules and guidance relating to special purpose acquisition companies, like us,
regarding, among other things, disclosure in SEC filings in connection with initial business combination transactions; the financial statement
requirements applicable to transactions involving shell companies; the use of projections in SEC filings in connection with proposed business
combination transactions; and the potential liability of certain participants in proposed business combination transactions. This evolution
may result in continuing uncertainty regarding compliance matters and additional costs necessitated by ongoing revisions to our disclosure
and governance practices. A failure to comply with applicable laws or regulations and any subsequent changes, as interpreted and applied,
could have a material adverse effect on our business, including our ability to negotiate and complete our initial business combination,
including the Sio Business Combination and results of operations.
If we are unable to consummate our initial
business combination within 30 months of the Public Offering, our public shareholders may be forced to wait beyond such to 30 months before
redemption from our Trust Account.
If we are unable to consummate our initial business
combination within 30 months of the Public Offering, the proceeds then on deposit in the Trust Account, including interest earned on the
funds held in the Trust Account (less taxes payable and up to $100,000 of interest to pay dissolution expenses), will be used to fund
the redemption of our public shares, as further described herein. Any redemption of public shareholders from the Trust Account will be
effected automatically by function of our Articles prior to any voluntary winding up. If we are required to wind-up, liquidate the Trust
Account and distribute such amount therein, pro rata, to our public shareholders, as part of any liquidation process, such winding up,
liquidation and distribution must comply with the applicable provisions of the Companies Act. In that case, investors may be forced to
wait beyond 30 months of the Public Offering before the redemption proceeds of our Trust Account become available to them, and they receive
the return of their pro rata portion of the proceeds from our Trust Account. We have no obligation to return funds to investors prior
to the date of our redemption or liquidation unless we consummate our initial business combination prior thereto and only then in cases
where investors have sought to redeem their Class A ordinary shares. Only upon our redemption or any liquidation will public shareholders
be entitled to distributions if we are unable to complete our initial business combination.
Our shareholders may be held liable for claims
by third parties against us to the extent of distributions received by them upon redemption of their shares.
If we are forced to enter into an insolvent liquidation,
any distributions received by shareholders could be viewed as an unlawful payment if it was proved that immediately following the date
on which the distribution was made, we were unable to pay our debts as they fall due in the ordinary course of business. As a result,
a liquidator could seek to recover some or all amounts received by our shareholders. Furthermore, our directors may be viewed as having
breached their fiduciary duties to us or our creditors and/or may have acted in bad faith, thereby exposing themselves and our Company
to claims, by paying public shareholders from the Trust Account prior to addressing the claims of creditors. We cannot assure you that
claims will not be brought against us for these reasons. We and our directors and officers who knowingly and willfully authorized or permitted
any distribution to be paid out of our share premium account while we were unable to pay our debts as they fall due in the ordinary course
of business would be guilty of an offence and may be liable to a fine of approximately $18,293 and to imprisonment for five years in the
Cayman Islands.
We may not hold an
annual general meeting of shareholders until after the consummation of our initial business combination, which could delay the opportunity
for our shareholders to appoint directors.
In accordance with NYSE
corporate governance requirements, we are not required to hold an annual general meeting until no later than one year after our first
fiscal year end following our listing on NYSE. There is no requirement under the Companies Act for us to hold annual or general meetings
to appoint directors. Until we hold an annual meeting of shareholders, public shareholders may not be afforded the opportunity to appoint
directors and to discuss company affairs with management. Our board of directors is divided into three classes with only one class of
directors being appointed in each year and each class (except for those directors appointed prior to our first annual meeting of
shareholders) serving a three-year term.
You will not be permitted to exercise your
warrants unless we register and qualify the underlying Class A ordinary shares or certain exemptions are available.
If the issuance of the Class A ordinary shares
upon exercise of the warrants is not registered, qualified or exempt from registration or qualification under the Securities Act and applicable
state securities laws, holders of warrants will not be entitled to exercise such warrants and such warrants may have no value and expire
worthless. In such event, holders who acquired their warrants as part of a purchase of units will have paid the full unit purchase price
solely for the Class A ordinary shares included in the units.
We have registered the Class A ordinary shares
issuable upon exercise of the warrants in the Public Offering because the warrants will become exercisable 30 days after the completion
of our initial business combination, which may be within one year of the Public Offering. However, because the warrants will be exercisable
until their expiration date of up to five years after the completion of our initial business combination, in order to comply with the
requirements of Section 10(a)(3) of the Securities Act following the consummation of our initial business combination under the terms
of the warrant agreement, we have agreed that, as soon as practicable, but in no event later than 15 business days, after the closing
of our initial business combination, we will use our best efforts to file with the SEC a post-effective amendment to the Public Offering
registration statement or a new registration statement covering the registration under the Securities Act of the Class A ordinary shares
issuable upon exercise of the warrants and thereafter will use our best efforts to cause the same to become effective within 60 business
days following our initial business combination and to maintain a current prospectus relating to the Class A ordinary shares issuable
upon exercise of the warrants until the expiration of the warrants in accordance with the provisions of the warrant agreement. We cannot
assure you that we will be able to do so if, for example, any facts or events arise which represent a fundamental change in the information
set forth in the registration statement or prospectus, the financial statements contained or incorporated by reference therein are not
current or correct or the SEC issues a stop order.
If the Class A ordinary shares issuable upon exercise
of the warrants are not registered under the Securities Act, under the terms of the warrant agreement, holders of warrants who seek to
exercise their warrants will not be permitted to do so for cash and, instead, will be required to do so on a cashless basis in accordance
with Section 3(a)(9) of the Securities Act or another exemption.
In no event will warrants be exercisable for cash
or on a cashless basis, and we will not be obligated to issue any shares to holders seeking to exercise their warrants, unless the issuance
of the shares upon such exercise is registered or qualified under the securities laws of the state of the exercising holder, or an exemption
from registration or qualification is available.
If our Class A ordinary shares are at the time
of any exercise of a warrant not listed on a national securities exchange such that they satisfy the definition of “covered
securities” under Section 18(b)(1) of the Securities Act, we may, at our option, not permit holders of warrants who seek to exercise
their warrants to do so for cash and, instead, require them to do so on a cashless basis in accordance with Section 3(a)(9) of the Securities
Act; in the event we so elect, we will not be required to file or maintain in effect a registration statement or register or qualify the
shares underlying the warrants under applicable state securities laws, and in the event we do not so elect, we will use our best efforts
to register or qualify the shares underlying the warrants under applicable state securities laws to the extent an exemption is not available.
In no event will we be required to net cash settle
any warrant, or issue securities (other than upon a cashless exercise as described above) or other compensation in exchange for the warrants
in the event that we are unable to register or qualify the shares underlying the warrants under the Securities Act or applicable state
securities laws.
The warrants may become exercisable and redeemable
for a security other than the Class A ordinary shares, and you will not have any information regarding such other security at this time.
In certain situations, including if we are not
the surviving entity in our initial business combination, the warrants may become exercisable for a security other than the Class A ordinary
shares. As a result, if the surviving company redeems your warrants for securities pursuant to the warrant agreement, you may receive
a security in a company of which you do not have information at this time. Pursuant to the warrant agreement, the surviving company will
be required to use commercially reasonable efforts to register the issuance of the security underlying the warrants within fifteen business
days of the closing of an initial business combination.
The grant of registration rights to our Sponsor
and holders of our Private Placement Warrants may make it more difficult to complete our initial business combination, and the future
exercise of such rights may adversely affect the market price of our Class A ordinary shares.
Pursuant to the registration rights agreement entered into at the Public
Offering, our Sponsor and its permitted transferees can demand that we register the Founder Shares, Private Placement Warrants and the
Class A ordinary shares issuable upon exercise of the Private Placement Warrants, and holders of warrants that may be issued upon conversion
of IPO Working Capital Loans and the Extension Note may demand that we register the Class A ordinary shares issuable upon exercise of
such warrants. We will bear the cost of registering these securities. The registration and availability of such a significant number of
securities for trading in the public market may have an adverse effect on the market price of our Class A ordinary shares. In addition,
the existence of the registration rights may make our initial business combination more costly or difficult to conclude. This is because
the shareholders of the target business may increase the equity stake they seek in the combined entity or ask for more cash consideration
to offset the negative impact on the market price of our Class A ordinary shares that is expected when the ordinary shares owned by our
Sponsor, holders of our Private Placement Warrants or holders of our IPO Working Capital Loans or the Extension Note or their respective
permitted transferees are registered.
Because we are not limited to evaluating a
target business in a particular industry sector you may be unable to ascertain the merits or risks of any particular target business’s
operations.
Our efforts to identify a prospective initial business combination
target have not been limited to a particular industry, sector or geographic region. While we may pursue an initial business combination
opportunity in any industry or sector, we intend to target companies that serve the growing segments in the energy transition ecosystem.
Specifically, we seek to focus on differentiated targets that provide products, services, equipment, and technologies that support a variety
of energy transition solutions. These include, but are not limited to renewable power generation, energy storage, the electrical grid,
zero-emission transportation, renewable fuels, carbon capture, utilization and storage, and zero/low-carbon industrial applications. Our
Articles prohibit us from effectuating a business combination solely with another blank check company or similar company with nominal
operations. To the extent we complete our initial business combination, including the Sio Business Combination, we may be affected by
numerous risks inherent in the business operations with which we combine. For example, we may combine with a financially unstable business
or an entity lacking an established record of sales or earnings, we may be affected by the risks inherent in the business and operations
of a financially unstable or a development stage entity. Although our officers and directors have and will endeavor to evaluate the risks
inherent in a particular target business, including Sio, we cannot assure you that we will properly ascertain or assess all of the significant
risk factors or that we will have adequate time to complete due diligence. Furthermore, some of these risks may be outside of our control
and leave us with no ability to control or reduce the chances that those risks will adversely impact a target business. We also cannot
assure you that an investment in our securities will ultimately prove to be more favorable to investors than a direct investment, if such
opportunity were available, in our business combination target. Accordingly, any shareholders who choose to remain shareholders following
the initial business combination could suffer a reduction in the value of their securities. Such shareholders are unlikely to have a remedy
for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors
of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws
that the proxy solicitation or tender offer materials, as applicable, relating to the initial business combination contained an actionable
material misstatement or material omission.
Although we have identified general criteria
and guidelines that we believe are important in evaluating prospective target businesses, we may enter into our initial business combination
with a target that does not meet such criteria and guidelines, and as a result, the target business with which we enter into our initial
business combination may not have attributes entirely consistent with our general criteria and guidelines.
Although we have identified general criteria and
guidelines for evaluating prospective target businesses, it is possible that a target business with which we enter into our initial business
combination will not have all of these positive attributes. If we complete our initial business combination with a target that does not
meet some or all of these guidelines, such combination may not be as successful as a combination with a business that does meet all of
our general criteria and guidelines. In addition, if we announce a prospective business combination with a target that does not meet our
general criteria and guidelines, a greater number of shareholders may exercise their redemption rights, which may make it difficult for
us to meet any closing condition with a target business that requires us to have a minimum net worth or a certain amount of cash. In addition,
if shareholder approval of the transaction is required by law, or we decide to obtain shareholder approval for business or other reasons,
it may be more difficult for us to attain shareholder approval of our initial business combination if the target business does not meet
our general criteria and guidelines. If we have not completed our initial business combination, our public shareholders may only receive
their pro rata portion of the funds in the Trust Account that are available for distribution to public shareholders, and our warrants
will expire worthless.
We may seek business combination opportunities
with an entity lacking an established record of revenue, cash flow or earnings, which could subject us to volatile revenues, cash flows
or earnings or difficulty in retaining key personnel.
To the extent we complete our initial business
combination with an entity lacking an established record of revenues or earnings, we may be affected by numerous risks inherent in the
operations of the business with which we combine. These risks include volatile revenues or earnings and difficulties in obtaining and
retaining key personnel. Although our officers and directors will endeavor to evaluate the risks inherent in a particular target business,
we may not be able to properly ascertain or assess all of the significant risk factors and we may not have adequate time to complete due
diligence. Furthermore, some of these risks may be outside of our control and leave us with no ability to control or reduce the chances
that those risks will adversely impact a target business.
We are not required to obtain an opinion from
an independent investment banking firm or from a valuation or appraisal firm, and consequently, you may have no assurance from an independent
source that the price we are paying for the business is fair to our shareholders from a financial point of view.
Unless we complete our initial business combination
with an affiliated entity or our board of directors cannot independently determine the fair market value of the target business or businesses
(including with the assistance of financial advisors), we are not required to obtain an opinion from an independent investment banking
firm which is a member of FINRA or from a valuation or appraisal firm that the price we are paying is fair to our shareholders from a
financial point of view. If no opinion is obtained, our shareholders will be relying on the judgment of our board of directors, who will
determine fair market value based on standards generally accepted by the financial community. Such standards used will be disclosed in
our proxy materials or tender offer documents, as applicable, related to our initial business combination.
Our letter agreement with the Sponsor, officers
and directors may be amended without shareholder approval.
Our letter agreement with the Sponsor, officers
and directors contains provisions relating to transfer restrictions of our Founder Shares and Private Placement Warrants, indemnification
of the Trust Account, waiver of redemption rights and participation in liquidating distributions from the Trust Account. The letter agreement
may be amended without shareholder approval. While we do not expect our board to approve any amendment to the letter agreement prior to
our initial business combination, it may be possible that our board, in exercising its business judgment and subject to its fiduciary
duties, chooses to approve one or more amendments to the letter agreement. Any such amendments to the letter agreement would not require
approval from our shareholders and may have an adverse effect on the value of an investment in our securities.
Our Sponsor controls a substantial interest
in us and thus may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner that you do not support.
Our Sponsor currently owns approximately 36% of our issued and outstanding
ordinary shares. Accordingly, they may exert a substantial influence on actions requiring a shareholder vote, potentially in a manner
that you do not support, including amendments to our Articles. In addition, prior to the closing of our initial business combination,
only holders of our Founder Shares will have the right to vote to continue the company in a jurisdiction outside the Cayman Islands (including
any special resolution required to amend the constitutional documents of the Company or to adopt new constitutional documents of the Company,
in each case, as a result of the Company approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands). This
provision of our Articles may only be amended by a special resolution passed by not less than 90% of our ordinary shares which are represented
in person or by proxy and are voted at our general meeting. As a result, you will not have any influence over our continuation in a jurisdiction
outside the Cayman Islands prior to our initial business combination.
If our Sponsor purchase any additional Class A ordinary shares in the
aftermarket or in privately negotiated transactions, this would increase their control. Neither our Sponsor nor, to our knowledge, any
of our officers or directors, have any current intention to purchase additional securities, other than as disclosed in this Annual Report.
Factors that would be considered in making such additional purchases would include consideration of the current trading price of our Class
A ordinary shares. In addition, our board of directors is and will be divided into three classes, each of which will generally serve for
a term for three years with only one class of directors being appointed in each year. We may not hold an annual or extraordinary general
meeting to appoint new directors prior to the completion of our initial business combination, in which case all of the current directors
will continue in office until at least the completion of the business combination. If there is an annual general meeting, as a consequence
of our “staggered” board of directors, only a minority of the board of directors will be considered for appointment and our
Sponsor, because of its ownership position, will have considerable influence regarding the outcome. Accordingly, our Sponsor will continue
to exert control at least until the completion of our initial business combination.
A provision of our warrant agreement may make
it more difficult for us to consummate an initial business combination.
If (i) we issue additional Class A ordinary
shares or equity-linked securities for capital raising purposes in connection with the closing of our initial business combination at
a Newly Issued Price of less than $9.20 per Class A ordinary share, (ii) the aggregate gross proceeds from such issuances represent more
than 60% of the total equity proceeds, and interest thereon, available for the funding of our initial business combination on the date
of the consummation of our initial business combination (net of redemptions), and (iii) the Market Value of our Class A ordinary shares
is below $9.20 per share, then the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher
of the Market Value and the Newly Issued Price, the $18.00 per share redemption trigger price will be adjusted (to the nearest cent) to
be equal to 180% of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price will
be adjusted (to the nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price. This may make it more difficult
for us to consummate an initial business combination with a target business.
Compliance obligations under the Sarbanes-Oxley
Act may make it more difficult for us to effectuate our initial business combination, require substantial financial and management resources,
and increase the time and costs of completing an initial business combination.
Section 404 of the Sarbanes-Oxley Act requires that we evaluate and
report on our system of internal controls beginning with this Annual Report. Only in the event we are deemed to be a large accelerated
filer or an accelerated filer, and no longer qualify as an emerging growth company, will we be required to comply with the independent
registered public accounting firm attestation requirement on our internal control over financial reporting. Further, for as long as we
remain an emerging growth company, we will not be required to comply with the independent registered public accounting firm attestation
requirement on our internal control over financial reporting. The fact that we are a blank check company makes compliance with the requirements
of the Sarbanes-Oxley Act particularly burdensome on us as compared to other public companies because a target business with which we
seek to complete our initial business combination may not be in compliance with the provisions of the Sarbanes-Oxley Act regarding adequacy
of its internal controls. The development of the internal control of any such entity to achieve compliance with the Sarbanes-Oxley Act
may increase the time and costs necessary to complete any such business combination.
We may reincorporate in another jurisdiction
in connection with our initial business combination and such reincorporation may result in taxes imposed on shareholders.
We may, in connection with our initial business
combination and subject to requisite shareholder approval by special resolution under the Companies Act, reincorporate in the jurisdiction
in which the target company or business is located or in another jurisdiction. For example, the Sio Business Combination contemplates
the Domestication pursuant to which we will transfer by way of continuation from the Cayman Islands to Alberta in accordance with the
Companies Act and continue as an Alberta corporation in accordance with the applicable provisions of the ABCA. The transaction may require
a shareholder to recognize taxable income in the jurisdiction in which the shareholder is a tax resident or in which its members are resident
if it is a tax transparent entity. We do not intend to make any cash distributions to shareholders to pay such taxes. Shareholders may
be subject to withholding taxes or other taxes with respect to their ownership of us after the reincorporation.
We may reincorporate in another jurisdiction
in connection with our initial business combination, and the laws of such jurisdiction may govern some or all of our future material agreements
and we may not be able to enforce our legal rights.
In connection with our initial business combination,
we may relocate the home jurisdiction of our business from the Cayman Islands to another jurisdiction. If we determine to do this, the
laws of such jurisdiction may govern some or all of our future material agreements. The system of laws and the enforcement of existing
laws in such jurisdiction may not be as certain in implementation and interpretation as in the United States. For example, the Sio Business
Combination contemplates the Domestication pursuant to which we will transfer by way of continuation from the Cayman Islands to Alberta
in accordance with the Companies Act and continue as an Alberta corporation in accordance with the applicable provisions of the ABCA.
The inability to enforce or obtain a remedy under any of our future agreements could result in a significant loss of business, business
opportunities or capital.
We may not be able to complete an initial business
combination since such initial business combination may be subject to regulatory review and approval requirements, including pursuant
to foreign investment regulations and review by governmental entities such as the Committee on Foreign Investment in the United States
(“CFIUS”), and may ultimately be prohibited.
Our initial business combination may be subject
to regulatory review and approval requirements by governmental entities, and ultimately prohibited. For example, CFIUS has authority to
review certain direct or indirect foreign investments in U.S. businesses. Among other things, CFIUS requires mandatory filings for certain
investments and is empowered to charge filing fees related to filings and to self-initiate national security reviews of certain foreign
direct and indirect investments in U.S. businesses if the parties choose not to file voluntarily. If CFIUS determines that an investment
subject to its jurisdiction presents national security risks, CFIUS has the power to require mitigation measures on the investment or
can recommend that the president of the United States prohibit the transaction or order divestment. Whether CFIUS has jurisdiction to
review an acquisition or investment transaction depends on, among other factors, the nature and structure of the transaction, the nationality
of the parties, the level of beneficial ownership interest and the nature of any information or governance rights involved.
We are organized in the Cayman Islands. Our Sponsor
is a Delaware limited liability company controlled by three managers, two of whom are U.S. citizens (Messrs. Duroc-Danner and Gustafson)
and one of whom (Thomas Major) is a Canadian citizen. Mr. Major does not have the ability to independently control the Sponsor because
any action by the Sponsor requires a majority vote of the three managers.
By virtue of being organized in the Cayman Islands
and for so long as the Sponsor retains a material ownership interest in us, we may be deemed a “foreign person” under the
CFIUS regulations. If CFIUS considers us to be a “foreign person,” our initial business combination could be subject to CFIUS
review. If our initial business combination is subject to CFIUS jurisdiction, the parties may be required to make a mandatory filing or
determine to submit a voluntary filing with CFIUS, or to proceed with such initial business combination without notifying CFIUS and risk
CFIUS intervention, before or after closing such initial business combination. In connection with a review, CFIUS may decide to delay
the business combination, require conditions to mitigate national security concerns with respect to the business combination, or recommend
that the president of the United States block the business combination or order divestment if the parties proceeded without first obtaining
CFIUS approval. Accordingly, the potential impact of a CFIUS review may prevent us from consummating the initial business combination.
Additionally, the laws and regulations of other government entities may impose review or approval procedures on account of any foreign
ownership by us or the Sponsor. The pool of potential targets with which we could complete an initial business combination may be limited
as a result of any such regulatory requirements or restrictions.
The process of government review, whether by CFIUS or otherwise, could
be lengthy. Because we have only a limited time to complete our initial business combination, our failure to obtain any required approvals
within the requisite time period may require us to liquidate. If we are unable to consummate our initial business combination within the
applicable time period required, including as a result of extended regulatory review, we will, as promptly as reasonably possible but
not more than ten business days thereafter, redeem the public shares for a pro rata portion of the funds held in the trust account and
as promptly as reasonably possible following such redemption, subject to the approval of our remaining shareholders and our board of directors,
liquidate and dissolve, subject in each case to our obligations under Cayman Islands law to provide for claims of creditors and the requirements
of other applicable law. In such event, our shareholders will miss the opportunity to benefit from an investment in a target company and
the potential appreciation in value of such investment. Additionally, our warrants will become worthless.
Risks Relating to the Post-Business Combination
Company
Subsequent to our completion of our initial
business combination, we may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have
a significant negative effect on our financial condition, results of operations and our share price, which could cause you to lose some
or all of your investment.
We cannot assure you that the due diligence we conduct on a target
business, including Sio, will identify all material issues that may be present within a particular target business, that it would be possible
to uncover all material issues through a customary amount of due diligence, or that factors outside of the target business and outside
of our control will not later arise. As a result of these factors, the combined company may be forced to later write-down or write-off
assets, restructure our operations, or incur impairment or other charges that could result in our reporting losses. Even if our due diligence
successfully identifies certain risks, unexpected risks may arise and previously known risks may materialize in a manner not consistent
with our preliminary risk analysis. Even though these charges may be non-cash items and not have an immediate impact on the combined company’s
liquidity, the fact that such company report charges of this nature could contribute to negative market perceptions about it or its securities.
In addition, charges of this nature may cause the combined company to violate net worth or other covenants to which it may be subject
as a result of assuming pre-existing debt held by a target business or by virtue of our obtaining debt financing to partially finance
the initial business combination or thereafter. Accordingly, any shareholders who choose to remain shareholders following the business
combination could suffer a reduction in the value of their securities. Such shareholders are unlikely to have a remedy for such reduction
in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors of a duty of
care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws that the proxy
solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material misstatement
or material omission.
Resources could be wasted in researching business
combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another
business. If we have not completed our initial business combination, our public shareholders may only receive their pro rata portion of
the funds in the Trust Account that are available for distribution to public shareholders, and our warrants will expire worthless.
We anticipate that the investigation of each specific
target business and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require
substantial management time and attention and substantial costs for accountants, attorneys, consultants and others. If we decide not to
complete a specific initial business combination, the costs incurred up to that point for the proposed transaction likely would not be
recoverable. Furthermore, if we reach an agreement relating to a specific target business, we may fail to complete our initial business
combination for any number of reasons including those beyond our control. Any such event will result in a loss to us of the related costs
incurred which could materially adversely affect subsequent attempts to locate and acquire or merge with another business. If we have
not completed our initial business combination, our public shareholders may only receive their pro rata portion of the funds in the Trust
Account that are available for distribution to public shareholders, and our warrants will expire worthless.
We are dependent upon our officers and directors
and their loss could adversely affect our ability to operate.
Our operations are dependent upon a relatively
small group of individuals and, in particular, our officers and directors. We believe that our success depends on the continued service
of our officers and directors, at least until we have completed our initial business combination. In addition, our officers and directors
are not required to commit any specified amount of time to our affairs and, accordingly, will have conflicts of interest in allocating
their time among various business activities, including identifying potential business combinations and monitoring the related due diligence.
We do not have an employment agreement with, or key-man insurance on the life of, any of our directors or officers. The unexpected loss
of the services of one or more of our directors or officers could have a detrimental effect on us.
Our ability to successfully effect our initial
business combination and to be successful thereafter will be dependent upon the efforts of our key personnel, some of whom may join us
following our initial business combination. The loss of key personnel could negatively impact the operations and profitability of our
post-combination business.
Our ability to successfully effect our initial
business combination is dependent upon the efforts of our key personnel. The role of our key personnel in the target business, however,
cannot presently be ascertained. Although some of our key personnel may remain with the target business in senior management or advisory
positions following our initial business combination, it is likely that some or all of the management of the target business will remain
in place. While we intend to closely scrutinize any individuals we engage after our initial business combination, we cannot assure you
that our assessment of these individuals will prove to be correct. These individuals may be unfamiliar with the requirements of operating
a company regulated by the SEC, which could cause us to have to expend time and resources helping them become familiar with such requirements.
In addition, the officers and directors of an
acquisition candidate may resign upon completion of our initial business combination. The departure of a business combination target’s
key personnel could negatively impact the operations and profitability of our post-combination business. The role of an acquisition candidate’s
key personnel upon the completion of our initial business combination cannot be ascertained at this time. Although we contemplate that
certain members of an acquisition candidate’s management team will remain associated with the acquisition candidate following our
initial business combination, it is possible that members of the management of an acquisition candidate will not wish to remain in place.
The loss of key personnel could negatively impact the operations and profitability of our post-combination business.
After our initial business combination, it
is possible that a majority of our directors and officers will live outside the United States and all of our assets will be located outside
the United States; therefore investors may not be able to enforce federal securities laws or their other legal rights.
It is possible that after our initial business
combination, a majority of our directors and officers will reside outside of the United States and all of our assets will be located outside
of the United States. As a result, it may be difficult, or in some cases not possible, for investors in the United States to enforce their
legal rights, to effect service of process upon all of our directors or officers or to enforce judgments of United States courts predicated
upon civil liabilities and criminal penalties on our directors and officers under United States laws.
Our key personnel may negotiate employment
or consulting agreements with a target business in connection with a particular business combination, and a particular business combination
may be conditioned on the retention or resignation of such key personnel. These agreements may provide for them to receive compensation
following our initial business combination and as a result, may cause them to have conflicts of interest in determining whether a particular
business combination is the most advantageous.
Our key personnel may be able to remain with the
combined company after the completion of our initial business combination only if they are able to negotiate employment or consulting
agreements in connection with the business combination. Such negotiations would take place simultaneously with the negotiation of the
business combination and could provide for such individuals to receive compensation in the form of cash payments and/or our securities
for services they would render to us after the completion of the business combination. Such negotiations also could make such key personnel’s
retention or resignation a condition to any such agreement. The personal and financial interests of such individuals may influence their
motivation in identifying and selecting a target business, subject to their fiduciary duties under Cayman Islands law.
We may have a limited ability to assess the
management of a prospective target business and, as a result, may effect our initial business combination with a target business whose
management may not have the skills, qualifications or abilities to manage a public company.
When evaluating the desirability of effecting
our initial business combination with a prospective target business, our ability to assess the target business’s management may
be limited due to a lack of time, resources or information. Our assessment of the capabilities of the target business’s management,
therefore, may prove to be incorrect and such management may lack the skills, qualifications or abilities we suspected. Should the target
business’s management not possess the skills, qualifications or abilities necessary to manage a public company, the operations and
profitability of the post-combination business may be negatively impacted. Accordingly, any shareholders who choose to remain shareholders
following the business combination could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy
for such reduction in value unless they are able to successfully claim that the reduction was due to the breach by our officers or directors
of a duty of care or other fiduciary duty owed to them, or if they are able to successfully bring a private claim under securities laws
that the proxy solicitation or tender offer materials, as applicable, relating to the business combination contained an actionable material
misstatement or material omission.
The officers and directors of an acquisition
candidate may resign upon completion of our initial business combination. The loss of a business combination target’s key personnel
could negatively impact the operations and profitability of our post-combination business.
The role of an acquisition candidate’s key
personnel upon the completion of our initial business combination cannot be ascertained at this time. Although we contemplate that certain
members of an acquisition candidate’s management team will remain associated with the acquisition candidate following our initial
business combination, it is possible that members of the management of an acquisition candidate will not wish to remain in place.
Our management may not be able to maintain
control of a target business after our initial business combination. We cannot provide assurance that, upon loss of control of a target
business, new management will possess the skills, qualifications or abilities necessary to profitably operate such business.
We may structure our initial business combination
so that the post-transaction company in which our public shareholders own shares will own less than 100% of the equity interests or assets
of a target business, but we will only complete such business combination if the post-transaction company owns or acquires 50% or more
of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for us not to
be required to register as an investment company under the Investment Company Act. We will not consider any transaction that does not
meet such criteria. Even if the post-transaction company owns 50% or more of the voting securities of the target, our shareholders prior
to the business combination may collectively own a minority interest in the post business combination company, depending on valuations
ascribed to the target and us in the business combination. For example, we could pursue a transaction in which we issue a substantial
number of new Class A ordinary shares in exchange for all of the outstanding share capital, shares or other equity interests of a target.
In this case, we would acquire a 100% interest in the target. However, as a result of the issuance of a substantial number of new Class
A ordinary shares, our shareholders immediately prior to such transaction could own less than a majority of our issued and outstanding
Class A ordinary shares subsequent to such transaction. In addition, other minority shareholders may subsequently combine their holdings
resulting in a single person or group obtaining a larger portion of the Company’s shares than we initially acquired. Accordingly,
this may make it more likely that our management will not be able to maintain control of the target business.
We may issue notes or other debt securities,
or otherwise incur substantial debt, to complete a business combination, which may adversely affect our leverage and financial condition
and thus negatively impact the value of our shareholders’ investment in us.
Although we have no commitments as of the date
of this report (other than the committed Sponsor loans) to issue any notes or other debt securities, or to otherwise incur outstanding
debt following the Public Offering, we may choose to incur substantial debt to complete our initial business combination. We and our officers
have agreed that we will not incur any indebtedness unless we have obtained from the lender a waiver of any right, title, interest or
claim of any kind in or to the monies held in the Trust Account. As such, no issuance of debt will affect the per share amount available
for redemption from the Trust Account. Nevertheless, the incurrence of debt could have a variety of negative effects, including:
| ● | default and foreclosure on our assets if our operating revenues
after an initial business combination are insufficient to repay our debt obligations; |
| ● | acceleration of our obligations to repay the indebtedness
even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of certain financial
ratios or reserves without a waiver or renegotiation of that covenant; |
| ● | our immediate payment of all principal and accrued interest,
if any, if the debt security is payable on demand; |
| ● | our inability to obtain necessary additional financing if
the debt security contains covenants restricting our ability to obtain such financing while the debt security is outstanding; |
| ● | our inability to pay dividends on our Class A ordinary shares; |
| ● | using a substantial portion of our cash flow to pay principal
and interest on our debt, which will reduce the funds available for dividends on our Class A ordinary shares if declared, expenses, capital
expenditures, acquisitions and other general corporate purposes; |
| ● | limitations on our flexibility in planning for and reacting
to changes in our business and in the industry in which we operate; |
| ● | increased vulnerability to adverse changes in general economic,
industry and competitive conditions and adverse changes in government regulation; and |
| ● | limitations on our ability to borrow additional amounts for
expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and other disadvantages
compared to our competitors who have less debt. |
We may only be able to complete one business
combination with the proceeds of the Public Offering and the sale of the Private Placement Warrants, which will cause us to be solely
dependent on a single business which may have a limited number of products or services. This lack of diversification may negatively impact
our operations and profitability.
The net proceeds from the Public Offering
and the Private Placement initially provided us with $197,837,500 that we may use to complete our initial business combination
(after taking into account the $8,443,750 of deferred underwriting commissions being held in the Trust Account). After redemptions
in connection with the Company’s first and second extensions of its deadline to consummate an initial business combination,
approximately $71.4 million remain in the Trust Account.
We may effectuate our initial business combination
with a single target business or multiple target businesses simultaneously or within a short period of time. However, we may not be able
to effectuate our initial business combination with more than one target business because of various factors, including the existence
of complex accounting issues and the requirement that we prepare and file pro forma financial statements with the SEC that present operating
results and the financial condition of several target businesses as if they had been operated on a combined basis. By completing our initial
business combination with only a single entity, our lack of diversification may subject us to numerous economic, competitive and regulatory
developments. Further, we would not be able to diversify our operations or benefit from the possible spreading of risks or offsetting
of losses, unlike other entities which may have the resources to complete several business combinations in different industries or different
areas of a single industry. Accordingly, the prospects for our success may be:
| ● | solely dependent upon the performance of a single business,
property or asset, or |
| ● | dependent upon the development or market acceptance of a
single or limited number of products, processes or services. |
This lack of diversification may subject us to
numerous economic, competitive and regulatory risks, any or all of which may have a substantial adverse impact upon the particular industry
in which we may operate subsequent to our initial business combination.
We may attempt to simultaneously complete business
combinations with multiple prospective targets, which may hinder our ability to complete our initial business combination and give rise
to increased costs and risks that could negatively impact our operations and profitability.
If we determine to simultaneously acquire several
businesses that are owned by different sellers, we will need for each of such sellers to agree that our purchase of its business is contingent
on the simultaneous closings of the other business combinations, which may make it more difficult for us, and delay our ability, to complete
our initial business combination. With multiple business combinations, we could also face additional risks, including additional burdens
and costs with respect to possible multiple negotiations and due diligence investigations (if there are multiple sellers) and the additional
risks associated with the subsequent assimilation of the operations and services or products of the acquired companies in a single operating
business. If we are unable to adequately address these risks, it could negatively impact our profitability and results of operations.
We may attempt to complete our initial business
combination with a private company about which little information is available, which may result in a business combination with a company
that is not as profitable as we suspected, if at all.
We may seek to effectuate our initial business
combination with a privately held company, such as Sio. Very little public information generally exists about private companies and we
could be required to make our decision on whether to pursue a potential initial business combination on the basis of limited information,
which may result in a business combination with a company that is not as profitable as we suspected, if at all.
We do not have a specified maximum redemption
threshold. The absence of such a redemption threshold may make it possible for us to complete our initial business combination with which
a substantial majority of our shareholders do not agree.
Our definitive business combination agreement,
including the Sio Business Combination Agreement, may impose a minimum cash requirement for (i) cash consideration to be paid to the target
or its owners, (ii) cash for working capital or other general corporate purposes or (iii) the retention of cash to satisfy other conditions.
As a result, we may be able to complete our initial business combination even though a substantial majority of our public shareholders
do not agree with the transaction and have redeemed their shares or, if we seek shareholder approval of our initial business combination
and do not conduct redemptions in connection with our initial business combination pursuant to the tender offer rules, have entered into
privately negotiated agreements to sell their shares to the Sponsor, officers, directors, advisors or any of their affiliates. In the
event the aggregate cash consideration we would be required to pay for all Class A ordinary shares that are validly submitted for redemption
plus any amount required to satisfy cash conditions pursuant to the terms of the proposed business combination exceed the aggregate amount
of cash available to us and such conditions are not otherwise modified or waived, we will not complete the business combination or redeem
any shares, all Class A ordinary shares submitted for redemption will be returned to the holders thereof, and we instead may search for
an alternate business combination.
In order to effectuate an initial business
combination, special purpose acquisition companies have, in the recent past, amended various provisions of their charters and other governing
instruments, including their warrant agreements. We cannot assure you that we will not seek to amend our Articles or governing instruments
in a manner that will make it easier for us to complete our initial business combination and that our shareholders may not support.
In order to effectuate a business combination,
special purpose acquisition companies have, in the recent past, amended various provisions of their charters and governing instruments,
including their warrant agreements. For example, special purpose acquisition companies have amended the definition of business combination,
increased redemption thresholds and extended the time to consummate an initial business combination and, with respect to their warrants,
amended their warrant agreements to require the warrants to be exchanged for cash and/or other securities. Amending our Articles will
require a special resolution under Cayman Islands law, which requires the affirmative vote of a majority of at least two-thirds of the
shareholders who attend and vote at a general meeting of the Company, and amending our warrant agreement will require a vote of holders
of at least 50% of the public warrants and, solely with respect to any amendment to the terms of the Private Placement Warrants or any
provision of the warrant agreement with respect to the Private Placement Warrants, 50% of the then outstanding Private Placement Warrants.
In addition, our Articles requires us to provide our public shareholders with the opportunity to redeem their public shares for cash if
we propose an amendment to our Articles (A) that would modify the substance or timing of our obligation to allow redemption in connection
with our initial business combination or to redeem 100% of our public shares if we do not complete an initial business combination by
the Extended Date or (B) with respect to any other material provisions relating to shareholders’ rights or pre-initial business
combination activity. We cannot assure you that we will not seek to amend our charter or governing instruments or extend the time to consummate
an initial business combination in order to effectuate our initial business combination.
The provisions of our Articles that relate
to our pre-business combination activity (and corresponding provisions of the agreement governing the release of funds from our Trust
Account) may be amended with the approval of holders of not less than two-thirds of our ordinary shares who attend and vote at a general
meeting of the Company (or 65% of our ordinary shares with respect to amendments to the trust agreement governing the release of funds
from our Trust Account), which is a lower amendment threshold than that of some other special purpose acquisition companies. It may be
easier for us, therefore, to amend our Articles to facilitate the completion of an initial business combination that some of our shareholders
may not support.
Our Articles provide that any of its provisions
related to pre-business combination activity (including the requirement to deposit proceeds of the Public Offering and the Private Placement
into the Trust Account and not release such amounts except in specified circumstances, and to provide redemption rights to public shareholders
as described herein) may be amended if approved by special resolution under Cayman Islands law, which requires the affirmative vote of
a majority of at least two-thirds of the shareholders who attend and vote at a general meeting of the Company, and corresponding provisions
of the trust agreement governing the release of funds from our Trust Account may be amended if approved by holders of 65% of our ordinary
shares. Our Sponsor, which currently beneficially owns approximately 36% of our ordinary shares, will participate in any vote to amend
our Articles and/or trust agreement and will have the discretion to vote in any manner they choose. As a result, we may be able to amend
the provisions of our Articles which governs our pre-business combination behavior more easily than some other special purpose acquisition
companies, and this may increase our ability to complete a business combination with which you do not agree. Our shareholders may pursue
remedies against us for any breach of our Articles.
Our Sponsor, officers and directors have agreed,
pursuant to a written agreement with us, that they will not propose any amendment to our Articles (A) that would modify the substance
or timing of our obligation to allow redemption in connection with our initial business combination or to redeem 100% of our public shares
if we do not complete our initial business combination by the Extended Date or (B) with respect to any other material provisions relating
to shareholders’ rights or pre-initial business combination activity, unless we provide our public shareholders with the opportunity
to redeem their Class A ordinary shares upon approval of any such amendment at a per-share price, payable in cash, equal to the aggregate
amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released
to us to pay our taxes, divided by the number of then outstanding public shares. Our shareholders are not parties to, or third-party beneficiaries
of, these agreements and, as a result, will not have the ability to pursue remedies against the Sponsor, officers or directors for any
breach of these agreements. As a result, in the event of a breach, our shareholders would need to pursue a shareholder derivative action,
subject to applicable law.
We may be unable to obtain additional financing
to complete our initial business combination or to fund the operations and growth of a target business, which could compel us to restructure
or abandon a particular business combination.
If the cash portion of the purchase price for
a target business exceeds the amount available from the Trust Account, net of amounts needed to satisfy any redemption by public shareholders,
we may be required to seek additional financing to complete such proposed initial business combination, including the Sio Business Combination.
We cannot assure you that such financing will be available on acceptable terms, if at all. To the extent that additional financing proves
to be unavailable when needed to complete our initial business combination, we would be compelled to either restructure the transaction
or abandon that particular business combination and seek an alternative target business candidate. Further, we may be required to obtain
additional financing in connection with the closing of our initial business combination for general corporate purposes, including for
maintenance or expansion of operations of the post-transaction businesses, the payment of principal or interest due on indebtedness incurred
in completing our initial business combination, or to fund the purchase of other companies. If we have not completed our initial business
combination, our public shareholders may only receive their pro rata portion of the funds in the Trust Account that are available for
distribution to public shareholders, and our warrants will expire worthless. In addition, even if we do not need additional financing
to complete our initial business combination, we may require such financing to fund the operations or growth of the target business. The
failure to secure additional financing could have a material adverse effect on the continued development or growth of the target business.
None of our officers, directors or shareholders is required to provide any financing to us in connection with or after our initial business
combination.
Risks Relating to Acquiring and Operating
a Business in Foreign Countries
If we effect our initial business combination
with a company located outside of the United States, we would be subject to a variety of additional risks that may adversely affect us.
If we pursue a target company with operations
or opportunities outside of the United States for our initial business combination, we may face additional burdens in connection with
investigating, agreeing to and completing such initial business combination, and if we effect such initial business combination, we would
be subject to a variety of additional risks that may negatively impact our operations.
If we pursue a target company with operations
or opportunities outside of the United States for our initial business combination, we would be subject to risks associated with cross-border
business combinations, including in connection with investigating, agreeing to and completing our initial business combination, conducting
due diligence in a foreign jurisdiction, having such transaction approved by any local governments, regulators or agencies and changes
in the purchase price based on fluctuations in foreign exchange rates.
If we effect our initial business combination
with such a company, we would be subject to any special considerations or risks associated with companies operating in an international
setting, including any of the following:
| ● | costs and difficulties inherent in managing cross-border
business operations and complying with different commercial and legal requirements of overseas markets; |
| ● | rules and regulations regarding currency redemption; |
| ● | complex corporate withholding taxes on individuals; |
| ● | laws governing the manner in which future business combinations
may be effected; |
| ● | exchange listing and/or delisting requirements; |
| ● | tariffs and trade barriers; |
| ● | regulations related to customs and import/export matters; |
| ● | local or regional economic policies and market conditions; |
| ● | unexpected changes in regulatory requirements; |
| ● | challenges in managing and staffing international operations; |
| ● | longer payment cycles and challenges in collecting accounts
receivable; |
| ● | tax issues, such as tax law changes and variations in tax
laws as compared to the United States; |
| ● | currency fluctuations and exchange controls; |
| ● | challenges in collecting accounts receivable; |
| ● | cultural and language differences; |
| ● | underdeveloped or unpredictable legal or regulatory systems; |
| ● | protection of intellectual property; |
| ● | social unrest, crime, strikes, riots and civil disturbances; |
| ● | regime changes and political upheaval; |
| ● | terrorist attacks, natural disasters and wars; and |
| ● | deterioration of political relations with the United States. |
We may not be able to adequately address these
additional risks. If we were unable to do so, we may be unable to complete such initial business combination, or, if we complete such
initial business combination, our operations might suffer, either of which may adversely impact our business, financial condition and
results of operations.
After our initial business combination, substantially
all of our assets may be located in a foreign country and substantially all of our revenue may be derived from our operations in such
country. Accordingly, our results of operations and prospects may be subject, to a significant extent, to the economic, political and
legal policies, developments and conditions in the country in which we operate.
The economic, political and social conditions,
as well as government policies, of the country in which our operations are located could affect our business. Economic growth could be
uneven, both geographically and among various sectors of the economy and such growth may not be sustained in the future. If in the future
such country’s economy experiences a downturn or grows at a slower rate than expected, there may be less demand for spending in
certain industries. A decrease in demand for spending in certain industries could materially and adversely affect our ability to find
an attractive target business with which to consummate our initial business combination and if we effect our initial business combination,
the ability of that target business to become profitable.
Exchange rate fluctuations and currency policies
may cause a target business’s ability to succeed in the international markets to be diminished.
In the event we acquire a non-U.S. target, all
revenues and income would likely be received in a foreign currency, and the dollar equivalent of our net assets and distributions, if
any, could be adversely affected by reductions in the value of the local currency. The value of the currencies in our target regions fluctuate
and are affected by, among other things, changes in political and economic conditions. Any change in the relative value of such currency
against our reporting currency may affect the attractiveness of any target business or, following consummation of our initial business
combination, our financial condition and results of operations. Additionally, if a currency appreciates in value against the dollar prior
to the consummation of our initial business combination, the cost of a target business as measured in dollars will increase, which may
make it less likely that we are able to consummate such transaction.
Risks Relating to our Management Team
None of the Sponsor, officers or directors
has any experience with a blank check company or special purpose acquisition company in the past.
None of the Sponsor, officers or directors has
had experience with a blank check company or special purpose acquisition company in the past. Accordingly, you may not have sufficient
information with which to evaluate their ability to identify and consummate a business combination using the proceeds of Public Offering.
Our management’s lack of experience in operating a special purpose acquisition corporation could adversely affect our ability to
consummate a business combination and could result in our not completing a business combination in the prescribed time frame.
We may not have sufficient funds to satisfy
indemnification claims of our directors and officers.
We have agreed to indemnify our officers and directors
to the fullest extent permitted by law. However, our officers and directors have agreed to waive any right, title, interest or claim of
any kind in or to any monies in the Trust Account and to not seek recourse against the Trust Account for any reason whatsoever. Accordingly,
any indemnification provided will be able to be satisfied by us only if (i) we have sufficient funds outside of the Trust Account or (ii)
we consummate an initial business combination. Our obligation to indemnify our officers and directors may discourage shareholders from
bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions also may have the effect of
reducing the likelihood of derivative litigation against our officers and directors, even though such an action, if successful, might
otherwise benefit us and our shareholders. Furthermore, a shareholder’s investment may be adversely affected to the extent we pay
the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.
Any failure to maintain effective internal control over financial
reporting could harm us.
Our management is responsible for establishing and maintaining adequate
internal control over financial reporting designed to provide reasonable assurance regarding the reliability of financial reporting and
the preparation of financial statements for external purposes in accordance with GAAP. Our management is likewise required, on an annual
and quarterly basis, to evaluate the effectiveness of our internal controls and to disclose any changes and material weaknesses identified
through such evaluation in those internal controls.
Our management concluded that our internal control over financial reporting
was not effective as of December 31, 2022 and each quarterly period thereafter because of an identified material weakness in our internal
control over financial reporting. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial
reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will
not be prevented or detected on a timely basis. In particular, our management concluded that our control around the interpretation and
accounting for certain complex financial instruments issued by the Company was not effectively designed or maintained.
If we are unable to maintain effective internal control over financial
reporting or disclosure controls and procedures, our ability to record, process and report financial information accurately, and to prepare
financial statements within required time periods could be adversely affected, which could subject us to litigation or investigations
requiring management resources and payment of legal and other expenses, negatively affect investor confidence in our financial statements
and adversely impact our stock price. If we are unable to assert that our internal control over financial reporting is effective, or when
required in the future, if our independent registered public accounting firm is unable to express an unqualified opinion as to the effectiveness
of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports,
the market price of our securities could be adversely affected and we could become subject to litigation or investigations by the stock
exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management
resources.
Our independent registered public accounting
firm’s report contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a “going
concern.”
As of December 31, 2023, the Company had $1,253
in cash and no cash equivalents. As of December 31, 2022, we had $13,372 in cash and no cash equivalents. Further, the Company has incurred
and expects to continue to incur significant costs in pursuit of its financing and acquisition plans. If the Company’s estimates
of the costs of identifying a target business, undertaking in-depth due diligence, and negotiating a Business Combination are less than
the actual amount necessary to do so, the Company may have insufficient funds available to operate its business prior to an initial business
combination. The liquidation deadline for the Company is also within the next twelve months if an initial Business Combination is not
consummated. The Company cannot assure that its plans to consummate an initial Business Combination will be successful.
As a result of the above, in connection with the
Company’s assessment of going concern considerations in accordance with Accounting Standards Update (“ASU”) 2014-15,
“Disclosures of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that
the liquidity conditions raise substantial doubt about the Company’s ability to continue as a going concern through approximately
one year from the date of filing. These financial statements do not include any adjustments relating to the recovery of the recorded assets
or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Past performance by our management team and
their affiliates, including investments and transactions in which they have participated and businesses with which they have been associated,
may not be indicative of future performance of an investment in the Company.
Information regarding our management team and
their affiliates, including investments and transactions in which they have participated and businesses with which they have been associated,
is presented for informational purposes only. Any past experience and performance by our management team and their affiliates and the
businesses with which they have been associated, is not a guarantee that we will be able to successfully identify a suitable candidate
for our initial business combination, that we will be able to provide positive returns to our shareholders, or of any results with respect
to any initial business combination we may consummate. You should not rely on the historical experiences of our management team and their
affiliates, including investments and transactions in which they have participated and businesses with which they have been associated,
as indicative of the future performance of an investment in us or as indicative of every prior investment by each of the members of our
management team or their affiliates. The market price of our securities may be influenced by numerous factors, many of which are beyond
our control, and our shareholders may experience losses on their investment in our securities.
Members of our management team and our board
of directors have significant experience as founders, board members, officers, executives and employees of other businesses. Certain of
these individuals have been, may be, or may become subject to media coverage or involved in litigation, investigations or other proceedings,
including related to such businesses or otherwise. This may have an adverse effect on us, which could impede our ability to consummate
an initial business combination.
Members of our management team and our board of
directors have been involved in a wide variety of businesses. Certain of these individuals have been, may be, or may become subject to
media coverage or involved in litigation, investigations or other proceedings, including related to such businesses or otherwise. Any
media coverage, litigation, investigations or other proceedings could divert the attention and resources of our management team and board
of directors away from identifying and selecting a target business or businesses for our initial business combination, and could negatively
affect our reputation or otherwise have an adverse effect on us, which could impede our ability to complete an initial business combination.
We may seek business combination opportunities
in industries or sectors that may be outside of our management’s areas of expertise.
We will consider a business combination outside
of our management’s areas of expertise if a business combination candidate is presented to us and we determine that such candidate
offers an attractive business combination opportunity for our Company. Although our management will endeavor to evaluate the risks inherent
in any particular business combination candidate, we cannot assure you that we will adequately ascertain or assess all of the significant
risk factors. We also cannot assure you that an investment in our Units will not ultimately prove to be less favorable to investors in
the Public Offering than a direct investment, if an opportunity were available, in a business combination candidate. In the event we elect
to pursue a business combination outside of the areas of our management’s expertise, our management’s expertise may not be
directly applicable to its evaluation or operation, and the information contained in this Annual Report regarding the areas of our management’s
expertise would not be relevant to an understanding of the business that we elect to acquire. As a result, our management may not be able
to ascertain or assess adequately all of the relevant risk factors. Accordingly, any shareholders who choose to remain shareholders following
our initial business combination could suffer a reduction in the value of their shares. Such shareholders are unlikely to have a remedy
for such reduction in value.
Our officers and directors will allocate their
time to other businesses thereby causing conflicts of interest in their determination as to how much time to devote to our affairs. This
conflict of interest could have a negative impact on our ability to complete our initial business combination.
Our officers and directors are not required to,
and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time between our operations
and our search for a business combination and their other businesses. We do not intend to have any full-time employees prior to the completion
of our initial business combination. Each of our officers is engaged in other business endeavors for which he may be entitled to substantial
compensation, and our officers are not obligated to contribute any specific number of hours per week to our affairs. Our independent directors
also serve as officers and board members for other entities. If our officers’ and directors’ other business affairs require
them to devote substantial amounts of time to such affairs in excess of their current commitment levels, it could limit their ability
to devote time to our affairs which may have a negative impact on our ability to complete our initial business combination.
Our officers and directors presently have,
and any of them in the future may have additional, fiduciary or contractual obligations to other entities and, accordingly, may have conflicts
of interest in determining to which entity a particular business opportunity should be presented.
Until we consummate our initial business combination,
we intend to engage in the business of identifying and combining with one or more businesses and closing the proposed Sio Business Combination.
Each of our officers and directors presently has, and any of them in the future may have, additional fiduciary or contractual obligations
to other entities pursuant to which such officer or director is or will be required to present a business combination opportunity to such
entities. Accordingly, they may have conflicts of interest in determining to which entity a particular business opportunity should be
presented. These conflicts may not be resolved in our favor and a potential target business may be presented to another entity prior to
its presentation to us, subject to their fiduciary duties under Cayman Islands law. Our Articles provide that, to the fullest extent permitted
by applicable law: (i) no individual serving as a director or an officer shall have any duty, except and to the extent expressly assumed
by contract, to refrain from engaging directly or indirectly in the same or similar business activities or lines of business as us; and
(ii) we renounce any interest or expectancy in, or in being offered an opportunity to participate in, any potential transaction or matter
which may be a corporate opportunity for any director or officer, on the one hand, and us, on the other.
In addition, the Sponsor and our officers and
directors may pursue other business or investment ventures during the period in which we are seeking an initial business combination.
Any such companies, businesses or investments may present additional conflicts of interest in pursuing an initial business combination.
However, our officers and directors have agreed not to participate in the formation of, or become an officer or director of, any other
special purpose acquisition company with a class of securities registered under the Exchange Act, until we have entered into a definitive
agreement regarding our initial business combination or we have failed to complete our initial business combination by the Extended Date.
Our officers, directors, security holders and
their respective affiliates may have competitive pecuniary interests that conflict with our interests.
We have not adopted a policy that expressly prohibits
our directors, officers, security holders or affiliates from having a direct or indirect pecuniary or financial interest in any investment
to be acquired or disposed of by us or in any transaction to which we are a party or have an interest. In fact, we may enter into a business
combination with a target business that is affiliated with the Sponsor, our directors or officers, although we do not intend to do so.
Nor do we have a policy that expressly prohibits any such persons from engaging for their own account in business activities of the types
conducted by us. Accordingly, such persons or entities may have a conflict between their interests and ours.
The personal and financial interests of our directors
and officers may influence their motivation in timely identifying and selecting a target business and completing a business combination.
Consequently, our directors’ and officers’ discretion in identifying and selecting a suitable target business may result in
a conflict of interest when determining whether the terms, conditions and timing of a particular business combination are appropriate
and in our shareholders’ best interest. If this were the case, it could be a breach of their fiduciary duties to us as a matter
of Cayman Islands law and we or our shareholders might have a claim against such individuals for infringing on our shareholders’
rights. However, we might not ultimately be successful in any claim we may make against them for such reason.
We may engage in a business combination with
one or more target businesses that have relationships with entities that may be affiliated with the Sponsor, officers, directors or existing
holders which may raise potential conflicts of interest.
In light of the involvement of the Sponsor, officers
and directors with other entities, we may decide to acquire one or more businesses affiliated with the Sponsor, officers, directors or
existing holders. Our directors also serve as officers and board members for other entities. Such entities may compete with us for business
combination opportunities. Our Sponsor, officers and directors are not currently aware of any specific opportunities for us to complete
our initial business combination with any entities with which they are affiliated, and there have been no substantive discussions concerning
a business combination with any such entity or entities. Although we will not be specifically focusing on, or targeting, any transaction
with any affiliated entities, we would pursue such a transaction if we determined that such affiliated entity met our criteria for a business
combination and such transaction was approved by a majority of our independent and disinterested directors. Despite our agreement to obtain
an opinion from an independent investment banking firm which is a member of FINRA or a valuation or appraisal firm regarding the fairness
to our Company from a financial point of view of a business combination with one or more domestic or international businesses affiliated
with the Sponsor, officers, directors or existing holders, potential conflicts of interest still may exist and, as a result, the terms
of the business combination may not be as advantageous to our public shareholders as they would be absent any conflicts of interest.
We have and may in the future engage our Public
Offering underwriter or one of its affiliates to provide additional services to us, which may include acting as financial advisor in connection
with an initial business combination or as placement agent in connection with a related financing transaction. If our underwriter is entitled
to receive deferred underwriting commissions that will be released from the Trust Account only upon a completion of an initial business
combination, this financial incentive may cause it to have potential conflicts of interest in rendering any such additional services to
us, including, for example, in connection with the sourcing and consummation of an initial business combination.
We have engaged and may engage our Public Offering
underwriter or one of its affiliates to provide additional services to us, including, for example, identifying potential targets, providing
financial advisory services, acting as a placement agent in a private offering or arranging debt financing transactions. We may pay such
underwriter or its affiliate fair and reasonable fees or other compensation that would be determined at that time in an arm’s length
negotiation. For example, as described elsewhere in this Annual Report, on June 8, 2023, we entered into an engagement letter with UBS,
the sole underwriter of our Public Offering, which was subsequently amended on October 26, 2023, pursuant to which we engaged UBS to act
as its exclusive capital markets advisor with respect to the Sio Business Combination. Pursuant to such engagement letter, UBS agreed
to waive the $8,443,750 of deferred underwriting commission owed to it in connection with the Public Offering in exchange for the right
to receive a transaction fee of $5,000,000, plus an incentive fee of up to $3,443,750, each of which is payable upon the closing of the
Sio Business Combination. To the extent the underwriter’s or its affiliate’s financial interests tied to the consummation
of a business combination transaction may give rise to potential conflicts of interest in providing any such additional services to us,
including potential conflicts of interest in connection with the sourcing and consummation of an initial business combination.
Since the Sponsor, officers and directors will
lose their entire investment in us if our initial business combination is not completed (other than with respect to public shares they
may acquire after the Public Offering), a conflict of interest may arise in determining whether a particular business combination target
is appropriate for our initial business combination. Additionally, since our Sponsor only paid approximately $0.004 per Founder Share,
our Sponsor and its permitted transferees could potentially make a substantial profit even if we acquire a target business that subsequently
declines in value.
On February 24, 2021, the Sponsor paid an aggregate
of $25,000 for certain expenses on our behalf in exchange for issuance of 5,750,000 Founder Shares, or approximately $0.004 per share.
On September 29, 2021, the Sponsor surrendered 718,750 Founder Shares to us for cancelation for no consideration, resulting in an aggregate
of 5,031,250 Founder Shares outstanding. Prior to the initial investment in the Company of $25,000 by the Sponsor, the Company had no
assets, tangible or intangible. The purchase price of the Founder Shares was determined by dividing the amount of cash contributed to
the Company by the number of Founder Shares issued. The number of Founder Shares outstanding was determined based on the expectation that
the total size of the Public Offering would be a maximum of 20,125,000 Units if the underwriter’s over-allotment option is exercised
in full, and therefore that such Founder Shares would represent 20% of the outstanding shares after the Public Offering.
The Founder Shares will be worthless if we do
not complete an initial business combination. In addition, our Sponsor purchased an aggregate of 10,156,250 warrants for an aggregate
purchase price of $10,156,250, or $1.00 per warrant. The Private Placement Warrants will also be worthless if we do not complete our initial
business combination. The personal and financial interests of our Sponsor as well as our officers and directors may influence their motivation
in identifying and selecting a target business combination, completing an initial business combination and influencing the operation of
the business following the initial business combination. This risk may become more acute as the deadline for our completion of an initial
business combination nears.
Additionally, since our Sponsor only paid approximately
$0.004 per Founder Share, our Sponsor and its permitted transferees could potentially make a substantial profit even if we acquire a target
business that subsequently declines in value and is unprofitable for public investors. Thus, such parties may have more of an economic
incentive for us to enter into an initial business combination with a riskier, weaker-performing entity or an entity lacking an established
record of revenues or earnings, than would be the case if such parties had paid the full offering price for their Founder Shares.
If our management following our initial business
combination is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar with such laws,
which could lead to various regulatory issues.
Following our initial business combination, our
management may resign from their positions as officers or directors of the Company and the management of the target business at the time
of the business combination will remain in place. Management of the target business may not be familiar with United States securities
laws. If new management is unfamiliar with United States securities laws, they may have to expend time and resources becoming familiar
with such laws. This could be expensive and time-consuming and could lead to various regulatory issues which may adversely affect our
operations.
Risks Relating to our Securities
You will not have any rights or interests in
funds from the Trust Account, except under certain limited circumstances. Therefore, to liquidate your investment, you may be forced to
sell your public shares or warrants, potentially at a loss.
Our public shareholders will be entitled to receive
funds from the Trust Account only upon the earliest to occur of: (i) our completion of an initial business combination, and then only
in connection with those Class A ordinary shares that such shareholder properly elected to redeem, subject to the limitations and the
conditions described herein, (ii) the redemption of any public shares properly submitted in connection with a shareholder vote to amend
our Articles (A) that would modify the substance or timing of our obligation to allow redemption in connection with our initial business
combination or to redeem 100% of our public shares if we do not complete our initial business combination by the Extended Date or (B)
with respect to any other material provisions relating to shareholders’ rights or pre-initial business combination activity, and
(iii) the redemption of our public shares if we have not completed an initial business combination by the Extended Date, subject to applicable
law and as further described herein. In no other circumstances will a public shareholder have any right or interest of any kind in the
Trust Account. Holders of warrants will not have any right to the proceeds held in the Trust Account with respect to the warrants. Accordingly,
to liquidate your investment, you may be forced to sell your public shares or warrants, potentially at a loss.
The NYSE may delist our securities from trading
on its exchange, which could limit investors’ ability to make transactions in our securities and subject us to additional trading
restrictions.
Our Units, Class A ordinary shares and public
warrants are listed on the NYSE. We cannot assure you that our securities will continue to be listed on the NYSE in the future or prior
to our initial business combination. In order to continue listing our securities on the NYSE prior to our initial business combination,
we must maintain certain financial, distribution and share price levels. Generally, we must maintain a minimum amount in shareholders’
equity (generally $2,500,000) and a minimum number of holders of our securities (generally 300 public holders). Additionally, we must
complete our initial business combination within three years of our initial listing date. Further, in connection with our initial business
combination, we will be required to demonstrate compliance with the NYSE’s initial listing requirements, which are more rigorous
than the NYSE’s continued listing requirements, in order to continue to maintain the listing of our securities on the NYSE. For
instance, our share price would generally be required to be at least $4.00 per share and our shareholders’ equity would generally
be required to be at least $5.0 million. We cannot assure you that we will be able to meet those initial listing requirements at that
time.
If the NYSE delists our securities from trading
on its exchange and we are not able to list our securities on another national securities exchange, we expect our securities could be
quoted on an over-the-counter market. If this were to occur, we could face significant material adverse consequences, including:
| ● | a limited availability of market quotations for our securities; |
| ● | reduced liquidity for our securities; |
| ● | a determination that our Class A ordinary shares are a “penny
stock” which will require brokers trading in our Class A ordinary shares to adhere to more stringent rules and possibly result
in a reduced level of trading activity in the secondary trading market for our securities; |
| ● | a limited amount of news and analyst coverage; and |
| ● | a decreased ability to issue additional securities or obtain
additional financing in the future. |
The National Securities Markets Improvement Act
of 1996, which is a federal statute, prevents or preempts the states from regulating the sale of certain securities, which are referred
to as “covered securities.” Our Units, Class A ordinary shares and warrants are listed on the NYSE, and, as a result, qualify
as covered securities under the statute. Although the states are preempted from regulating the sale of our securities, the federal statute
does allow the states to investigate companies if there is a suspicion of fraud, and, if there is a finding of fraudulent activity, then
the states can regulate or bar the sale of covered securities in a particular case. While we are not aware of a state having used these
powers to prohibit or restrict the sale of securities issued by blank check companies, other than the State of Idaho, certain state securities
regulators view blank check companies unfavorably and might use these powers, or threaten to use these powers, to hinder the sale of securities
of blank check companies in their states. Further, if we were no longer listed on the NYSE, our securities would not qualify as covered
securities under the statute and we would be subject to regulation in each state in which we offer our securities.
We may issue additional Class A ordinary shares
or preferred shares to complete our initial business combination or under an employee incentive plan after completion of our initial business
combination. We may also issue Class A ordinary shares upon the conversion of the Founder Shares at a ratio greater than one-to-one at
the time of our initial business combination as a result of the anti-dilution provisions contained therein. Any such issuances would dilute
the interest of our shareholders and likely present other risks.
Our Articles authorize the issuance of up to 200,000,000
Class A ordinary shares, par value $0.0001 per share, 20,000,000 Class B ordinary shares, par value $0.0001 per share, and 1,000,000 preferred
shares, par value $0.0001 per share. There are 185,994,913 and 20,000,000 authorized but unissued Class A ordinary shares and Class B
ordinary shares, respectively, available for issuance, which amount does not take into account shares reserved for issuance upon exercise
of outstanding warrants or shares issuable upon conversion of the Class B ordinary shares. The Class B ordinary shares are automatically
convertible into Class A ordinary shares concurrently with or immediately following the consummation of our initial business combination,
initially at a one-for-one ratio but subject to adjustment as set forth herein and in our Articles, including in certain circumstances
in which we issue Class A ordinary shares or equity-linked securities related to our initial business combination. Immediately after the
Public Offering, there will be no preferred shares issued and outstanding.
We may issue a substantial number of additional
Class A ordinary shares or preferred shares to complete our initial business combination or under an employee incentive plan after completion
of our initial business combination. We may also issue Class A ordinary shares upon conversion of the Class B ordinary shares at a ratio
greater than one-to-one at the time of our initial business combination as a result of the anti-dilution provisions as set forth therein.
However, our Articles provide, among other things, that prior to our initial business combination, we may not issue additional shares
that would entitle the holders thereof to (i) receive funds from the Trust Account or (ii) vote on any initial business combination. These
provisions of our Articles, like all provisions of our Articles, may be amended with a shareholder vote. The issuance of additional ordinary
or preferred shares:
| ● | may significantly dilute the equity interest of investors
in the Public Offering; |
| ● | may subordinate the rights of holders of Class A ordinary
shares if preferred shares are issued with rights senior to those afforded our Class A ordinary shares; |
| ● | could cause a change in control if a substantial number of
Class A ordinary shares are issued, which may affect, among other things, our ability to use our net operating loss carry forwards, if
any, and could result in the resignation or removal of our present officers and directors; and |
| ● | may adversely affect prevailing market prices for our Units,
Class A ordinary shares and/or warrants. |
Resources could be wasted in researching business
combinations that are not completed, which could materially adversely affect subsequent attempts to locate and acquire or merge with another
business. If we have not completed our initial business combination, our public shareholders may only receive their pro rata portion of
the funds in the Trust Account that are available for distribution to public shareholders, and our warrants will expire worthless.
We anticipate that the investigation of each specific
target business and the negotiation, drafting and execution of relevant agreements, disclosure documents and other instruments will require
substantial management time and attention and substantial costs for accountants, attorneys, consultants and others. If we decide not to
complete a specific initial business combination, including the Sio Business Combination, the costs incurred up to that point for the
proposed transaction likely would not be recoverable. Furthermore, if we reach an agreement relating to a specific target business, including
Sio, we may fail to complete our initial business combination for any number of reasons including those beyond our control. Any such event
will result in a loss to us of the related costs incurred which could materially adversely affect subsequent attempts to locate and acquire
or merge with another business. If we have not completed our initial business combination, our public shareholders may only receive their
pro rata portion of the funds in the Trust Account that are available for distribution to public shareholders, and our warrants will expire
worthless.
We may amend the terms of the warrants in a
manner that may be adverse to holders of public warrants with the approval by the holders of at least a majority of the then outstanding
public warrants. As a result, the exercise price of your warrants could be increased, the exercise period could be shortened and the number
of Class A ordinary shares purchasable upon exercise of a warrant could be decreased, all without your approval.
Our warrants were issued in registered form under
a warrant agreement between Continental Stock Transfer & Trust Company, as warrant agent, and us. The warrant agreement provides that
the terms of the warrants may be amended without the consent of any holder to cure any ambiguity or correct any defective provision, but
requires the approval by the holders of at least a majority of the then outstanding public warrants to make any change that adversely
affects the interests of the registered holders of public warrants. Accordingly, we may amend the terms of the public warrants in a manner
adverse to a holder of public warrants if holders of at least a majority of the then outstanding public warrants approve of such amendment.
Although our ability to amend the terms of the public warrants with the consent of at least a majority of the then outstanding public
warrants is unlimited, examples of such amendments could be amendments to, among other things, increase the exercise price of the warrants,
convert the warrants into cash or shares, shorten the exercise period or decrease the number of Class A ordinary shares purchasable upon
exercise of a warrant.
Our warrant agreement designates the courts
of the State of New York or the United States District Court for the Southern District of New York as the sole and exclusive forum for
certain types of actions and proceedings that may be initiated by holders of our warrants, which could limit the ability of warrant holders
to obtain a favorable judicial forum for disputes with our Company.
Our warrant agreement provides that, subject to
applicable law, (i) any action, proceeding or claim against us arising out of or relating in any way to the warrant agreement, including
under the Securities Act, will be brought and enforced in the courts of the State of New York or the United States District Court for
the Southern District of New York, and (ii) that we irrevocably submit to such jurisdiction, which jurisdiction shall be the exclusive
forum for any such action, proceeding or claim. We will waive any objection to such exclusive jurisdiction and that such courts represent
an inconvenient forum.
Notwithstanding the foregoing, these provisions
of the warrant agreement will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim
for which the federal district courts of the United States of America are the sole and exclusive forum. Any person or entity purchasing
or otherwise acquiring any interest in any of our warrants shall be deemed to have notice of and to have consented to the forum provisions
in our warrant agreement. If any action, the subject matter of which is within the scope the forum provisions of the warrant agreement,
is filed in a court other than a court of the State of New York or the United States District Court for the Southern District of New York
(a “foreign action”) in the name of any holder of our warrants, such holder shall be deemed to have consented to: (x) the
personal jurisdiction of the state and federal courts located in the State of New York in connection with any action brought in any such
court to enforce the forum provisions (an “enforcement action”), and (y) having service of process made upon such warrant
holder in any such enforcement action by service upon such warrant holder’s counsel in the foreign action as agent for such warrant
holder.
This choice-of-forum provision may limit a warrant
holder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with our Company, which may discourage
such lawsuits. Alternatively, if a court were to find this provision of our warrant agreement inapplicable or unenforceable with respect
to one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters
in other jurisdictions, which could materially and adversely affect our business, financial condition and results of operations and result
in a diversion of the time and resources of our management and board of directors.
Our Articles provide that the courts of the
Cayman Islands will be the exclusive forums for certain disputes between us and our shareholders, which could limit our shareholders’
ability to obtain a favorable judicial forum for complaints against us or our directors, officers or employees.
Our Articles provide that unless we consent in
writing to the selection of an alternative forum, the courts of the Cayman Islands shall have exclusive jurisdiction over any claim or
dispute arising out of or in connection with our Articles or otherwise related in any way to each shareholder’s shareholding in
us, including but not limited to (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach
of any fiduciary or other duty owed by any of our current or former director, officer or other employee to us or our shareholders, (iii)
any action asserting a claim arising pursuant to any provision of the Companies Act or our Articles, or (iv) any action asserting a claim
against us governed by the internal affairs doctrine (as such concept is recognized under the laws of the United States of America) and
that each shareholder irrevocably submits to the exclusive jurisdiction of the courts of the Cayman Islands over all such claims or disputes.
The forum selection provision in our Articles will not apply to actions or suits brought to enforce any liability or duty created by the
Securities Act, Exchange Act or any claim for which the federal district courts of the United States of America are, as a matter of the
laws of the United States of America, the sole and exclusive forum for determination of such a claim.
Our Articles also provide that, without prejudice
to any other rights or remedies that we may have, each of our shareholders acknowledges that damages alone would not be an adequate remedy
for any breach of the selection of the courts of the Cayman Islands as exclusive forum and that accordingly we shall be entitled, without
proof of special damages, to the remedies of injunction, specific performance or other equitable relief for any threatened or actual breach
of the selection of the courts of the Cayman Islands as exclusive forum.
This choice of forum provision may increase a
shareholder’s cost and limit the shareholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes
with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other
employees. Any person or entity purchasing or otherwise acquiring any of our shares or other securities, whether by transfer, sale, operation
of law or otherwise, shall be deemed to have notice of and have irrevocably agreed and consented to these provisions. There is uncertainty
as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies’
charter documents has been challenged in legal proceedings. It is possible that a court could find this type of provisions to be inapplicable
or unenforceable, and if a court were to find this provision in our Articles to be inapplicable or unenforceable in an action, we may
incur additional costs associated with resolving the dispute in other jurisdictions, which could have adverse effect on our business and
financial performance.
We may redeem your unexpired warrants prior
to their exercise at a time that is disadvantageous to you, thereby making your warrants worthless.
We have the ability to redeem outstanding warrants
at any time after they become exercisable and prior to their expiration, at a price of $0.01 per warrant, provided that the closing price
of our Class A ordinary shares equals or exceeds $18.00 per share (adjustments to the number of shares issuable upon exercise or the exercise
price of a warrant) for any 20 trading days within a 30 trading-day period ending on the third trading day prior to the date on which
we send notice of such redemption to the warrants holders and provided certain other conditions are met. If and when the warrants become
redeemable by us, we may exercise our redemption right even if we are unable to register or qualify the underlying securities for sale
under all applicable state securities laws. As a result, we may redeem the warrants as set forth above even if the holders are otherwise
unable to exercise the warrants. Redemption of the outstanding warrants could force you to (i) exercise your warrants and pay the exercise
price therefor at a time when it may be disadvantageous for you to do so, (ii) sell your warrants at the then-current market price when
you might otherwise wish to hold your warrants or (iii) accept the nominal redemption price which, at the time the outstanding warrants
are called for redemption, is likely to be substantially less than the market value of your warrants.
In addition, we have the ability to redeem the
outstanding public warrants at any time after they become exercisable and prior to their expiration, at a price of $0.10 per warrant upon
a minimum of 30 days’ prior written notice of redemption provided that the closing price of our Class A ordinary shares equals or
exceeds $10.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise price of a warrant)
for any 20 trading days within a 30-trading day period ending on the third trading day prior to proper notice of such redemption and provided
that certain other conditions are met, including that holders will be able to exercise their warrants prior to redemption for a number
of Class A ordinary shares determined based on the redemption date and the fair market value of our Class A ordinary shares. The value
received upon exercise of the warrants (1) may be less than the value the holders would have received if they had exercised their warrants
at a later time where the underlying share price is higher and (2) may not compensate the holders for the value of the warrants, including
because the number of ordinary shares received is capped at 0.361 Class A ordinary shares per warrant (subject to adjustment) irrespective
of the remaining life of the warrants.
None of the Private Placement Warrants will be
redeemable by us so long as they are held by the Sponsor or its permitted transferees.
Our warrants may have an adverse effect on
the market price of our Class A ordinary shares and make it more difficult to effectuate our initial business combination.
We issued warrants to purchase 10,062,500 of our
Class A ordinary shares as part of the Units sold in the Public Offering and, simultaneously with the Public Offering, we issued in a
Private Placement an aggregate of 10,156,250 Private Placement Warrants, each exercisable to purchase one Class A ordinary share at $11.50
per share. In addition, the Sponsor may convert any of the IPO Working Capital Loans into up to an additional 1,500,000 Private Placement
Warrants, at the price of $1.00 per warrant and it may also convert the Extension Note into up to 1,920,000 Private Placement Warrants,
at a price of $1.00 per warrant. To the extent we issue ordinary shares to effectuate a business combination transaction, the potential
for the issuance of a substantial number of additional Class A ordinary shares upon exercise of these warrants could make us a less attractive
acquisition vehicle to a target business. Such warrants, when exercised, will increase the number of issued and use outstanding Class
A ordinary shares and reduce the value of the Class A ordinary shares issued to complete the business transaction. Therefore, our warrants
may make it more difficult to effectuate a business transaction or increase the cost of acquiring the target business.
The Private Placement Warrants are identical to
the warrants included in the Units sold in the Public Offering, except that, so long as they are held by their initial purchasers or their
permitted transferees, (i) they will not be redeemable by the Company, (ii) they (including the Class A ordinary shares issuable upon
exercise of these warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the Company
completes its initial business combination, (iii) they may be exercised by the holders on a cashless basis and (iv) they will be entitled
to registration rights.
Our warrants are expected to be accounted for
as a warrant liability and will be recorded at fair value upon issuance with changes in fair value each period reported in earnings, which
may have an adverse effect on the market price of our Class A ordinary shares or may make it more difficult for us to consummate an initial
business combination.
We issued an aggregate of 20,218,750 warrants
in connection with the Public Offering and Private Placement. We expect to account for these warrants as a warrant liability and will
record at fair value upon issuance any changes in fair value each period reported in earnings as determined by us based upon a valuation
report obtained from its independent third party valuation firm. The impact of changes in fair value on earnings may have an adverse effect
on the market price of our Class A ordinary shares. In addition, potential targets may prefer combining with a special purpose acquisition
company that does not have warrants that are accounted for as a warrant liability, which may make it more difficult for us to consummate
an initial business combination with a target business.
Because each Unit contains one-half of one
warrant and only a whole warrant may be exercised, the Units may be worth less than Units of other special purpose acquisition companies.
Each Unit contains one-half of one warrant. Pursuant
to the warrant agreement, no fractional warrants were issued upon separation of the Units, and only whole Units can trade. If, upon exercise
of the warrants, a holder would be entitled to receive a fractional interest in a share, we will, upon exercise, round down to the nearest
whole number the number of Class A ordinary shares to be issued to the warrant holder. This is different from other offerings similar
to ours whose Units include one ordinary share and one warrant to purchase one whole share. We have established the components of the
Units in this way in order to reduce the dilutive effect of the warrants upon completion of a business combination since the warrants
will be exercisable in the aggregate for one-half of the number of shares compared to Units that each contain a whole warrant to purchase
one share, thus making us, we believe, a more attractive merger partner for target businesses. Nevertheless, this unit structure may cause
our Units to be worth less than if it included a warrant to purchase one whole share.
The Private Placement Warrants are identical to
the warrants included in the Units sold in the Public Offering, except that, so long as they are held by their initial purchasers or their
permitted transferees, (i) they will not be redeemable by the Company, (ii) they (including the Class A ordinary shares issuable upon
exercise of these warrants) may not, subject to certain limited exceptions, be transferred, assigned or sold until 30 days after the Company
completes its initial business combination, (iii) they may be exercised by the holders on a cashless basis and (iv) they will be entitled
to registration rights.
General Risk Factors
We are an emerging growth company and a smaller
reporting company within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements
available to emerging growth companies or smaller reporting companies, this could make our securities less attractive to investors and
may make it more difficult to compare our performance with other public companies.
We are an “emerging growth company”
within the meaning of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting
requirements that are applicable to other public companies that are not emerging growth companies, including, but not limited to, not
being required to comply with the auditor internal controls attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced
disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements
of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously
approved. As a result, our shareholders may not have access to certain information they may deem important. We could be an emerging growth
company for up to five years, although circumstances could cause us to lose that status earlier, including if the market value of our
Class A ordinary shares held by non-affiliates exceeds $700 million as of any June 30 before that time, in which case we would no longer
be an emerging growth company as of the following December 31. We cannot predict whether investors will find our securities less attractive
because we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions,
the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities
and the trading prices of our securities may be more volatile.
Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such an election to opt out is irrevocable. We have elected not to opt out of such extended transition period which means that when
a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company,
can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our
financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has
opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards
used.
Additionally, we are a “smaller
reporting company” as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain
reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will
remain a smaller reporting company until the last day of the fiscal year in which (1) the market value of our ordinary shares held
by non-affiliates exceeds $250 million as of the prior June 30, or (2) our annual revenues exceeded $100 million during such
completed fiscal year and the market value of our ordinary shares held by non-affiliates exceeds $700 million as of the prior June
30th. To the extent we take advantage of such reduced disclosure obligations, it may also make comparison of our financial statements
with other public companies difficult or impossible.
Provisions in our Articles may inhibit a takeover
of us, which could limit the price investors might be willing to pay in the future for our Class A ordinary shares and could entrench
management.
Our Articles contain provisions that may discourage
unsolicited takeover proposals that shareholders may consider to be in their best interests. These provisions include a staggered board
of directors and the ability of the board of directors to designate the terms of and issue new series of preferred shares, which may make
the removal of management more difficult and may discourage transactions that otherwise could involve payment of a premium over prevailing
market prices for our securities.
Our Sponsor, which has committed to provide
certain loans to us, may not have the necessary funds to do so.
While the Sponsor has committed to loan us an
aggregate of $1,500,000 for working capital purposes at any time upon our request and $1.92 million to fund the Extension Contributions.
We cannot provide any assurances that such funding will occur. We are an early-stage company without operating revenues or significant
financial support. Accordingly, a failure by the Sponsor to fund such committed sponsor loans may impact our ability to obtain director
and officer insurance on favorable terms, fund our activities or consummate an initial business combination.
Because we are incorporated under the laws
of the Cayman Islands, you may face difficulties in protecting your interests, and your ability to protect your rights through the U.S.
Federal courts may be limited.
We are an exempted company incorporated under
the laws of the Cayman Islands. As a result, it may be difficult for investors to effect service of process within the United States upon
our directors or officers, or enforce judgments obtained in the United States courts against our directors or officers.
Our corporate affairs will be governed by our
Articles, the Companies Act (as the same may be supplemented or amended from time to time) and the common law of the Cayman Islands. We
will also be subject to the federal securities laws of the United States. The rights of shareholders to take action against the directors,
actions by minority shareholders and the fiduciary responsibilities of our directors to us under Cayman Islands law are to a large extent
governed by the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial
precedent in the Cayman Islands as well as from English common law, the decisions of whose courts are of persuasive authority, but are
not binding on a court in the Cayman Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under
Cayman Islands law are different from what they would be under statutes or judicial precedent in some jurisdictions in the United States.
In particular, the Cayman Islands has a different body of securities laws as compared to the United States, and certain states, such as
Delaware, may have more fully developed and judicially interpreted bodies of corporate law. In addition, Cayman Islands companies may
not have standing to initiate a shareholders derivative action in a Federal court of the United States.
We have been advised by Maples and Calder (Cayman)
LLP, Cayman Islands legal counsel that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments
of courts of the United States predicated upon the civil liability provisions of the federal securities laws of the United States or any
state; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability
provisions of the federal securities laws of the United States or any state, so far as the liabilities imposed by those provisions are
penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the
United States, the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction
without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an
obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced
in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine
or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained
in a manner, or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards
of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings
if concurrent proceedings are being brought elsewhere.
As a result of all of the above, public shareholders
may have more difficulty in protecting their interests in the face of actions taken by management, members of the board of directors or
controlling shareholders than they would as public shareholders of a United States company.
Cyber incidents or attacks directed at us
or third parties could result in information theft, data corruption, operational disruption and/or financial loss.
We depend on digital technologies, including
information systems, infrastructure and cloud applications and services, including those of third parties with which we may deal.
Sophisticated and deliberate attacks on, or security breaches in, the systems or infrastructure or the cloud that we utilize,
including those of third parties, could lead to corruption or misappropriation of our assets, proprietary information and sensitive
or confidential data. As an early stage company without significant investments in data security protection, we may not be
sufficiently protected against such occurrences. We may not have sufficient resources to adequately protect against, or to
investigate and remediate any vulnerability to, cyber incidents. It is possible that any of these occurrences, or a combination of
them, could have adverse consequences on our business and lead to financial loss.
The 1% U.S. federal excise tax on stock
buybacks could be imposed on redemptions of our stock if we were to become a “covered corporation” in the future.
On August 16, 2022, President Biden signed into
law the Inflation Reduction Act of 2022 (the “IR Act”), which, among other things, generally imposes a 1% U.S. federal excise
tax (the “Excise Tax”) on certain repurchases of stock by “covered corporations” (which include publicly traded
domestic (i.e., U.S.) corporations and certain domestic subsidiaries of publicly traded foreign (i.e., non-U.S.) corporations) occurring
on or after January 1, 2023. The Excise Tax is imposed on the repurchasing corporation itself, not its shareholders from which the stock
is repurchased. The amount of the Excise Tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase.
However, for purposes of calculating the Excise Tax, repurchasing corporations are permitted to net the fair market value of certain new
stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply
to the Excise Tax. The U.S. Department of the Treasury (the “Treasury”) has authority to provide regulations and other guidance
to carry out, and prevent the abuse or avoidance of the Excise Tax. On December 27, 2022, the Treasury issued a notice that provides interim
operating rules for the Excise Tax, including rules governing the calculation and reporting of the Excise Tax, on which taxpayers may
rely until the forthcoming proposed Treasury regulations addressing the Excise Tax are published. Although such notice clarifies certain
aspects of the Excise Tax, the interpretation and operation of other aspects of the Excise Tax remain unclear, and such interim operating
rules are subject to change.
We are currently not a covered corporation for
purposes of the Excise Tax. If we were to become a covered corporation in the future, whether in connection with the consummation of our
business combination with a U.S. company (including if we were to redomicile as a U.S. corporation in connection therewith) or otherwise,
whether and to what extent we would be subject to the Excise Tax on a redemption of our stock would depend on a number of factors, including
(i) whether the redemption is treated as a repurchase of stock for purposes of the Excise Tax, (ii) the fair market value of the redemption
treated as a repurchase of stock, (iii) the structure of our business combination, (iv) the nature and amount of any “PIPE”
or other equity issuances (whether in connection with our business combination or otherwise) issued within the same taxable year of a
redemption treated as a repurchase of stock and (v) the content of forthcoming regulations and other guidance from the Treasury. As noted
above, the Excise Tax would be payable by the repurchasing corporation, and not by the redeeming holder, and only limited guidance on
the mechanics of any required reporting and payment of the Excise Tax on which taxpayers may rely have been issued to date. If we were
to become a covered corporation in the future, the per-share redemption amount payable from the Trust Account (including any interest
earned on the funds held in the Trust Account) to our public shareholders in connection with a redemption of our stock is not expected
to be reduced by any Excise Tax imposed on us. The imposition of the Excise Tax on us could, however, cause a reduction in the cash available
on hand to complete our business combination and may affect our ability to complete our business combination or fund future operations.
We identified material weaknesses in our
internal control over financial reporting during the year ended December 31, 2023 related to our internal control over financial reporting.
If we are unable to maintain an effective system of disclosure controls and procedures and internal control over financial reporting,
we may not be able to accurately report our financial results in a timely manner, which may adversely affect investor confidence in us
and materially and adversely affect our business and financial results.
In connection with the preparation and audit
of our financial statements, material weaknesses were identified in our internal control over financial reporting as of December 31, 2023.
We experienced difficulty in the accounting
and reporting related to the existence of assets, the accounting and reporting for the completeness and accuracy of our liabilities and
the corresponding expenses, as well as the accounting for complex financial instruments, and related party transactions which we experienced
and reported as a material weakness in our Annual Report on Form 10-K for the year ended December 31, 2023.
A material weakness is a deficiency, or combination
of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement
of our annual or interim financial statements will not be prevented or detected on a timely basis. Effective internal controls are necessary
for us to provide reliable financial reports and prevent fraud. We have and continue to take steps to remediate the material weakness,
but there is no assurance that any remediation efforts will ultimately have the intended effects.
If we identify any new material weaknesses
in the future, any such newly identified material weakness could limit our ability to prevent or detect a misstatement of our accounts
or disclosures that could result in a material misstatement of our annual or interim financial statements. In such case, we may be unable
to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange
listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. We cannot
assure stockholders that the measures we have taken to date, or any measures we may take in the future, will be sufficient to avoid potential
future material weaknesses.
ITEM 1B. UNRESOLVED STAFF COMMENTS.
None.
ITEM 1C. Cybersecurity.
As a blank check company, we have no operations
and therefore do not have any operations of our own that face cybersecurity threats. However, we do depend on the digital technologies
of third parties, and as noted in Item 1A. Risk Factors of this Annual Report, any sophisticated and deliberate attacks on, or security
breaches in, systems or infrastructure or the cloud that we utilize, including those of third parties, could lead to corruption or misappropriation
of our assets, proprietary information and sensitive or confidential data. Because of our reliance on the technologies of third parties,
we also depend upon the personnel and the processes of third parties to protect against cybersecurity threats, and we have no personnel
or processes of our own for this purpose. Our board of directors oversees risk for our Company, and prior to filings with the SEC, our
board of directors reviews our risk factors, including the descriptions of the risks we face from cybersecurity threats, as described
in Item 1A. Risk Factors of this Annual Report.
ITEM 2. PROPERTIES.
We maintain executive offices at 3262 Westheimer
Road, Suite 706, Houston, TX 77098 pursuant to an agreement with the Sponsor. We consider our current office space, combined with the office space otherwise
available to our executive officers, adequate for our current operations.
ITEM 3. LEGAL PROCEEDINGS.
As of December 31, 2023, to the knowledge of our
management, there was no material litigation, arbitration or governmental proceeding pending against us or any members of our management
team in their capacity as such, and we and the members of our management team have not been subject to any such proceeding.
ITEM 4. MINE SAFETY DISCLOSURES.
Not applicable.
PART II
ITEM 5. MARKET FOR REGISTRANT’S COMMON
EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.
Market Information
Our Units, Class A ordinary shares and warrants
listed on the NYSE under the symbols “PHYT.U”, “PHYT” and “PHYT WS”, respectively.
Holders
As of December 31, 2023, there was one holder
of record of our Units, two holders of record of our Class A ordinary shares and two holders of record of our warrants. The number of
holders of record does not include a substantially greater number of “street name” holders or beneficial holders whose Units,
Class A ordinary shares and warrants are held of record by banks, brokers and other financial institutions.
Dividends
We have not paid any cash dividends on our ordinary
shares to date and do not intend to pay cash dividends prior to the completion of an initial business combination. The payment of cash
dividends in the future will be dependent upon our revenues and earnings, if any, capital requirements and general financial conditions
subsequent to completion of an initial business combination. The payment of any cash dividends subsequent to an initial business combination
will be within the discretion of our board of directors at such time. If we incur any indebtedness, our ability to declare dividends may
be limited by restrictive covenants we may agree to in connection therewith.
Securities Authorized for Issuance under
Equity Compensation Plans
None.
Recent Sales of Unregistered Securities;
Use of Proceeds from Registered Offerings
None.
ITEM 6. [RESERVED].
ITEM 7. MANAGEMENT’S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.
References to the
“Company,” “us,” “our” or “we” refer Pyrophyte Acquisition Corp. The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with our audited consolidated financial
statements and related notes included herein.
Cautionary Note Regarding Forward-Looking
Statements
All statements other
than statements of historical fact included in this Annual Report including, without limitation, statements under “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” regarding the Company’s financial position, business
strategy and the plans and objectives of management for future operations, are forward-looking statements. When used in this Annual Report,
words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and
similar expressions, as they relate to us or the Company’s management, identify forward-looking statements. Such forward-looking
statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s
management. Actual results could differ materially from those contemplated by the forward- looking statements as a result of certain factors
detailed in our filings with the SEC. All subsequent written or oral forward-looking statements attributable to us or persons acting on
the Company’s behalf are qualified in their entirety by this paragraph.
Overview
We are a blank check company formed under the
laws of Cayman Islands on February 12, 2021 for the purpose of effecting a merger, share exchange, asset acquisition, share purchase,
reorganization or other similar business combination with one or more businesses. While we may pursue an initial business combination
opportunity in any industry or sector, we will seek targets around the world that we believe are market leaders in facilitating energy
transition toward decarbonization and sustainable use of energy and natural resources, and are positioned to generate long-term value
and growing cash flows. In particular, we will seek to identify companies provide the necessary products, equipment, services and technologies
to support the energy transition, without the need to have their business rely solely on a single type of technology. We believe our leadership
team’s broad and diverse global network of transaction sources and relationships across a wide spectrum of renewable energy sectors
will allow us to effectively and efficiently identify and evaluate potential opportunities for our initial business combination.
We intend to effectuate our initial business combination,
including the Sio Business Combination, using cash from the proceeds of the Initial Public Offering and the sale of the Private Placement
Warrants, and our capital stock, debt or a combination of cash, stock and debt. Our registration statement for the Initial Public Offering
became effective on October 26, 2021. We consummated the Initial Public Offering of 20,125,000 Units on October 29, 2021. Each Unit consisted
of one Class A ordinary share and one-half of one redeemable warrant, including the issuance of 2,625,000 Units as a result of the underwriter’s
exercise of its over-allotment option in full. Each Unit consists of one Class A ordinary share and one-half of one redeemable warrant,
with each public warrant entitling the holder thereof to purchase one Class A ordinary share for $11.50 per share, subject to adjustment.
The Units were sold at a price of $10.00 per Unit, generating gross proceeds to the Company of $201,250,000, and incurred $11,068,750
in underwriting fees (inclusive of $8,443,750 in deferred underwriting fees).
Simultaneously with the closing of the Initial
Public Offering on October 29, 2021, we completed the closing of the Private Placement of an aggregate 10,156,250 Private Placement Warrants
at a price of $1.00 per Private Placement Warrant to the Sponsor, generating proceeds of $10,156,250.
Upon the closing of the Initial Public Offering,
the over-allotment and the Private Placement, $206,281,250 ($10.25 per unit) of the net proceeds of the sale of the Units in the Initial
Public Offering, the over-allotment and the Private Placement were placed in the Trust Account with Continental Stock Transfer & Trust
Company acting as trustee. Such proceeds were invested in United States government treasury bills with a maturity of 185 days or less
or in money market funds investing solely in U.S. Treasuries and meeting certain conditions under Rule 2a-7 under the Investment Company
Act, as determined by us, until April 2024, when the trustee liquidated such investments and moved the proceeds to an interest-bearing
demand deposit account. The proceeds will be held in such account until the earlier of: (i) the completion of a business combination and
(ii) the distribution of the Trust Account as described below.
On April 24, 2023, we held an extraordinary general
meeting of shareholders (the “First Extension Meeting”), pursuant to which our shareholders approved an amendment to the Articles
to extend the date by which the Company must complete initial business combination from April 29, 2023 to April 29, 2024 (or such earlier
date as determined by our board of directors and included in a public announcement) (the “Extension”). In connection therewith,
the Sponsor agreed to loan us $160,000 for each calendar month beginning on April 30, 2023 and ending on the earlier of the completion
of a business combination or the date of the our liquidation in accordance with the terms of the Extension, up to a maximum aggregate
amount of $1.92 million (the “Extension Contribution”). On May 4, 2023, we issued a convertible promissory note (the “Extension
Note”) to the Sponsor with a principal amount up to $1.92 million. The Sponsor deposited the first Extension Contribution on April
30, 2023. As of December 31, 2023, $960,000 has been drawn on the Extension Note and there were Trust Account deposits in connection with
the Extension Note, totaling $960,000. On April 22, 2024, the Company deposited $960,000 into the Trust Account, which amount reflected
the payment in full of the Company’s remaining commitment to make an aggregate of $1.92 million of cash contributions to the Trust
Account in connection with the Extension. Pursuant to the Extension Note, the Sponsor may convert the principal outstanding into Private
Placement Warrants at $1.00 per warrant. In connection with the vote to approve the Extension, the holders of 11,151,163 Class A ordinary
shares properly exercised their right to redeem their shares for cash at a redemption price of approximately $10.56 per share, for an
aggregate redemption amount of approximately $118 million, resulting in 8,973,837 public shares remaining.
At the First Extension Meeting, the shareholders also approved a proposal
to provide the holders of the Class B ordinary shares with the right to convert such shares into Class A ordinary shares on a one-for-one
basis prior to the closing of an initial business combination at the election of such holder. On April 28, 2023, the Sponsor elected to
convert 5,031,250 Class B ordinary shares held by it, which represented all of the Class B ordinary shares outstanding into Class A ordinary
shares on a one-for-one basis for no consideration.
Our management and our board of directors have
broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering, the over-allotment and the
sale of Private Placement Warrants, although substantially all of the net proceeds are intended to be applied generally toward consummating
a business combination.
If we have not completed our initial business
combination by the Extended Date, we will (i) cease all operations except for the purpose of winding up; (ii) as promptly as reasonably
possible but not more than ten business days thereafter, redeem the public shares, at a per-share price, payable in cash, equal to the
aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously
released to us (less taxes payable and up to $100,000 of interest to pay dissolution expenses), divided by the number of the then-outstanding
public shares, which redemption will completely extinguish public shareholders’ rights as shareholders (including the right to receive
further liquidation distributions, if any); and (iii) as promptly as reasonably possible following such redemption, subject to the approval
of the remaining shareholders and the board of directors, liquidate and dissolve, subject in the case of clauses (ii) and (iii), to our
obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law.
Business Combination with Sio
On November 13, 2023, Pyrophyte, Sio, Sio Newco
and Pyrophyte Newco entered into a Business Combination Agreement, pursuant to which, among other things and subject to the terms and
conditions contained in the Business Combination Agreement and the Plan of Arrangement, (i) Pyrophyte will deregister in the Cayman Islands
and transfer by way of continuation from the Cayman Islands to the Province of Alberta, Canada in accordance with the Pyrophyte Articles
and the Companies Act and continue as an Alberta corporation in accordance with the applicable provisions of ABCA, (ii) Pyrophyte will
amalgamate with Sio Newco, with Sio Newco surviving as Pubco in accordance with the terms of the Plan of Arrangement and (iii) Sio and
Pyrophyte Newco will amalgamate, with Sio surviving the Sio Amalgamation as a wholly-owned subsidiary of Pubco, and such entity will continue
the business operations currently undertaken by Sio.
Subscription Agreements
Concurrently with the execution of the Sio Business
Combination Agreement, Pyrophyte, Sio and Sio Newco entered into subscription agreements with (i) a certain accredited investor (the “Non-Insider
PIPE Investor”) and (ii) certain other accredited investors who are existing shareholders of Sio or the Company (the “Insider
PIPE Investors” and, together with the Non-Insider PIPE Investor, the “PIPE Investors”), pursuant to which, among other
things, Sio Newco agreed to issue and sell, in a private placement to close concurrently with and conditioned upon the effectiveness of
the consummation of the Sio Business Combination, an aggregate of 3,114,258 Pubco Class A Common Shares (the “PIPE Investment”)
to the PIPE Investors for an aggregate purchase price equal to $20,122,474.
Non-Redemption Agreement
Concurrently with the execution of the Sio Business Combination Agreement,
Pyrophyte and Sio Newco entered into a non-redemption agreement (the “Non-Redemption Agreement”) with a Company shareholders
with respect to 100,000 Class A ordinary shares held by such shareholder (the “Non-Redemption SPAC Shares”), pursuant to which,
among other things, the Company agreed to issue 58,570 Class A ordinary shares to such shareholder in consideration of such shareholder’s
commitment not to redeem the Non-Redemption SPAC Shares held by it in connection with the approval of the Sio Business Combination by
the Company’s shareholders (the “Non-Redemption Transaction”).
Sponsor Support Agreement
Concurrently with the execution of the Sio Business
Combination Agreement, the Sponsor, entered into a letter agreement (the “Sponsor Support Agreement”) with Sio, Sio Newco,
Pyrophyte and the directors and officers (or otherwise a part of the management team) of Pyrophyte, solely for purposes of amending certain
of the terms of the letter agreement signed by them in connection with the Company’s Initial Public Offering, pursuant to which,
among other things, the Sponsor agreed to among other things, vote all Class A ordinary shares, or any securities convertible into, exercisable
or exchangeable for Class A ordinary shares, held by it or acquired after the date of the Sponsor Support Agreement (the “Covered
Shares”) at the meeting of Pyrophyte shareholders to be held in connection with the Sio Business Combination in favor of the adoption
and approval of the Sio Business Combination and each other proposal related to the Sio and not transfer any Covered Shares (other than
Pubco Class A Common Shares issued upon exercise of any Private Placement Warrants held by the Sponsor) until the earlier of (A) one year
after the Closing, (B) the first day the last sale price of Pubco Class A Common Shares equals or exceeds $12.00 per share for any 20
trading days within a 30-day trading period commencing at least 150 days after the Closing or (C) after the Closing, the date on which
Pubco completes a liquidation, amalgamation, share exchange or similar transaction resulting in the shareholders of Pubco having the right
to exchange their shares for consideration.
In addition, under the terms of the Sponsor Support
Agreement, the Pyrophyte Sponsor has agreed to subject up to 4,025,000 Class A ordinary shares (“Restricted Owned Shares”)
to certain earn out restrictions, if and only to the extent such shares are used to obtain any additional PIPE Financing or other financing
arrangements in connection with the consummation of the Sio Business Combination; provided that in no event shall the aggregate number
of Restricted Owned Shares equal more than 4,025,000 Class A ordinary shares (the “Maximum Restricted Owned Shares”). If,
prior to the Closing, the SPAC Proceeds are less than $70,000,000, then the number of Restricted Owned Shares will be adjusted pursuant
to the terms of the Sponsor Support Agreement.
In connection with the Closing, each Restricted
Owned Share will be exchanged on a one-for-one basis for Pubco Class A Common Shares pursuant to the Sio Business Combination and the
Plan of Arrangement and such shares will be subject to forfeiture or release as follows: (i) half of the Restricted Owned Shares will
be released to the Sponsor on the first day that the Trading Price (as defined in the Sio Business Combination Agreement) is at least
$12.50, (ii) the other half of the Restricted Owned Shares will be released from forfeiture on the first day that the Trading Price is
at least $15.00, in each case during the period commencing on the Closing Date and ending on the date that is three (3) years after the
Closing Date (the “End Date”), and (iii) after the End Date, any Restricted Owned Shares that have not been released to the
Sponsor pursuant to clauses (i) or (ii) above will be automatically forfeited for no consideration. If a change of control of Pubco occurs
at any time between the Closing Date and the End Date and the price achieved per Restricted Owned Shares is at least $12.50 or $15.00,
then the vesting conditions outlined will be considered to be met.
Sio Securityholder Support Agreements
In connection with the execution of the Sio Business
Combination Agreement, on November 13, 2023, the Company, Sio, and certain securityholders of Sio entered into support agreements (the
“Sio Securityholder Support Agreements”), pursuant to which, among other things, such shareholders agreed to vote (or cause
to be voted) all of their Sio shares and other voting securities of Sio (“Subject Securities”) in favor of the special resolution
of Sio shareholders in respect of the Plan of Arrangement, to be considered at Sio’s shareholders meeting to approve the Sio Business
Combination. Additionally, such shareholders have agreed, among other things, not to, prior to the Closing, (a) transfer any of their
Subject Securities (or enter into any agreement, arrangement or understanding in connection therewith other than pursuant to the Plan
of Arrangement), subject to certain customary exceptions, or (b) enter into any voting arrangement that is inconsistent with the Sio
Securityholder Support Agreements. Sio covenants in the Sio Business Combination Agreement that it will use commercially reasonable efforts
to obtain Sio Securityholder Support Agreements from at least 66⅔% of its shareholders as promptly as possible, but in any event, within
five days of the execution date of the Sio Business Combination Agreement.
Results of Operations
We have neither engaged in any operations nor
generated any revenues to date. Our only activities since February 12, 2021 (inception) have been organizational activities, the Initial
Public Offering and identifying and evaluating a target company for an initial business combination and activities in connection with
the Sio Business Combination. and those necessary to prepare for the Initial Public Offering. We have not generated any operating revenues
until after completion of our initial business combination. We will generate non-operating income in the form of interest or dividend
income on the investments held in the Trust Account. There has been no significant change in our financial or trading position and no
material adverse change has occurred since the date of our audited consolidated financial statements. Since the Initial Public Offering,
we have incurred increased expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance),
as well as for due diligence expenses.
For the year ended December 31, 2023, we had a
net income of $2,530,622, which consists of general and administrative expenses of $3,371,589 and a change in fair value of derivative
warrant liabilities of $101,094, offset by a gain on investments held in Trust Account of $6,003,305.
For the year ended December 31, 2022, we had a net income of $10,643,117,
which consists of general and administrative expenses of $2,699,342 and a change in fair value of derivative warrant liabilities of $9,990,487,
offset by a gain on investments held in Trust Account of $3,351,889 and other income of $83.
Liquidity and Capital Resources
For the year ended December 31, 2023, cash used
in operating activities was $760,441. This was made up of a net income of $2,530,622, changes in operating assets and liabilities of $2,611,148,
offset by a change in fair value of derivative warrant liabilities of $101,094 and a $6,003,305 gain on investments held in Trust Account.
For the year ended December 31, 2022, cash used in operating activities
was $903,823. This was made up of a net income of $10,643,117 changes in operating assets and liabilities of $1,795,444, a decrease in
fair value of derivative warrant liabilities of $9,990,487 and a $3,351,897 gain on marketable securities.
We intend to use substantially all of the funds
held in the Trust Account, including any amounts representing interest earned on the Trust Account, excluding deferred underwriting commissions,
to complete our initial Business Combination. We may withdraw interest from the Trust Account to pay taxes, if any. To the extent that
our share capital or debt is used, in whole or in part, as consideration to complete a Business Combination, the remaining proceeds held
in the Trust Account will be used as working capital to finance the operations of the target business or businesses, make other acquisitions
and pursue our growth strategies.
We intend to use the funds held outside the Trust
Account primarily to identify and evaluate target businesses, perform business due diligence on prospective target businesses, travel
to and from the offices, plants or similar locations of prospective target businesses or their representatives or owners, review corporate
documents and material agreements of prospective target businesses, structure, negotiate and complete a business combination.
Going Concern Considerations
As of December 31, 2023, the Company had $1,253
in cash and no cash equivalents. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its
financing and acquisition plans. Management’s plans to address this need for capital through completing the Sio Business Combination
and the IPO Working Capital Loan. The Company cannot assure that its plans to consummate an initial business combination will be successful.
If the Company’s estimates of the costs of identifying a target business, undertaking in-depth due diligence, and negotiating a
Business Combination are less than the actual amount necessary to do so, the Company may have insufficient funds available to operate
its business prior to an initial business combination. The liquidation deadline for the Company is also currently within the next twelve
months if an initial business combination is not consummated. The Company cannot assure that its plans to consummate the Sio Business
Combination or any initial business combination will be successful.
The Company
is a Special Purpose Acquisition Corporation with a currently scheduled liquidation date of April 29, 2025. There can be no assurance
that the Company will be able to consummate an initial business combination by April 29, 2025 (or such date as such deadline may
be extended). In connection with the Company’s assessment of going concern considerations in accordance with Financial Accounting
Standard Board’s Accounting Standards Update (“ASU”) 2014-15, “Disclosures
of Uncertainties about an Entity’s Ability to Continue as a Going Concern,” management has determined that if the Company
is unable to complete an initial business combination and raise additional funds to alleviate liquidity needs and since the mandatory
liquidation deadline is less than 12 months away, there is substantial doubt that the Company will operate as a going concern. No adjustments
have been made to the carrying amounts of assets or liabilities should the Company be required to liquidate after the Extended Date. These
consolidated financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification
of the liabilities that might be necessary should the Company be unable to continue as a going concern.
Commitments and Contractual Obligations
For the years ended December 31, 2023 and 2022,
we did not have any long-term debt, capital lease obligations, operating lease obligations or long-term liabilities.
Registration Rights
The holders of Founder Shares and Private Placement Warrants that may
be issued upon conversion of the IPO Working Capital Loan or the Extension Note (and any Class A ordinary shares issuable upon the exercise
of the Private Placement Warrants issued upon conversion of such loans), are entitled to registration rights pursuant to a registration
rights agreement signed in connection with the Initial Public Offering. These holders are entitled to certain demand and “piggyback”
registration rights.
The holders of
these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. These holders
will be entitled to certain demand and “piggyback” registration rights. We will bear the expenses incurred in connection with
the filing of any such registration statements.
Underwriting Agreement
We granted the underwriter a 45-day option from
the final prospectus relating to the Initial Public Offering to purchase up to 2,625,000 additional Units to cover over-allotments, if
any, at the Initial Public Offering price less the underwriting discounts and commissions. On October 29, 2021, the underwriter fully
exercised its over-allotment option.
Additionally, the underwriter is entitled to
a deferred underwriting discount of 4% of the gross proceeds of the base portion of the Public Offering and a deferred underwriting discount
of 5.5% of the gross proceeds per over-allotment unit upon the completion of the Company’s initial business combination.
On June 8, 2023, the Company modified the terms of UBS’s deferred
underwriting discount, which is effective as of the closing of the Sio Business Combination. See “—Modifications to the
Initial Public Offering Underwriters’ Deferred Discount” for more information.
Administrative Support Agreement
The Company agreed to pay the Sponsor a total
of $15,000 per month, commencing on the effective date of the Initial Public Offering, for utilities, secretarial and administrative
support services provided to members of the management team, which amount was decreased to $5,000 per month in July 2022. Upon completion
of the initial business combination or the liquidation, we will cease paying these monthly fees. The Company incurred $60,000 and $120,000
for the years ended December 31, 2023 and 2022, respectively, in Sponsor administrative fees.
Due to Related Party
As of December 31, 2023 and 2022, the Company
has an outstanding balance of $25,000 and $0 respectively due to the Sponsor for administrative support services, respectively.
Extension Note
In connection with the First Extension Meeting,
the Sponsor agreed to loan the Company an amount equal to the lesser of (i) $0.04 per public share multiplied by the number of public
shares then outstanding and (ii) $160,000, for each calendar month beginning on April 30, 2023 (each an “Extension Contribution”)
until the earlier of (i) the completion of a business combination and (ii) the Company’s liquidation in accordance with the terms
of the Extension, up to a maximum aggregate amount of $1.92 million. In connection with the vote to approve the Extension, the holders
of 11,151,163 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately
$10.56 per share, for an aggregate redemption amount of approximately $118 million, resulting in 8,973,837 public shares remaining. As
of December 31, 2023, there were Trust Account deposits in connection with the extension loan, totaling $960,000. As of December 31, 2023,
the Company had extension deposits of $480,000 due from Sponsor.
On May 4, 2023, we issued a convertible promissory
note (the “Extension Note”) to the Sponsor with a principal amount up to $1.92 million. The Sponsor deposited the first Extension
Contribution on April 30, 2023 into the Trust Account. In accordance with the terms of the Extension Note, the Sponsor may convert the
principal outstanding thereunder into Private Placement Warrants at a price of $1.00 per warrant. If the Company does not consummate an
initial business combination by the Extended Date, the convertible promissory note will be repaid only from funds held outside of the
Trust Account or will be forfeited, eliminated or otherwise forgiven. Upon maturity, the outstanding principal of the Note may be converted
into warrants identical to the Private Placement Warrants, at a price of $1.00 per warrant, at the option of the Sponsor. As of December
31, 2023, $960,000 has been drawn on the Note.
IPO Working Capital Loan
The Sponsor has committed to loan us up to $1,500,000
for working capital loans (as amended and restated, the “IPO Working Capital Loan”). If the Company completes an initial business
combination, the Company would repay the IPO Working Capital Loans out of the proceeds of the Trust Account released to the Company. In
the event that an initial business combination does not close, the Company may use a portion of proceeds held outside the Trust Account
to repay the IPO Working Capital Loans but no proceeds held in the Trust Account would be used to repay the IPO Working Capital Loans.
The IPO Working Capital Loans would either be repaid upon consummation of an initial business combination or, at the lender’s discretion,
up to $1,500,000 of such IPO Working Capital Loans may be convertible into Private Placement Warrants of the post-initial business combination
entity at a price of $1.00 per warrant. As of December 31, 2023 and 2022, the Company had $723,322 and $0 outstanding under the IPO Working
Capital Loans.
Other Commitments
On March 18 and March 28, 2022, respectively,
the Company engaged UBS, the underwriter in the Initial Public Offering, as a placement agent and to serve as financial advisor and capital
markets advisor in connection with a specified de-SPAC transaction. Under that arrangement, the Company agreed to pay UBS a cash fee for
such services upon the consummation of such transaction in an amount equal to $3,000,000. The letter of intent related to such potential
de-SPAC transaction expired on July 1, 2022 and, as such, rendered the engagement letter void and no future accrual or expense thereunder
was booked. The engagement letter also provided for up to $25,000 in reimbursable fees to UBS and as of the expiration date of the agreement,
there are no reimbursable fees incurred by the Company.
On
June 5, 2023, Sio Silica Corporation entered into an engagement letter with UBS and BMO Capital Markets (“BMO”
and together with UBS, the “Placement Agents”), pursuant to which the Placement Agents agreed to serve as co-placement agents
in connection with a proposed PIPE offering of securities of Sio NewCo in connection with the Sio Business Combination. Pursuant to a
separate letter agreement entered into on the same day between the Company and the Placement Agents, the Company agreed that, in the event
that the Sio Business Combination is not consummated, it would reimburse the Placement Agents for its reasonable, documented, out of pocket
expenses incurred by such Placement Agent in their role as Placement Agents up to an aggregate amount of $300,000.
Non-Redemption Agreement
Concurrently with the execution of the Business Combination Agreement,
the Company and Sio Newco entered into a non-redemption agreement with a Pyrophyte shareholder with respect to 100,000 Class A ordinary
shares held by such shareholder (the “Non-Redemption SPAC Shares”), pursuant to which, among other things, Pyrophyte agreed
to issue 58,570 Class A ordinary shares to such shareholder in consideration of such shareholder’s commitment not to redeem the
Non-Redemption SPAC Shares held by it in connection with the approval of the Sio Business Combination by Pyrophyte’s shareholders.
Critical Accounting Policies and Estimates
Class A Ordinary Shares Subject to Possible
Redemption
All of the Class A ordinary shares sold as part
of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such public shares in connection
with the Company’s liquidation if there is a shareholder vote or tender offer in connection with the Business Combination and in
connection with certain amendments to the Company’s Charter. In accordance with SEC and its staff’s guidance on redeemable
equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require
ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares subject to
possible redemption have been classified outside of permanent equity.
The Company recognizes changes in redemption value
immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each
reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional
paid in capital and accumulated deficit.
Net Income Per Ordinary Share
The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income per ordinary share is computed by dividing net income
by the weighted average number of ordinary share outstanding during the period. The Company has not considered the effect of the warrants
sold in the Initial Public Offering and Private Placements to purchase Class A ordinary shares in the calculation of diluted income per
share, since their inclusion would be anti-dilutive under the treasury stock method. As a result, diluted income per share is the same
as basic income per share for the period presented.
The Company historically had two classes of ordinary
shares -- Class A ordinary shares and Class B ordinary shares. Upon the conversion event in April 2023 to convert the Class B ordinary
shares into Class A ordinary shares, the Company now have redeemable and non-redeemable Class A ordinary shares. Income and losses are
shared pro rata between the redeemable and non-redeemable Class A ordinary shares. Net income per share, basic and diluted for redeemable
Class A ordinary shares is calculated by dividing the pro rata allocation of net income to redeemable Class A ordinary shares for the
year ended December 31, 2023 and 2022 by the weighted average number of redeemable Class A ordinary shares outstanding for the periods.
Net income per share basic and diluted for non-redeemable Class A ordinary shares is calculated by dividing the pro rata allocation of
net income to non-redeemable ordinary shares or the for the year ended December 31, 2023 and 2022 by the weighted average number of non-redeemable
Class A ordinary shares outstanding for the periods. Remeasurement associated with the redeemable shares of Class A ordinary shares is
excluded from earnings per share as the redemption value approximates fair value.
Derivative Instruments
The Company does not use derivative instruments
to hedge its exposures to cash flow, market, or foreign currency risks. Management evaluates all of the Company’s financial instruments,
including issued warrants to purchase its Class A ordinary shares, to determine if such instruments are derivatives or contain features
that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
The Company issued 10,062,500 Public Warrants to purchase Class A ordinary
shares to investors in the Company’s Initial Public Offering and simultaneously issued 10,156,250 Private Placement Warrants. All
of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize
the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities
are subject to re- measurement at each balance sheet date until exercised, and any change in fair value is recognized in our consolidated
statements of income. The Company initially utilized a Monte Carlo simulation model to value the Public Warrants and Private Placement
Warrants at each balance sheet date, with changes in fair value recognized in the consolidated statements of income. Inherent in pricing
models are assumptions and inputs used to arrive the fair value of the Public and Private Placement warrants. The subsequent measurements
of the Public Warrants after the detachment of the Public Warrants from the Units on December 17, 2021 were classified as Level 1 due
to the use of an observable market quote in an active market under the ticker PHYT.WS. There was zero trading volume of the Company’s
public warrants on December 31, 2023, a level 2 measurement. The close price of the Public Warrant was used as the fair value of the Public
Warrants as of December 31, 2023. The Private Placement Warrants have a make-whole provision in place, which will enable them to have
a fair value similar to Public Warrants as of December 31, 2023.
Both the Extension Note and the IPO Working Capital
Loan (together, the “Promissory Notes”), contain a conversion feature, for which upon maturity, the outstanding principal
of the Promissory Notes, at the option of the Sponsor, may be converted into warrants identical to the Private Placement capital warrants.
The Company determined that the conversion option should be bifurcated and accounted for as a derivative in accordance with ASC 815. However,
the exercise price of the underlying warrants was greater than the closing price of the Company’s Class A ordinary shares as of
December 31, 2023, and when the Promissory Notes were drawn on. The Company believes that the likelihood of the Sponsor’s exercise
of the option to convert the Promissory Notes to warrants is de minimis. As a result, the Company recorded zero liability related to the
conversion option on the Promissory Notes.
Investments held in Trust Account
Our portfolio of investments held in the Trust Account is money market
funds solely comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act,
with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities, or a combination
thereof, until April 2024. The investments held in the Trust Account are classified as trading securities. Trading securities are presented
on the balance sheet at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these
securities are included in gain on investments held in Trust Account on the statements of income. The estimated fair values of investments
held in the Trust Account are determined using available market information.
On April 24, 2024, the Company amended the Trust Agreement to permit
the Trustee, to hold the assets in the Trust Account in an interest-bearing demand deposit account or cash until the earlier of the consummation
of an initial business combination or the Company’s liquidation. On the same day, the Company instructed the Trustee to liquidate
the investments held in the Trust Account and move the funds to an interest-bearing demand deposit account, with Continental continuing
to act as trustee. As a result, following the liquidation of investments in the Trust Account, the remaining proceeds from the initial
public offering and the sale of the private placement warrants are no longer invested in U.S. government securities or money market funds.
Recent Accounting Standards
Management does not believe that any recently
issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Company’s consolidated
financial statements.
JOBS Act
On April 5, 2012, the Jumpstart Our Business Startups Act of 2012 (the
“JOBS Act”) was signed into law. The JOBS Act contains provisions that, among other things, relax certain reporting requirements
for qualifying public companies. We qualify as an “emerging growth company” under the JOBS Act and are allowed to comply with
new or revised accounting pronouncements based on the effective date for private (not publicly traded) companies. We elected to delay
the adoption of new or revised accounting standards, and as a result, we may not comply with new or revised accounting standards on the
relevant dates on which adoption of such standards is required for non-emerging growth companies. As a result, our consolidated financial
statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective
dates.
As an “emerging growth company,” we are not required to,
among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial reporting, (ii)
provide all of the compensation disclosure that may be required of non-emerging growth public companies, (iii) comply with any requirement
that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s
report providing additional information about the audit and the consolidated financial statements (auditor discussion and analysis), and
(iv) disclose comparisons of the CEO’s compensation to median employee compensation. These exemptions will apply for a period of
five (5) years following the completion of our Public Offering or until we otherwise no longer qualify as an “emerging growth company.”
Recent Developments
On April 1, 2024, the Company amended and restated
the Working Capital Loan to extend the maturity date thereunder to the earlier of (i) thirty months after the closing of the Public Offering
and (ii) the consummation of a Business Combination. The Company also increased the principal amount from $1,500,000 to $1,840,616.
On April 22, 2024, the Company deposited $960,000
into the Trust Account, which amount reflected the payment in full of the Company’s remaining commitment to make an aggregate of
$1.92 million of cash contributions to the Trust Account in connection with the Extension.
In addition, on April 24, 2024, the Company entered
into an amendment to the Trust Agreement, to permit the Trustee to hold the assets in the Trust Account in an interest-bearing demand
deposit account or cash until the earlier of the consummation of an initial business combination or the Company’s liquidation. The
Company then instructed the Trustee to liquidate the Trust Account and move the proceeds into an interest-bearing demand deposit account.
On April 26, 2024, the Company held an
extraordinary general meeting of shareholders (the “Second Extension Meeting”) to vote on an amendment to its Articles
to extend the date on which it had to consummate an initial business combination from April 29, 2024 to April 29, 2025. The
shareholders voted to approve the amendment. The Sponsor agreed that if such amendment was approved and implemented, then it or its
designee would deposit (the “Second Extension Contributions”) into the Trust Account as a loan $90,000 per month beginning on April
30, 2024 and ending on the earlier of (i) the Company’s liquidation, (ii) the consummation of an initial business combination and
(iii) April 30, 2025. In connection with the Second Extension Meeting, holders of 2,683,126 Class A Ordinary Shares exercised their
right to redeem their shares for cash at a redemption price of approximately $11.35 per share, for an aggregate redemption amount of
approximately $30.4 million, resulting in 6,290,711 public shares remaining.
On April 26, 2024, in connection with the Second Extension Meeting, the Company issued a promissory note to the Sponsor in the amount
of $1.08 million in connection with the Second Extension Contributions.
On April 26, 2024, the Company amended and restated the Working Capital
Loan to extend the maturity date thereunder to the earlier of (i) forty-two months after the closing of the Public Offering and (ii) the
consummation of a Business Combination.
ITEM 7A.
Quantitative and Qualitative Disclosures
About Market Risk.
We are a smaller reporting
company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this
item.
ITEM 8.
Financial Statements and Supplementary
Data.
Reference is made to pages F-1 through
F-20 comprising a portion of this Annual Report.
ITEM 9.
Changes In and Disagreements with
Accountants on Accounting and Financial Disclosure.
None.
ITEM 9A.
Controls and Procedures.
Evaluation of Disclosure Controls and Procedures
Disclosure controls and
procedures are designed to ensure that information required to be disclosed by us in our Exchange Act reports is recorded, processed,
summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated
and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar
functions, as appropriate to allow timely decisions regarding required disclosure. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed in company reports filed or submitted
under the Exchange Act is accumulated and communicated to management, including our principal executive officer and principal financial
and accounting officer, to allow timely decisions regarding required disclosure.
In connection with the
preparation of this Annual Report as of December 31, 2023, an evaluation was performed under the supervision and with the participation
of our management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls
and procedures (as defined in Rule 13a-15I under the Exchange Act). Based on such evaluation, our Chief Executive Officer and Chief Financial
Officer concluded that, as of December 31, 2023, our disclosure controls and procedures were not effective as we experienced difficulty
in the accounting and reporting related to the existence of assets, the accounting and reporting for the completeness and accuracy of
our liabilities and the corresponding expenses, as well as the accounting for complex financial instruments, and related party transactions
which we experienced and reported as a material weakness in our Annual Report on Form 10-K for the year ended December 31, 2023. As a
result, we performed additional analysis as deemed necessary to ensure that our consolidated financial statements were prepared in accordance
with GAAP. Accordingly, management believes that the consolidated financial statements included in this Annual Report present fairly in
all material respects our financial position, results of operations and cash flows for the periods presented.
Management’s Report on Internal Controls
Over Financial Reporting
Management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f)
and 15d-15(f). Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of assets of the Company; (ii)
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with
GAAP, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors
of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition
of the Company’s assets that could have a material effect on the financial statements.
Internal control over
financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements prepared for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over
financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies
or procedures may deteriorate.
Our management, with
the participation of our Chief Executive Officer and Chief Financial Officer, assessed the effectiveness of our internal control over
financial reporting as of December 31, 2023 using the criteria established in Internal Control - Integrated Framework (2013) issued
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on this assessment and those criteria, management
concluded that our internal control over financial reporting were not effective as of December 31, 2023.
Changes in Internal Control over Financial
Reporting
There were no changes in our internal control
over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal
quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
ITEM 9B.
Other Information.
None.
ITEM 9C.
Disclosure Regarding Foreign Jurisdictions
That Prevent Inspections.
Not applicable.
PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND
CORPORATE GOVERNANCE.
Directors and Executive Officers
Our directors and executive officers are as follows:
Name |
|
Age |
|
Position |
Bernard J. Duroc-Danner |
|
70 |
|
Chief Executive Officer and Chairman |
Sten L. Gustafson |
|
57 |
|
Chief Financial Officer and Director |
Bryan Guido Hassin |
|
45 |
|
Director |
Per Hornung Pedersen |
|
70 |
|
Director |
Adam Pierce |
|
45 |
|
Director |
Dr. Bernard J. Duroc-Danner has
been our Chief Executive Officer since March 2023 and has served as the chairman of our board of directors since October 2021. Since 2018,
Dr. Duroc-Danner co-founded, raised the seed and second round capital and co-managed the incubation of an energy sensing and artificial
intelligence software company with applications in emissions control energy. In addition, Dr. Duroc-Danner has been involved in the planning
of the development of a solar power generation and CO2 sequestration project as part of a broader energy project in the Eastern Hemisphere.
Dr. Duroc-Danner currently serves as advisory director to the Energy Intelligence Group (EIG). As an internationally recognized energy
executive, Dr. Duroc-Danner is well qualified to serve as chairman of our Board of Directors, having built two global market and industry
leaders through hundreds of focused acquisitions around the world. Dr. Duroc-Danner started EVI, Inc. (NYSE: EVI), an oilfield service
and equipment company in May 1987, for which he served as Chairman, President and CEO until he retired in 2016, and upon retirement was
given the distinction of Chairman Emeritus of Weatherford, EVI’s successor company Dr. Duroc-Danner was a director for a number
of many public companies with global operations. Prior to the startup of EVI, Dr. Duroc-Danner was a management consultant with Arthur
D. Little in Boston working in the metals, minerals and power generating industry. Dr. Duroc-Danner received his MBA and a PhD degree
from The Wharton School of the University of Pennsylvania. Dr. Duroc-Danner is qualified to serve on our board of directors because of
his extensive operational and transactional experience in building companies around the globe.
Sten L. Gustafson has served as
our Chief Financial Officer since March 30, 2023 and a director since February 12, 2021. Mr. Gustafson is a highly experienced energy
service industry executive, investment banker, and corporate securities attorney. Since 2020, Mr. Gustafson has served an independent
director for Western Rare Earths, the U.S. subsidiary of Australian rare earth mining company, American Rare Earths. From 2012 to 2014,
Mr. Gustafson was Chief Executive Officer and Director of Era Group Inc. (previously NYSE: ERA), where he led the successful spin out
of Era from Seacor Holdings in January 2013, generating record quarterly revenues every quarter during his tenure while meaningfully de-leveraging
the balance sheet. From 2017 to 2018, Mr. Gustafson served as a member of the Founding Steering Committee created by the Public Investment
Fund of Saudi Arabia to establish a private commercial helicopter operator (The Helicopter Company) in the Kingdom of Saudi Arabia. From
2017 to 2019, Mr. Gustafson served as a director at CHC Helicopter. From 2018 to 2024, Mr. Gustafson served as Chairman of the Board of
Directors of the publicly traded Norwegian company, Golden Energy Offshore. Mr. Gustafson earned a B.A. in English from Rice University
and earned a Juris Doctor from the University of Houston Law Center. Previously, Mr. Gustafson was our Chief Executive Officer from February
12, 2021 until March 29, 2023. With over 25 years of experience in the global energy sector, Mr. Gustafson is well qualified to serve
on our board of directors, having advised on over 100 corporate transactions around the world for over $100 billion of transaction value.
Bryan Guido Hassin has served on
our board of directors since October 2021. Mr. Hassin is a global energy technology entrepreneur and since October 2022 has been the
Chief Executive Officer of DexMat and served as the Co-Founder & Chief Executive Officer of The Third Derivative, a joint venture
between Rocky Mountain Institute and New Energy Nexus that is transforming the way that innovative startups, investment funds, and large
corporations accelerate the energy transition by creating a global, vertically integrated engine for climate innovation between March
2021 and September 2022. Prior to Third Derivative, Mr. Hassin spent 20 years as a global energy technology entrepreneur and executive,
founding, leading and scaling high-growth energy transition startups. Mr. Hassin is well qualified to act as a Director, having spent
much of his career in the private sector raising venture capital, building and leading startup teams, scaling operations, and negotiating
partnerships and acquisitions. Mr. Hassin received his MBA with Honors and Leadership Distinction from IMD in Lausanne, Switzerland.
He has a Master’s in Computer Science and undergraduate degrees in Computer Science and Electrical and Computer Engineering from
Rice University. Mr. Hassin is qualified to serve on our board of directors because of his long career in operating and advising energy
transition companies, and the broad network of relationships in the sector that he has developed.
Per Hornung Pedersen has served
on our board of directors since October 2021. Since 2011, Mr. Pedersen has worked as an Independent Director and Industry Advisor in the
renewable energy industry. Mr. Pedersen is currently the Chairman of PNE AG Germany, one of Europe’s largest project developers
in onshore and offshore wind as well as solar. Mr. Pedersen also serves as Independent Director in Suzlon Energy Ltd India (since 2015),
Independent Director in Swire Energy Services and Independent Director in SeaTower AS Norway. Since 2017, Mr. Pedersen has served as a
Senior Advisor to McKinsey and an independent member of the Investment Committee of Caribbean Clean Energy Fund. Since 2023, Mr. Pederson
also serves as a member of the advisory board of EQT ActionCore infrastructure investment in Tion AG. Mr. Pedersen is well-qualified to
serve on our board of directors as a highly experienced veteran in the renewable energy industry, with 20 years of experience as a senior
executive as well as an independent director in leading global companies in the renewable energy industry across the value chain. Mr.
Pedersen received his MBA with honors from Copenhagen Business School (University of Copenhagen) and holds a BSc in Finance and Accounting
from Copenhagen Business School. Mr. Pedersen is qualified to serve on our board of directors because of his decades of operating experience
in the renewable energy industry, particularly in Europe and Asia.
Adam Pierce has served on our board
of directors since October 2021. Since 2020, Mr. Pierce has been the Founder and Managing Partner of Tenkara Capital, an investment firm
focused on opportunistic credit and structured equity investments across multiple industries. Prior to founding Tenkara Capital in 2020,
Mr. Pierce spent nearly 17 years as an investment professional at Oaktree Capital Management, most recently as Managing Director and a
member of the Investment Committee for the Special Situations and Global Principal Opportunities Group. During this time, Mr. Pierce identified,
executed and subsequently oversaw nearly $2 billion in direct capital investments into 35 new investment vehicles, five of which were
international companies. In addition, Mr. Pierce led over 30 debt financing transactions, four IPOs, nearly 20 add-on acquisitions and
17 merger transactions, and served on 12 different boards of directors. A number of these investments Mr. Pierce was involved in and board
positions he held were in companies participating in the Energy Transition. Prior to joining Oaktree in 2003, Mr. Pierce was an investment
banker with J.P. Morgan and Goldman Sachs. Mr. Pierce received a B.A. in Economics with a focus on business administration from Vanderbilt
University. Mr. Pierce is qualified to serve on our board of directors because of his decades of deal experience, and his extensive network
of relationships in the private equity industry.
Number and Terms of Office of Officers and
Directors
Our board of directors consists of five members
and is divided into three classes with only one class of directors being elected in each year, and with each class (except for those directors
elected prior to our first annual general meeting) serving a three-year term. In accordance with NYSE corporate governance requirements,
we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on the NYSE. The term
of office of the first class of directors, consisting of Mr. Pedersen, will expire at our first annual general meeting. The term of office
of the second class of directors, consisting of Messrs. Pierce and Hassin, will expire at the second annual general meeting. The term
of office of the third class of directors, consisting of Messrs. Duroc-Danner and Gustafson, will expire at the third annual general meeting.
Our officers are appointed by the board of directors
and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized
to appoint officers as it deems appropriate pursuant to our Articles.
Director Independence
NYSE listing standards require that a
majority of our board of directors be independent. Our board of directors has determined that each of Messrs. Hassin, Pedersen and
Pierce is an “independent director” as defined in the NYSE listing standards and applicable SEC rules. Our independent
directors will have regularly scheduled meetings at which only independent directors are present.
Board Committees
Our board of directors has three standing committees:
an audit committee, a compensation committee and a nominating and corporate governance committee. Both our audit committee and our compensation
committee are composed solely of independent directors. Subject to phase-in rules, the rules of the NYSE and Rule 10A-3 of the Exchange
Act require that the audit committee of a listed company be comprised solely of independent directors, and the rules of the NYSE require
that the compensation committee and the nominating and corporate governance committee of a listed company be comprised solely of independent
directors. Each committee operates under a charter that was approved by our board and have the composition and responsibilities described
below. The charter of each committee is available on our website.
Audit Committee
We established an audit committee of the board
of directors. Messrs. Hassin, Pedersen and Pierce serve as members of our audit committee, and Mr. Pierce chairs the audit committee.
Under the NYSE listing standards and applicable SEC rules, we are required to have at least three members of the audit committee, all
of whom must be independent. Each of Messrs. Hassin, Pedersen and Pierce meet the independent director standard under NYSE listing standards
and under Rule 10-A-3(b)(1) of the Exchange Act.
Each member of the audit committee is financially
literate and our board of directors has determined that Mr. Pierce qualifies as an “audit committee financial expert” as defined
in applicable SEC rules and has accounting or related financial management expertise.
We adopted an audit committee charter, which details
the principal functions of the audit committee, including:
| ● | assisting board oversight of (1) the integrity of
our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent registered public accounting
firm’s qualifications and independence, and (4) the performance of our internal audit function and registered public accounting
firm; the appointment, compensation, retention, replacement, and oversight of the work of the registered public accounting firm and any
other independent registered public accounting firm engaged by us; |
| ● | pre-approving all audit and non-audit services to be provided
by the registered public accounting firm or any other registered public accounting firm engaged by us, and establishing pre-approval
policies and procedures; reviewing and discussing with the registered public accounting firm all relationships the auditors have with
us in order to evaluate their continued independence; |
| ● | setting clear policies for audit partner rotation in compliance
with applicable laws and regulations; obtaining and reviewing a report, at least annually, from the independent registered public accounting
firm describing (1) the registered public accounting firm’s internal quality-control procedures and (2) any material issues raised
by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or investigation by governmental
or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any
steps taken to deal with such issues; |
| ● | meeting to review and discuss our annual audited financial
statements and quarterly financial statements with management and the registered public accounting firm, including reviewing our specific
disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; reviewing
and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC prior
to us entering into such transaction; and |
| ● | reviewing with management, the registered public accounting
firm, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators
or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements
or accounting policies and any significant changes in accounting standards or rules promulgated by the Financial Accounting Standards
Board, the SEC or other regulatory authorities. |
Compensation Committee
We established a compensation committee of the
board of directors. Messrs. Pedersen and Pierce serve as members of our compensation committee. Under the NYSE listing standards and applicable
SEC rules, we are required to have at least two members of the compensation committee, all of whom must be independent. Messrs. Pedersen
and Pierce are independent and Mr. Pedersen chairs the compensation committee. We have adopted a compensation committee charter, which
details the principal functions of the compensation committee, including:
| ● | reviewing and approving on an annual basis the corporate
goals and objectives relevant to our chief executive officer’s compensation, evaluating our chief executive officer’s performance
in light of such goals and objectives and determining and approving the remuneration (if any) of our chief executive officer based on
such evaluation; |
| ● | reviewing and making recommendations to our board of directors
with respect to the compensation, and any incentive compensation and equity based plans that are subject to board approval of all of
our other officers; |
| ● | reviewing our executive compensation policies and plans;
implementing and administering our incentive compensation equity-based remuneration plans; |
| ● | assisting management in complying with our proxy statement
and annual report disclosure requirements; |
| ● | approving all special perquisites, special cash payments
and other special compensation and benefit arrangements for our officers and employees; |
| ● | producing a report on executive compensation to be included
in our annual proxy statement; and |
| ● | reviewing, evaluating and recommending changes, if appropriate,
to the remuneration for directors. |
Notwithstanding the foregoing, as indicated above,
other than the payment to the Sponsor of $5,000 per month for utilities and secretarial and administrative support
and reimbursement of expenses, and the reimbursement of certain expenses relating to acquisition activities as discussed elsewhere in
this Annual Report, no compensation of any kind, including finders, consulting or other similar fees, will be paid to any of our existing
shareholders, officers, directors or any of their respective affiliates, prior to, or for any services they render in order to effectuate
the consummation of an initial business combination. Accordingly, it is likely that prior to the consummation of an initial business combination,
the compensation committee will only be responsible for the review and recommendation of any compensation arrangements to be entered into
in connection with such initial business combination.
The charter also provides that the compensation
committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, independent legal counsel or other adviser
and will be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging
or receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider
the independence of each such adviser, including the factors required by the NYSE and the SEC.
Nominating and Corporate Governance
Committee
We have established a nominating and corporate
governance committee of the board of directors. The members of our nominating and corporate governance are Messrs. Hassin and Pedersen.
Mr. Hassin serves as chair of the nominating and corporate governance committee. We have adopted a nominating and corporate governance
committee charter, which details the purpose and responsibilities of the nominating and corporate governance committee, including:
| ● | identifying, screening and reviewing individuals qualified
to serve as directors, consistent with criteria approved by the board, and recommending to the board of directors candidates for nomination
for election at the annual meeting of shareholders or to fill vacancies on the board of directors; |
| ● | developing and recommending to the board of directors and
overseeing implementation of our corporate governance guidelines; |
| ● | coordinating and overseeing the annual self-evaluation of
the board of directors, its committees, individual directors and management in the governance of the company; and |
| ● | reviewing on a regular basis our overall corporate governance
and recommending improvements as and when necessary. |
The charter also provides that the nominating
and corporate governance committee may, in its sole discretion, retain or obtain the advice of, and terminate, any search firm to be used
to identify director candidates, and will be directly responsible for approving the search firm’s fees and other retention terms.
We have not formally established any specific,
minimum qualifications that must be met or skills that are necessary for directors to possess. In general, in identifying and evaluating
nominees for director, the board of directors considers educational background, diversity of professional experience, knowledge of our
business, integrity, professional reputation, independence, wisdom, and the ability to represent the best interests of our shareholders.
Prior to our initial business combination, holders of our public shares will not have the right to recommend director candidates for nomination
to our board of directors.
Code of Business Conduct and Ethics
We have adopted a Code of Business Conduct and
Ethics applicable to our directors, officers and employees. We have filed a copy of our Code of Business Conduct and Ethics as an exhibit
to our registration statement in connection with the Public Offering. You are able to review this document by accessing our public filings
at the SEC’s web site at www.sec.gov. In addition, a copy of the Code of Business Conduct and Ethics and the charters of the committees
of our board of directors will be provided without charge upon request from us in writing at 3262 Westheimer Road, Suite 706, Houston,
Texas 77098 or by telephone at (281) 701-4234. If we make any amendments to our Code of Business Conduct and Ethics other than technical,
administrative or other non-substantive amendments, or grant any waiver, including any implicit waiver, from a provision of the Code of
Business Conduct and Ethics applicable to our principal executive officer, principal financial officer principal accounting officer or
controller or persons performing similar functions requiring disclosure under applicable SEC or NYSE rules, we will disclose the nature
of such amendment or waiver on our website.
ITEM 11. EXECUTIVE COMPENSATION.
None of our officers or directors have received
any cash compensation for services rendered to us. In 2023, we paid the Sponsor $5,000 per month for utilities, secretarial
and administrative support services provided to members of our management team. Upon completion of our initial business combination or
our liquidation, we will cease paying this monthly fee. In addition, the Sponsor, officers and directors, or any of their respective affiliates
will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target
businesses and performing due diligence on suitable business combinations. For the year ended December 21, 2023 and for the year ended
December 31, 2022, the Company reimbursed expenses to management in the amount of $21,205 and $101,870, respectively, these expenses are
related to acquisition activities. Our audit committee will review on a quarterly basis all payments that were made to the Sponsor, officers
or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made from funds held outside
the Trust Account. Other than quarterly audit committee review of such reimbursements, we do not expect to have any additional controls
in place governing our reimbursement payments to our directors and officers for their out-of-pocket expenses incurred in connection with
our activities on our behalf in connection with identifying and consummating an initial business combination. Other than these payments
and reimbursements, no compensation of any kind, including finder’s and consulting fees, will be paid by the company to the Sponsor,
officers and directors, or any of their respective affiliates, prior to completion of our initial business combination.
After the completion of our initial business combination,
directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All
of these fees will be fully disclosed to shareholders, to the extent then known, in the proxy solicitation materials or tender offer materials
furnished to our shareholders in connection with a proposed business combination. We have not established any limit on the amount of such
fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation
will be known at the time of the proposed business combination, because the directors of the post-combination business will be responsible
for determining officer and director compensation. Any compensation to be paid to our officers will be determined, or recommended to the
board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority
of the independent directors on our board of directors.
We do not intend to take any action to ensure
that members of our management team maintain their positions with us after the consummation of our initial business combination, although
it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after
our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with
us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability
of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision
to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for
benefits upon termination of employment.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL
OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS.
We have no compensation plans under which equity
securities are authorized for issuance.
The following table sets forth information regarding
the beneficial ownership of our ordinary shares as of May 23, 2024, by:
| ● | each person known by us to be a beneficial owner of more
than 5% of our outstanding ordinary shares of, on an as-converted basis; |
| ● | each of our officers and directors; and |
| ● | all of our officers and directors as a group. |
The following table is based on 11,321,961
ordinary shares outstanding as of May 23, 2024, all of which were Class A ordinary shares. Unless otherwise indicated, it
is believed that all persons named in the table below have sole voting and investment power with respect to all ordinary shares
beneficially owned by them.
Name and Address of Beneficial Owner(1) | |
Number of
Shares
Beneficially
Owned | | |
Percentage of
Outstanding
Ordinary
Shares | |
Directors and Officers | |
| | |
| |
Bernard Duroc-Danner | |
| - | | |
| - | |
Sten L. Gustafson | |
| - | | |
| - | |
Brian Guido Hassin | |
| - | | |
| - | |
Per Hornung Pedersen | |
| - | | |
| - | |
Adam Pierce | |
| - | | |
| - | |
All officers and directors as a group (5 individuals) | |
| - | | |
| - | |
Holders of more than 5% of our outstanding ordinary shares | |
| | | |
| | |
Pyrophyte Acquisition LLC(2)(3) | |
| 5,031,250 | | |
| 44.4 | % |
Balyasny Asset Management L.P. (4) | |
| 1,442,387 | | |
| 12.7 | % |
First Trust Capital Management L.P. (5) | |
| 819,583 | | |
| 7.2 | % |
Cowen and Company LLC (6) | |
| 751,626 | | |
| 6.6 | % |
Meteora Capital, LLC (7) | |
| 705,742 | | |
| 6.2 | % |
(1) | Unless otherwise noted, the business address of each of our shareholders listed is 3262 Westheimer Road,
Suite 706, Houston, TX, 77098. |
(2) | Interests shown consist solely of Founder Shares. |
(3) | Our Sponsor is managed by a board of managers consisting of Sten L.
Gustafson, Bernard Duroc-Danner and Thomas W. Major. Any action by the Sponsor with respect to our company or the Founder Shares, including
voting and dispositive decisions, requires a majority vote of the managers of the board of managers. Under the so-called “rule of
three,” because voting and dispositive decisions are made by a majority of the Sponsor’s managers, none of the managers of
the Sponsor is deemed to be a beneficial owner of the Sponsor’s securities, even those in which such manager holds a pecuniary interest.
Accordingly, none of the Sponsor’s managers is deemed to have or share beneficial ownership of the Founder Shares held by the Sponsor. |
(4) | According to a Schedule 13G filed with the SEC on February 14, 2024
on behalf of Balyasny Asset Management L.P., a Delaware limited partnership (“BAM”), BAM GP LLC, a Delaware limited liability
corporation (“BAM GP”), Balyasny Asset Management Holdings LP, a Delaware limited partnership (“BAM Holdings”),
Dames GP LLC, a Delaware limited liability company (“Dames”), and Dmitry Balyasny, interests shown are held by Atlas Diversified
Fund, Ltd. (“ADMF”). BAM is the investment manager of ADMF BAM GP is the general partner of BAM. BAM Holdings is the sole
member of BAM GP.. Dames is the general partner of BAM Holdings. Mr. Balyasny is the managing member of Dames and may be deemed to beneficially
own the Class A Ordinary Shares reported. The principal business address for each shareholder is 444 West Lake Street, 50th
Floor, Chicago, IL 60606. |
(5) |
According to a Schedule 13G filed with the SEC
on February 14, 2024, interests shown are held by (i) First Trust Merger Arbitrage Fund (“VARBX”), a series of Investment
Managers Series Trust II, an investment company registered under the Investment Company Act of 1940, (ii) First Trust Capital Management
L.P. (“FTCM”), an investment adviser registered with the SEC that provides investment advisory services to, among others,
(a) series of Investment Managers Series Trust II, an investment company registered under the Investment Company Act of 1940, specifically
First Trust Multi-Strategy Fund and VARBX, (b) First Trust Alternative Opportunities Fund, an investment company registered under the
Investment Company Act of 1940 and (c) Highland Capital Management Institutional Fund II, LLC, a Delaware limited liability company, (iii)
First Trust Capital Solutions L.P., a Delaware limited liability partnership and control person of FTCM, and (iv) FTCS Sub GP LLC, a Delaware
limited liability company and control person of FTCM. The address of the shareholder is 225 W. Wacker Drive, 21st Floor, Chicago, IL 60606. |
(6) | According to a Schedule 13G filed with the SEC
on February 1, 2024 on behalf of Cowen and Company LLC (“Cowen”) and Cowen Financial Products LLC (“Cowen Financial”),
Cowen directly owns 251,626 Class A Ordinary Shares and Cowen Financial directly owns 500,000 Class A Ordinary Shares. The address of
this shareholder is 599 Lexington Avenue, New York, New York 10022.
|
| (7) | According to a Schedule 13G filed with the SEC on February 14,
2024, interests shown are held by Meteora Capital, LLC, a Delaware limited liability company (“Meteora”). Vik Mittal serves
as the Managing Member of Meteora. The address of this shareholder is 1200 N Federal Hwy, #200, Boca Raton FL 33432. |
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED
TRANSACTIONS, AND DIRECTOR INDEPENDENCE.
Founder
Shares
On February 24, 2021, the Company issued 5,750,000
Class B ordinary shares to the Sponsor. On September 29, 2021, the Sponsor surrendered 718,750 Founder Shares to the Company for cancellation
for no consideration, resulting in the Sponsor holding 5,031,250 Founder Shares. In connection with the Extension, all 5,031,250 Founder
Shares were converted from Class B ordinary shares into Class A ordinary shares on a one-for-one basis for no consideration.
The Founder Shares are identical to the Class
A ordinary shares included in the Units sold in the Public Offering, except that:
| ● | only holders of the Founder Shares will have the right to
vote on continuing the Company in a jurisdiction outside of the Cayman Islands (including any special resolution required to amend the
constitutional documents of the company or to adopt new constitutional documents of the Company, in each case, as a result of the company
approving a transfer by way of continuation in a jurisdiction outside the Cayman Islands); |
| ● | the Founder Shares are subject to certain transfer restrictions; |
| ● | the Founder Shares are entitled to registration rights; the Sponsor,
officers and directors have entered into a letter agreement with us, pursuant to which they have agreed to (i) waive their redemption
rights with respect to their Founder Shares and public shares in connection with the completion of our initial business combination; (ii)
waive their redemption rights with respect to their Founder Shares and public shares in connection with a shareholder vote to approve
an amendment to our Articles (A) to modify the substance or timing of our obligation to allow redemption in connection with our initial
business combination or to redeem 100% of our public shares if we have not consummated an initial business combination by the Extended
Date or (B) with respect to any other provisions relating to shareholders’ rights or pre-initial business combination activity;
(iii) waive their rights to liquidating distributions from the Trust Account with respect to their Founder Shares if we fail to complete
our initial business combination by the Extended Date, although they will be entitled to liquidating distributions from the Trust Account
with respect to any public shares they hold if we fail to complete our initial business combination within the prescribed time frame;
and (iv) vote any Founder Shares held by them and any public shares purchased during or after the Initial Public Offering (including in
open market and privately-negotiated transactions) in favor of our initial business combination; and |
Private
Placement Warrants
The Sponsor purchased an aggregate of 10,156,250
Private Placement Warrants at a price of $1.00 per Private Placement Warrant ($10,156,250 in the aggregate) in a Private Placement that
occurred simultaneously with the closing of the Public Offering.
The Private Placement Warrants are identical to
the warrants sold in the Public Offering except that the underlying Private Placement Warrants, so long as they are held by the Sponsor
or its permitted transferees, (i) are not redeemable by us (except in certain circumstances), (ii) may not (including the Class A ordinary
shares issuable upon exercise of these warrants), subject to certain limited exceptions, be transferred, assigned or sold by the holders
until 30 days after the completion of our initial business combination, (iii) may be exercised by the holders on a cashless basis and
(iv) are entitled to registration rights. The Private Placement Warrants (including the Class A ordinary shares issuable upon exercise
thereof) may not, subject to certain limited exceptions, be transferred, assigned or sold by the holder.
Related
Party Loans
The Sponsor also loaned the Company an aggregate
of $300,000 to cover expenses related to the Initial Public Offering pursuant to the Note. This loan was non-interest bearing and payable
on completion of the Initial Public Offering. The Note was fully repaid on October 29, 2021.
In addition, in order to finance transaction costs
in connection with an intended initial business combination, the Sponsor or an affiliate of the Sponsor or certain of our officers and
directors may, but are not obligated to (except in the case of the committed Sponsor loans), loan us funds as may be required. If we complete
our initial business combination, we would repay such loaned amounts. In the event that our initial business combination does not close,
we may use a portion of the working capital held outside the Trust Account to repay such loaned amounts but no proceeds from our Trust
Account would be used to repay such loaned amounts. Up to $1,500,000 of such loans (which amount includes the committed Sponsor loans)
may be convertible into Private Placement Warrants of the post business combination entity at a price of $1.00 per warrant at
the option of the lender. Such warrants would be identical to the Private Placement Warrants. Except as set forth above, the terms of
such loans, if any, have not been determined and no written agreements exist with respect to such loans. Prior to the completion of our
initial business combination, we do not expect to seek loans from parties other than the Sponsor or an affiliate of the Sponsor as we
do not believe third parties will be willing to loan such funds and provide a waiver against any and all rights to seek access to funds
in our Trust Account.
Administrative
Support Agreement
From the date of the Initial Public Offering until July 1, 2022, the
Company paid the Sponsor $15,000 per month for utilities, secretarial and administrative support services provided to the
members of the Company’s management team, of which Mr. Major, our former Chief Financial Officer and Executive Vice President of
Business Development was paid $10,000 per month. On July 1, 2022 the Company amended the administrative support agreement with the Sponsor
from $15,000 per month to $5,000 per month. Upon completion of the initial business combination or the Company’s liquidation, the
Company will cease paying these monthly fees. The Company had incurred and paid $60,000 and $120,000 for the year ended December 31, 2023
and for the year ended December 31, 2022, in Sponsor administrative fees.
For the year ended December 21, 2023 and for the year ended December
31, 2022, the Company reimbursed expenses to management in the amount of $21,205 and $101,870, respectively, these expenses are related
to acquisition activities.
Registration Rights Agreement
The holders of Founder Shares, Private Placement
Warrants and warrants that may be issued upon conversion of the IPO Working Capital Loans or the Extension Note (and any Class A ordinary
shares issuable upon the exercise of the Private Placement Warrants and warrants that may be issued upon conversion of the IPO Working
Capital Loans and the Extension Note) are entitled to registration rights pursuant to a registration rights agreement. The holders of
these securities are entitled to make up to three demands, excluding short form demands, that we register such securities. These holders
will be entitled to certain demand and “piggyback” registration rights. We will bear the expenses incurred in connection with
the filing of any such registration statements.
IPO Working Capital Loan
The Sponsor has committed to loan us up to $1,500,000
for working capital loans (the “IPO Working Capital Loan”). If the Company completes an initial business combination, the
Company would repay the IPO Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the event that
an initial business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the
IPO Working Capital Loans but no proceeds held in the Trust Account would be used to repay the IPO Working Capital Loans. The IPO Working
Capital Loans would either be repaid upon consummation of an initial business combination or, at the lender’s discretion, up to
$1,500,000 of such IPO Working Capital Loans may be convertible into Private Placement Warrants of the post-initial business combination
entity at a price of $1.00 per warrant. As of December 31, 2023 and 2022, the Company had $723,322 and $0 outstanding under the IPO Working
Capital Loans.
Extension Note
In connection with the First Extension Meeting,
the Sponsor agreed to loan the Company an amount equal to the lesser of (i) $0.04 per public share multiplied by the number of public
shares then outstanding and (ii) $160,000, for each calendar month beginning on April 30, 2023 (each an “Extension Contribution”)
until the earlier of (i) the completion of a business combination and (ii) the Company’s liquidation in accordance with the terms
of the Extension, up to a maximum aggregate amount of $1.92 million. In connection with the vote to approve the Extension, the holders
of 11,151,163 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of approximately
$10.56 per share, for an aggregate redemption amount of approximately $118 million, resulting in 8,973,837 public shares remaining. As
of December 31, 2023, there were Trust Account deposits in connection with the extension loan, totaling $960,000.
On May 4, 2023, we issued a convertible promissory
note (the “Extension Note”) to the Sponsor with a principal amount up to $1.92 million. The Sponsor deposited the first Extension
Contribution on April 30, 2023 into the Trust Account. In accordance with the terms of the Extension Note, the Sponsor may convert the
principal outstanding thereunder into Private Placement Warrants at a price of $1.00 per warrant. If the Company does not consummate an
initial business combination by the Extended Date, the convertible promissory note will be repaid only from funds held outside of the
Trust Account or will be forfeited, eliminated or otherwise forgiven. Upon maturity, the outstanding principal of the Note may be converted
into warrants identical to the Private Placement Warrants, at a price of $1.00 per warrant, at the option of the Sponsor. As of December
31, 2023, $960,000 has been drawn on the Note.
Agreements Related
to the Business Combination
Sponsor Support Agreement
Concurrently with the execution of the Sio Business Combination Agreement,
the Sponsor, entered into a letter agreement (the “Sponsor Support Agreement”) with Sio, Sio Newco, the Company and the directors
and officers (or otherwise a part of the management team) of the Company, solely for purposes of amending certain of the terms of the
letter agreement signed by them in connection with the Company’s Initial Public Offering, pursuant to which, among other things,
the Sponsor agreed to among other things, vote all Class A ordinary shares, or any securities convertible into, exercisable or exchangeable
for Class A ordinary shares, held by it or acquired after the date of the Sponsor Support Agreement (the “Covered Shares”)
at the meeting of Pyrophyte shareholders to be held in connection with the Sio Business Combination in favor of the adoption and approval
of the Sio Business Combination and each other proposal related to the Sio and not transfer any Covered Shares (other than Pubco Class
A Common Shares issued upon exercise of any Private Placement Warrants held by the Sponsor) until the earlier of (A) one year after the
Closing, (B) the first day the last sale price of Pubco Class A Common Shares equals or exceeds $12.00 per share for any 20 trading days
within a 30-day trading period commencing at least 150 days after the Closing or (C) after the Closing, the date on which Pubco completes
a liquidation, amalgamation, share exchange or similar transaction resulting in the shareholders of Pubco having the right to exchange
their shares for consideration.
In addition, under the terms of the Sponsor Support
Agreement, the Pyrophyte Sponsor has agreed to subject up to 4,025,000 Pyrophyte Class A ordinary shares (“Restricted Owned Shares”)
to certain earn out restrictions, if and only to the extent such shares are used to obtain any additional PIPE Financing or other financing
arrangements in connection with the consummation of the Sio Business Combination; provided that in no event shall the aggregate number
of Restricted Owned Shares equal more than 4,025,000 Class A ordinary shares (the “Maximum Restricted Owned Shares”). If,
prior to the Closing, the SPAC Proceeds are less than $70,000,000, then the number of Restricted Owned Shares will be adjusted pursuant
to the terms of the Sponsor Support Agreement.
In connection with the Closing, each Restricted
Owned Share will be exchanged on a one-for-one basis for Pubco Class A Common Shares pursuant to the Sio Business Combination and the
Plan of Arrangement and such shares will be subject to forfeiture or release as follows: (i) half of the Restricted Owned Shares will
be released to the Sponsor on the first day that the Trading Price (as defined in the Sio Business Combination Agreement) is at least
$12.50, (ii) the other half of the Restricted Owned Shares will be released from forfeiture on the first day that the Trading Price is
at least $15.00, in each case during the period commencing on the Closing Date and ending on the date that is three (3) years after the
Closing Date (the “End Date”), and (iii) after the End Date, any Restricted Owned Shares that have not been released to the
Sponsor pursuant to clauses (i) or (ii) above will be automatically forfeited for no consideration. If a change of control of Pubco occurs
at any time between the Closing Date and the End Date and the price achieved per Restricted Owned Shares is at least $12.50 or $15.00,
then the vesting conditions outlined will be considered to be met.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES.
The following is a summary of fees paid to Marcum
LLP, for services rendered.
Audit Fees. Audit fees consist of fees
billed for professional services rendered for the audit for our annual financial statements, reviews of our quarterly financial statements
and services that are normally provided by our independent registered public accounting firm in connection with statutory and regulatory
filings. The aggregate fees billed by Marcum LLP for audit fees, inclusive of required filings with the SEC, for the years ended December
31, 2023 and 2022, totaled $208,275 and $128,750, respectively.
Audit-Related Fees. Audit-related fees
consist of fees billed for assurance and related services that are reasonably related to performance of the audit or review of the year
end financial statements and are not reported under “Audit Fees.” For the years ended December 31, 2023 and 2022, Marcum
LLP did not render such services.
Tax Fees. Tax fees consist of fees billed
for professional services relating to tax compliance, tax planning and tax advice. For the years ended December 31, 2023 and 2022, the
aggregate fees billed by Marcum LLP totaled $12,360 and $11,330, respectively, for rendering such services.
All Other Fees. All other fees consist
of fees billed for all other services. For the year ended December 31, 2023 and 2022, Marcum LLP did not render any of these other services.
Pre-Approval Policy
Our audit committee was formed upon the consummation
of our Initial Public Offering. As a result, the audit committee did not pre-approve all of the foregoing services, although any services
rendered prior to the formation of our audit committee were approved by our board of directors. Since the formation of our audit committee,
and on a going-forward basis, the audit committee has and will pre-approve all auditing services and permitted non-audit services to be
performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions for non-audit services described
in the Exchange Act which are approved by the audit committee prior to the completion of the audit).
ITEM 15. EXHIBIT
AND FINANCIAL STATEMENT SCHEDULES
| (a) | The following documents are filed as part of this Annual Report: |
Report
of Independent Registered Public Accounting Firm
To the Shareholders and Board of Directors of
Pyrophyte Acquisition Corp.
Opinion on the Financial Statements
We have audited the accompanying consolidated
balance sheets of Pyrophyte Acquisition Corp. (the “Company”) as of December 31, 2023 and 2022, the related consolidated
statements of income, shareholders’ deficit and cash flows for each of the two years ended December 31, 2023 and 2022, and the related
notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in
all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its
cash flows for each of the two years in the period ended December 31, 2023, in conformity with accounting principles generally accepted
in the United States of America.
Explanatory Paragraph – Going Concern
The accompanying consolidated financial statements
have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 1 the Company is a Special
Purpose Acquisition Corporation that was formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock
purchase, reorganization or similar business combination with one or more businesses or entities on or before April 29, 2025. The Company
entered into business combination agreement with a business combination target on November 13, 2023; however the completion of this transaction
is subject to the approval of the Company’s stockholders among other conditions. There is no assurance that the Company will obtain
the necessary approvals, satisfy the required closing conditions, raise the additional capital it needs to fund its business operations,
and complete the transaction prior to April 29, 2025, if at all. The Company also has no approved plan in place to extend the business
combination deadline and fund operations for any period of time after April 29, 2025, in the event that it is unable to complete a business
combination by that date. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's
plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that
might result from the outcome of this uncertainty.
Basis for Opinion
These financial statements are the responsibility
of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits.
We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and
are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules
and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were
we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain
an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of
the Company's internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that
respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as
well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis
for our opinion.
/s/ Marcum llp
Marcum llp
We have served as the Company’s auditor since 2021.
New York, NY
May 24, 2024
PYROPHYTE ACQUISITION CORP.
CONSOLIDATED BALANCE SHEETS
ASSETS | |
DECEMBER 31, 2023 | | |
DECEMBER 31, 2022 | |
Cash | |
$ | 1,253 | | |
$ | 13,372 | |
Prepaid expenses | |
| 108,458 | | |
| 298,422 | |
Due from related party | |
| - | | |
| 49,500 | |
Extension contribution due from Sponsor | |
| 480,000 | | |
| - | |
Total current assets | |
| 589,711 | | |
| 361,294 | |
Investments held in Trust Account | |
| 98,870,109 | | |
| 209,651,193 | |
Total Assets | |
$ | 99,459,820 | | |
$ | 210,012,487 | |
| |
| | | |
| | |
LIABILITIES, ORDINARY SHARES SUBJECT TO POSSIBLE REDEMPTION, AND SHAREHOLDERS’ DEFICIT | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 585,305 | | |
$ | - | |
Promissory note - extension loan | |
| 960,000 | | |
| - | |
Promissory note - working capital loan | |
| 723,322 | | |
| - | |
Due to related party | |
| 25,000 | | |
| - | |
Accrued expenses | |
| 281,839 | | |
| 222,020 | |
Total current liabilities | |
| 2,575,466 | | |
| 222,020 | |
Deferred underwriting fees payable | |
| 8,443,750 | | |
| 8,443,750 | |
Derivative warrant liabilities | |
| 1,617,500 | | |
| 1,516,406 | |
Deferred legal fees | |
| 3,048,734 | | |
| 1,322,174 | |
Total liabilities | |
| 15,685,450 | | |
| 11,504,350 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 5) | |
| | | |
| | |
| |
| | | |
| | |
Class A ordinary shares subject to possible redemption, $0.0001 par value; 8,973,837 and 20,125,000 shares at $11.06 and 10.41 per share at December 31, 2023 and December 31, 2022, respectively | |
| 99,250,100 | | |
| 209,551,185 | |
| |
| | | |
| | |
Shareholders’ deficit | |
| | | |
| | |
Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding | |
| - | | |
| - | |
Class A ordinary shares, $0.0001 par value; 200,000,000 shares authorized; 5,031,250 and -0- issued and outstanding at December 31, 2023 and December 31, 2022 respectively (excluding 8,973,837 and 20,125,000 shares subject to possible redemption, respectively) | |
| 503 | | |
| - | |
Class B ordinary shares, $0.0001 par value; 20,000,000 shares authorized; -0- and 5,031,250 shares issued and outstanding at December 31, 2023 and December 31, 2022 respectively | |
| - | | |
| 503 | |
Additional paid-in capital | |
| - | | |
| - | |
Accumulated deficit | |
| (15,476,233 | ) | |
| (11,043,551 | ) |
Total shareholders’ deficit | |
| (15,475,730 | ) | |
| (11,043,048 | ) |
Total Liabilities, Ordinary Shares Subject to Possible Redemption, and Shareholders’ Deficit | |
$ | 99,459,820 | | |
$ | 210,012,487 | |
The accompanying notes are an integral part
of these consolidated financial statements.
PYROPHYTE ACQUISITION CORP.
CONSOLIDATED STATEMENTS OF INCOME
| |
For The Year Ended December 31, 2023 | | |
For The Year Ended December 31, 2022 | |
| |
| | |
| |
General and administrative expenses | |
$ | 3,371,589 | | |
$ | 2,699,342 | |
Loss from operations | |
| (3,371,589 | ) | |
| (2,699,342 | ) |
Change in fair value of derivative warrant liabilities | |
| (101,094 | ) | |
| 9,990,487 | |
Gain on investments held in Trust Account | |
| 6,003,305 | | |
| 3,351,889 | |
Other Income | |
| - | | |
| 83 | |
Net income | |
$ | 2,530,622 | | |
$ | 10,643,117 | |
Weighted average shares outstanding of Class A ordinary shares subject to possible redemption, basic and diluted | |
| 12,426,115 | | |
| 20,125,000 | |
Basic and diluted net income per share, Class A subject to possible redemption | |
$ | 0.14 | | |
$ | 0.42 | |
Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted | |
| 5,031,250 | | |
| 5,031,250 | |
Basic and diluted net income per share, non-redeemable ordinary shares | |
$ | 0.14 | | |
$ | 0.42 | |
The accompanying notes
are an integral part of these consolidated financial statements.
PYROPHYTE ACQUISITION CORP.
CONSOLIDATED STATEMENTS OF ORDINARY SHARES SUBJECT
TO POSSIBLE REDEMPTION AND
SHAREHOLDERS’ DEFICIT
For the year ended December 31, 2023
| |
Ordinary Shares Subject to Possible Redemption | | |
Ordinary Shares | | |
Additional | | |
| | |
Total | |
| |
Class A | | |
Class A | | |
Class B | | |
Paid-In | | |
Accumulated | | |
Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balance as of January 1, 2023 | |
| 20,125,000 | | |
$ | 209,551,185 | | |
| - | | |
$ | - | | |
| 5,031,250 | | |
$ | 503 | | |
$ | - | | |
$ | (11,043,551 | ) | |
$ | (11,043,048 | ) |
Conversion of Class B ordinary shares to Class A ordinary shares | |
| - | | |
| - | | |
| 5,031,250 | | |
| 503 | | |
| (5,031,250 | ) | |
| (503 | ) | |
| - | | |
| - | | |
| - | |
Redemption of Class A ordinary shares | |
| (11,151,163 | ) | |
| (117,744,389 | ) | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Capital contribution made for non-redemption agreement | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 482,324 | | |
| - | | |
| - | |
Cost of raising capital related to shareholder non-redemption agreements | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (482,324 | ) | |
| - | | |
| - | |
Remeasurement of Class A ordinary shares to redemption value | |
| - | | |
| 6,963,304 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (6,963,304 | ) | |
| (6,963,304 | ) |
Extension contribution due from Sponsor | |
| - | | |
| 480,000 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | |
Net income | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 2,530,622 | | |
| 2,530,622 | |
Balance as of December 31, 2023 | |
| 8,973,837 | | |
$ | 99,250,100 | | |
| 5,031,250 | | |
$ | 503 | | |
$ | - | | |
$ | | | |
$ | - | | |
$ | (15,476,233 | ) | |
$ | (15,475,730 | ) |
For the year ended December 31, 2023
| |
Ordinary
Shares Subject to Possible Redemption | | |
Ordinary
Shares | | |
Additional | | |
| | |
Total | |
| |
Class
A | | |
Class
A | | |
Class
B | | |
Paid-In | | |
Accumulated | | |
Shareholders’ | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Deficit | |
Balance
as of January 1, 2022 | |
| 20,125,000 | | |
$ | 206,281,250 | | |
| - | | |
$ | - | | |
| 5,031,250 | | |
$ | 503 | | |
$ | - | | |
$ | (18,416,733 | ) | |
$ | (18,416,230 | ) |
Remeasurement
of Class A ordinary shares to redemption value | |
| - | | |
| 3,269,935 | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (3,269,935 | ) | |
| (3,269,935 | ) |
Net
income | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| 10,643,117 | | |
| 10,643,117 | |
Balance
as of December 31, 2022 | |
| 20,125,000 | | |
$ | 209,551,185 | | |
| - | | |
$ | - | | |
| 5,031,250 | | |
$ | 503 | | |
$ | - | | |
$ | (11,043,551 | ) | |
$ | (11,043,048 | ) |
The accompanying notes
are an integral part of these consolidated financial statements.
PYROPHYTE ACQUISITION CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
| |
For The Year Ended December 31, 2023 | | |
For The Year Ended December 31, 2022 | |
Cash Flows from Operating Activities | |
| | |
| |
Net income | |
$ | 2,530,622 | | |
$ | 10,643,117 | |
Adjustments to reconcile net income to net cash used in operating activities: | |
| | | |
| | |
Gain on investments held in Trust Account | |
| (6,003,305 | ) | |
| (3,351,889 | ) |
Change in fair value of derivative warrant liabilities | |
| 101,094 | | |
| (9,990,487 | ) |
Changes in operating assets and liabilities: | |
| | | |
| | |
Prepaid expenses | |
| 189,964 | | |
| 66,184 | |
Other current assets | |
| - | | |
| 290,089 | |
Due from related party | |
| 49,500 | | |
| (24,500 | ) |
Accounts payable | |
| 585,305 | | |
| - | |
Deferred legal fees | |
| 1,726,560 | | |
| 1,322,174 | |
Accrued expenses | |
| 59,819 | | |
| 91,889 | |
Net cash used in operating activities | |
| (760,441 | ) | |
| (953,323 | ) |
Cash Flows from Investing Activities | |
| | | |
| | |
Extension contribution deposit into the Trust Account | |
| (960,000 | ) | |
| - | |
Trust Account withdrawal - redemption | |
| 117,744,389 | | |
| - | |
Net cash provided by investing activities | |
| 116,784,389 | | |
| - | |
Cash Flows from Financing Activities | |
| | | |
| | |
Due to related party | |
| 25,000 | | |
| - | |
Proceeds from Promissory note – working capital loan | |
| 723,322 | | |
| - | |
Proceeds from Promissory note – extension loan | |
| 960,000 | | |
| - | |
Redemption of Class A ordinary shares | |
| (117,744,389 | ) | |
| - | |
Net cash used in financing activities | |
| (116,036,067 | ) | |
| - | |
| |
| | | |
| | |
Net decrease in cash | |
| (12,119 | ) | |
| (953,323 | ) |
Cash - beginning of period | |
| 13,372 | | |
| 966,695 | |
Cash - end of period | |
$ | 1,253 | | |
$ | 13,372 | |
| |
| | | |
| | |
Supplemental disclosure of noncash investing and financing activities: | |
| | | |
| | |
Remeasurement of Class A ordinary shares to redemption value | |
$ | 6,963,304 | | |
$ | 3,269,935 | |
Offering costs associated with non-redemption agreement | |
$ | 482,324 | | |
$ | - | |
Extension contribution due from Sponsor | |
$ | 480,000 | | |
$ | - | |
The accompanying notes
are an integral part of these consolidated financial statements.
PYROPHYTE ACQUISITION CORP.
NOTES
TO FINANCIAL STATEMENTS
Note 1 – Description of Organization, Business Operations,
Going Concern and Basis of Presentation
Pyrophyte Acquisition Corp. (the “Company” or “Pyrophyte”,
“we”, “our”) is a blank check company incorporated in Cayman Islands on February 12, 2021. The Company was formed
for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination
with one or more businesses (the “initial business combination”). The Company is an emerging growth company and, as such, the Company
is subject to all of the risks associated with emerging growth companies. Snowbank Newco Alberta ULC is a wholly owned subsidiary of the
Company formed as an Alberta unlimited liability company on October 20, 2023.
As of December 31, 2023, the Company had not yet
commenced any operations. All activity for the period from February 12, 2021 (inception) through December 31, 2023 relates to the Company’s
formation and the preparation of the initial public offering (the “Initial Public Offering”) described below, and since the
Initial Public Offering, the search for a prospective initial business combination. The Company will not generate any operating revenues
until after the completion of its initial business combination, at the earliest. The Company generates non-operating income in the form
of interest or dividend income on investments from the proceeds derived from the Initial Public Offering.
On November 13, 2023, the Company, Sio Silica Corporation, an Alberta
corporation (“Sio”), Sio Silica Incorporated, a newly-formed Alberta corporation formed solely for the purpose of engaging
in the Sio Business Combination and that is wholly owned by Feisal Somji, a nominee (“Nominee”) of Sio (“Sio Newco”),
and Snowbank NewCo Alberta ULC, an Alberta unlimited liability corporation and wholly-owned subsidiary of the Company (“Pyrophyte
Newco”) entered into a business combination agreement (the “Business Combination Agreement” and the transactions contemplated
thereby, the “Sio Business Combination”) subject to terms and conditions.
The Company’s sponsor is Pyrophyte
Acquisition LLC, a Delaware limited liability company (the “Sponsor”). The registration statement for the
Company’s Initial Public Offering was declared effective on October 26, 2021. On October 29, 2021, the Company consummated its
Initial Public Offering of 20,125,000 units (the “Units” and, with respect to the Class A ordinary shares included in
the Units offered, the “Public Shares”), including 2,625,000 additional Units to cover over-allotments (the
“Over-Allotment Units”), at $10.00 per Unit, generating gross proceeds of $201,250,000, and incurring $181,216 in other
offering costs, $2,625,000 in upfront underwriting fees (Note 5).
Simultaneously with the closing of the Initial
Public Offering, the Company consummated the private placement (“Private Placement”) of 10,156,250 warrants (each, a “Private
Placement Warrant” and collectively, the “Private Placement Warrants”) at a price of $1.00 per Private Placement Warrant
to the Sponsor, generating proceeds of $10,156,250 (Note 4).
Upon the closing of the Initial Public Offering and the Private Placement,
$206,281,250 ($10.25 per Unit) of the proceeds of the Initial Public Offering and the sale of the Private Placement Warrants were deposited
into a trust account (the “Trust Account”) in the United States at J.P. Morgan Chase Bank, N.A. maintained by Continental
Stock Transfer & Trust Company, acting as trustee, to be invested in U.S. government securities, within the meaning
set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or in money market funds meeting
certain conditions of Rule 2a-7 of the Investment Company Act of 1940, as amended (the “Investment Company Act”), which invest
only in direct U.S, government treasury obligations until the earlier of: (i) the consummation of a Business Combination or (ii) the distribution
of the funds in the Trust Account to the Company’s shareholders, as described below. On April 24, 2024, the Company amended the investment management trust agreement, dated as of October 26, 2021,
by and between the Company and Continental Stock Transfer and Trust Company, as trustee (as amended, the “Trust Agreement”),
to permit Continental Stock Transfer & Trust Company (the “Trustee”), to hold the assets in the Trust Account in an interest-bearing
demand deposit account or cash until the earlier of the consummation of an initial business combination or the Company’s liquidation.
On the same day, the Company instructed the Trustee to liquidate the investments held in the Trust Account and move the funds to an interest-bearing
demand deposit account, with Continental continuing to act as trustee. As a result, following the liquidation of investments in the Trust
Account, the remaining proceeds from the initial public offering and the sale of the private placement warrants are no longer invested
in U.S. government securities or money market funds.
The Company’s management has broad discretion
with respect to the specific application of the net proceeds of the Initial Public Offering and sale of the Private Placement Warrants,
although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. The New
York Stock Exchange rules provide that the Business Combination must occur with one or more target businesses that together have an aggregate
fair market value equal to at least 80% of the balance in the Trust Account (excluding the deferred underwriting commissions and taxes
payable on income earned on the Trust Account) at the time of the signing a definitive agreement to enter a Business Combination. The
Company will only complete a Business Combination if the post-Business Combination company owns or acquires 50% or more of the outstanding
voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register
as an investment company under the Investment Company Act. There is no assurance that the Company will be able to successfully effect
a Business Combination.
The Company will provide its holders of the outstanding Public Shares
(the “Public Shareholders”) with the opportunity to redeem all or a portion of their Public Shares upon the completion of
a Business Combination either (i) in connection with a shareholders meeting called to approve the Business Combination or (ii) by means
of a tender offer. In connection with an initial business combination, the Company may seek shareholder approval of a Business Combination
at a meeting called for such purpose at which Public Shareholders may seek to redeem their shares, regardless of whether they vote for
or against a Business Combination.
If the Company seeks shareholder approval of a Business Combination
and it does not conduct redemptions pursuant to the tender offer rules, the Company’s amended and restated memorandum and articles
of association (the “Articles”) provides that, a Public Shareholder, together with any affiliate of such shareholder or any
other person with whom such shareholder is acting in concert or as a “group” (as defined under Section 13 of the Exchange
Act), will be restricted from seeking redemption rights with respect to 15% or more of the Public Shares without the Company’s prior
written consent.
The Public Shareholders will be entitled to redeem their shares for
a pro rata portion of the amount then in the Trust Account (initially $10.25 per share, plus any pro rata interest or dividend earned
on the funds held in the Trust Account and not previously released to the Company to pay its tax obligations). The per-share amount to
be distributed to Public Shareholders who redeem their shares will not be reduced by the deferred underwriting commissions the Company
will pay to the representative of the underwriter (as discussed in Note 5). There will be no redemption rights upon the completion of
a Business Combination with respect to the Company’s warrants. These Class A ordinary shares were recorded at a redemption value
and classified as temporary equity upon the completion of the Initial Public Offering, in accordance with Accounting Standards Codification
(“ASC”) Topic 480 “Distinguishing Liabilities from Equity.”
If a shareholder vote is not required and the Company does not decide
to hold a shareholder vote for business or other legal reasons, the Company will, pursuant to its Articles, offer such redemption pursuant
to the tender offer rules of the Securities and Exchange Commission (the “SEC”), and file tender offer documents containing
substantially the same information as would be included in a proxy statement with the SEC prior to completing a Business Combination.
The Company’s Sponsor, officers and directors agreed (a) to vote
its Founder Shares (as defined in Note 4) and any Public Shares purchased during or after the Initial Public Offering in favor of a Business
Combination, (b) not to propose an amendment to the Company’s Articles with respect to the Company’s pre-Business Combination
activities prior to the consummation of a Business Combination unless the Company provides dissenting Public Shareholders with the opportunity
to redeem their Public Shares in conjunction with any such amendment; (c) not to redeem any shares (including the Founder Shares) and
Private Placement Warrants (including underlying securities) into the right to receive cash from the Trust Account in connection with
a shareholder vote to approve a Business Combination (or to sell any shares in a tender offer in connection with a Business Combination
if the Company does not seek shareholder approval in connection therewith) or a vote to amend the provisions of the Articles relating
to shareholders’ rights of pre- Business Combination activity and (d) that the Founder Shares and Private Placement Warrants (including
underlying securities) shall not participate in any liquidating distributions upon winding up if a Business Combination is not consummated.
However, the Sponsor will be entitled to liquidating distributions from the Trust Account with respect to any Public Shares purchased
during or after the Initial Public Offering if the Company fails to complete its Business Combination.
If the Company is unable to complete a Business Combination by the
April 29, 2025 (“Extended Date”) as approved at the Second Extension Meeting on April 26, 2024 (Note 9), the Company will
(i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but no more than ten business days
thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust
Account, including interest or dividend earned on the funds held in the Trust Account, which interest or dividend shall be net of taxes
payable and $100,000 of interest or dividend to pay dissolution expenses, divided by the number of then outstanding public shares, which
redemption will completely extinguish Public Shareholders’ rights as shareholders (including the right to receive further liquidation
distributions, if any), subject to applicable law, and (iii) as promptly as reasonably possible following such redemption, subject to
the approval of the remaining shareholders and the Company’s board of directors, proceed to commence a voluntary liquidation and
thereby a formal dissolution of the Company, subject in each case to its obligations to provide for claims of creditors and the requirement
of applicable law. The representative of the underwriter agreed to waive its rights to the deferred underwriting commission held in the
Trust Account in the event the Company does not complete a Business Combination by the Extended Date and, in such event, such amounts
will be included with the funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event
of such distribution, it is possible that the per share value of the assets remaining available for distribution will be less than the
Initial Public Offering price per Unit ($10.25).
The Sponsor agreed that it will be liable to the Company if and to
the extent any claims by a third party for services rendered or products sold to the Company, or a prospective target business with which
the Company has entered into a written letter of intent, confidentiality or similar agreement or Business Combination agreement, reduce
the amount of funds in the Trust Account to below the lesser of (i) $10.25 per Public Share and (ii) the actual amount per Public Share
held in the Trust Account as of the day of liquidation of the Trust Account, if less than $10.25 per share due to reductions in the value
of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or prospective target
business who executed a waiver of any and all rights to monies held in the Trust Account (whether or not such waiver is enforceable) nor
will it apply to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities,
including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). However, the Company has not asked
the Sponsor to reserve for such indemnification obligations, nor has the Company independently verified whether the Sponsor has sufficient
funds to satisfy its indemnity obligations. None of the Company’s officers or directors will indemnify the Company for claims by
third parties including, without limitation, claims by vendors and prospective target businesses.
First Extension Meeting
On April 24, 2023, we held an extraordinary
general meeting of shareholders (the “Extension Meeting”), pursuant to which our shareholders approved an amendment to
the Articles to extend the date by which the Company must complete initial business combination from April 29, 2023 to April 29,
2024 (the “Extended Date”) (or such earlier date as determined by our board of directors and included in a public announcement) (the
“Extension”). In connection therewith, the Sponsor agreed to loan us $160,000 for each calendar month beginning on April
30, 2023 and ending on the earlier of the completion of a business combination or the date of the our liquidation in accordance with
the terms of the Extension, up to a maximum aggregate amount of $1.92 million (the “Extension Contribution”). On May 4,
2023, we issued a convertible promissory note (the “Extension Note”) to the Sponsor with a principal amount up to $1.92
million. The Sponsor deposited the first Extension Contribution on April 30, 2023. As of December 31, 2023, $960,000 has been drawn
on the Extension Note and there were Trust Account deposits in connection with the Extension Note, totaling $960,000. Pursuant to
the Extension Note, the Sponsor may convert the principal outstanding into warrants at $1.00 per warrant. Such warrants will be
identical to the terms of the Private Placement Warrants. In connection with the vote to approve the Extension, the holders of
11,151,163 Class A ordinary shares properly exercised their right to redeem their shares for cash at a redemption price of
approximately $10.56 per share, for an aggregate redemption amount of approximately $118 million, resulting in 8,973,837 public
shares remaining. In addition, on April 28, 2023, holders of 5,031,250 Class B ordinary shares elected to convert such shares into
Class A ordinary shares on a one-for-one basis for no consideration.
The shareholders also approved a proposal to amend the Articles to permit the Company’s board of directors (the “Board”),
in its sole discretion, to elect to wind up the Company’s operations on an earlier date than the Extended Date as determined by
the Board and included in a public announcement. The shareholders also approved a proposal to amend the Articles to eliminate the limitation
that the Company may not redeem public shares in an amount that would cause the Company’s net tangible assets to be less than $5,000,001
in connection with the Company’s initial business combination. The shareholders also approved a proposal to provide for the right
of a holder of the Company’s Class B ordinary shares, par value $0.0001 per share (the “Class B ordinary shares”), to
convert into Class A ordinary shares, par value $0.0001 per share, on a one-for-one basis prior to the closing of an initial business
combination at the election of the holder.
Sio Business Combination
On November 13, 2023, the Company entered
into a business combination agreement (the “Sio Business Combination Agreement” and the transactions contemplated by the
Sio Business Combination Agreement, the “Sio Business Combination”) with Sio Silica Corporation, an Alberta corporation
(“Sio”), Sio Silica Incorporated, a newly-formed Alberta corporation that is wholly owned by Feisal Somji, a nominee
(“Nominee”) of Sio (“Sio Newco”), and Snowbank NewCo Alberta ULC, an Alberta unlimited liability corporation
and wholly-owned subsidiary of Pyrophyte (“Pyrophyte Newco”), pursuant to which, among other things and subject to the
terms and conditions contained therein, (i) the Company will transfer by way of continuation from the Cayman Islands to Alberta in
accordance with the Cayman Islands Companies Act (as revised) (the “Companies Act”) and continue as an Alberta
corporation in accordance with the applicable provisions of the Business Corporations Act (Alberta) (the “ABCA”) (such
continuation, the “Domestication”), (ii) following the Domestication, Pyrophyte will amalgamate with Sio Newco (the
“SPAC Amalgamation”), with Sio Newco surviving the SPAC Amalgamation (“Pubco”) in accordance with the terms
of a Plan of Arrangement (the “Plan of Arrangement”), and (iii) Sio and Pyrophyte Newco will amalgamate (the “Sio
Amalgamation” and together with the SPAC Amalgamation, the “Amalgamations”), with Sio surviving the Sio
Amalgamation as a wholly-owned subsidiary of Pubco and such entity will continue the business operations currently undertaken by
Sio. See “Management’s Discussion and Analysis of Financial Condition and Results of Operation--Business Combination
with Sio” for more information.
Subscription Agreements
Concurrently with the execution of the Sio Business
Combination Agreement, Pyrophyte, Sio and Sio Newco entered into subscription agreements with (i) a certain accredited investor (the “Non-Insider
PIPE Investor”) and (ii) certain other accredited investors who are existing shareholders of Sio or the Company (the “Insider
PIPE Investors” and, together with the Non-Insider PIPE Investor, the “PIPE Investors”), pursuant to which, among other
things, Sio Newco agreed to issue and sell, in a private placement to close concurrently with and conditioned upon the effectiveness of
the consummation of the Sio Business Combination, an aggregate of 3,114,258 Pubco Class A Common Shares (the “PIPE Investment”)
to the PIPE Investors for an aggregate purchase price equal to $20,122,474.
Sio Securityholder Support Agreements
In connection with the execution of the Sio Business Combination Agreement, on November 13, 2023, the Company,
Sio, and certain securityholders of Sio entered into support agreements (the “Sio Securityholder Support Agreements”), pursuant
to which, among other things, such shareholders agreed to vote (or cause to be voted) all of their Sio shares and other voting securities
of Sio (“Subject Securities”) in favor of the special resolution of Sio shareholders in respect of the Plan of Arrangement,
to be considered at Sio’s shareholders meeting to approve the Sio Business Combination. Additionally, such shareholders have agreed,
among other things, not to, prior to the Closing, (a) transfer any of their Subject Securities (or enter into any agreement, arrangement
or understanding in connection therewith other than pursuant to the Plan of Arrangement), subject to certain customary exceptions, or
(b) enter into any voting arrangement that is inconsistent with the Sio Securityholder Support Agreements. Sio covenants in the Sio Business
Combination Agreement that it will use commercially reasonable efforts to obtain Sio Securityholder Support Agreements from at least 66⅔%
of its shareholders as promptly as possible, but in any event, within five days of the execution date of the Sio Business Combination
Agreement.
Liquidity and Capital Resources and Going Concern
As of December 31, 2023, the Company had $1,253
in cash and no cash equivalents. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of its
financing and acquisition plans. If the Company’s estimates of the costs of identifying a target business, undertaking in-depth
due diligence, and negotiating a Business Combination are less than the actual amount necessary to do so, the Company may have insufficient
funds available to operate its business prior to an initial business combination. The liquidation deadline for the Company is also within
the next twelve months if an initial business combination is not consummated. The Company cannot assure that its plans to consummate an
initial business combination will be successful.
As a result of the above, in connection with the
Company’s assessment of going concern considerations in accordance with ASC Subtopic 205-40, “Presentation of Financial
Statements – Going Concern,” management has determined that the liquidity conditions and the proximity to liquidation date
raises substantial doubt about the Company’s ability to continue as a going concern. No adjustments have been made to the carrying
amounts of assets or liabilities should the Company be required to liquidate after the Extended Date. These consolidated financial statements
do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be
necessary should the Company be unable to continue as a going concern.
Note 2 – Summary of Significant Accounting Policies
Use of Estimates
The preparation of consolidated financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities
and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues
and expenses during the reporting period. The most significant estimates are related to the fair value of the warrants.
Making estimates requires management to exercise
significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances
that existed at the date of the consolidated financial statements, which management considered in formulating its estimate, could change
in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Basis of Presentation
The accompanying consolidated financial statements are presented in
U.S. dollars in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”) and pursuant to
the rules and regulations of the Securities and Exchange Commission.
Principles of Consolidation
The consolidated financial statements include the accounts of the Company
and its wholly owned subsidiary, Snowbank NewCo Alberta ULC, as of December 31, 2023. Snowbank NewCo Alberta ULC had no assets or liabilities
as of December 31, 2023. All significant intercompany transactions and balances have been eliminated in consolidation.
Cash and Cash Equivalents
The Company considers all short-term investments
with an original maturity of three months or less when purchased to be cash equivalents. As of December 31, 2023 and 2022, the Company
had cash of $1,253 and $13,372, respectively. The Company did not have any cash equivalents as of December 31, 2023 and 2022.
Concentration of Credit Risk
Financial instruments that potentially subject
the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal
depository insurance coverage of $250,000. The Company had not experienced losses on this account and management believes the Company
is not exposed to significant risks on such account.
Investments held in Trust Account
As of December 31, 2023 and 2022, the assets held
in the Trust Account were held in money market funds. The Company’s investments held in the Trust Account are classified as trading
securities. Trading securities are presented on the consolidated balance sheets at fair value at the end of each reporting period. Interest
or dividend income is included in gain on investments held in Trust Account in the accompanying consolidated statements of income. The
estimated fair values of investments held in Trust Account are determined using available market information.
Net Income Per Ordinary Share
The Company complies with accounting and disclosure
requirements of FASB ASC Topic 260, “Earnings Per Share.” Net income per ordinary share is computed by dividing net income
by the weighted average number of ordinary share outstanding during the period. The Company has not considered the effect of the warrants
sold in the Initial Public Offering and Private Placements to purchase Class A ordinary shares in the calculation of diluted income per
share, since their inclusion is contingent on a future event. As a result, diluted income per share is the same as basic income per share
for the periods presented.
The Company historically had two classes of ordinary
shares, which are referred to as Class A ordinary shares and Class B ordinary shares. Upon the conversion event in April 2023 to convert
Class B ordinary shares into Class A ordinary shares, the Company now has Class A redeemable and non-redeemable ordinary shares. Income
and losses are shared pro rata between the redeemable and non-redeemable ordinary shares. Net income per share, basic and diluted for
redeemable Class A ordinary shares is calculated by dividing the pro rata allocation of net income to redeemable Class A ordinary shares
for the year ended December 31, 2023 and 2022 by the weighted average number of redeemable Class A ordinary shares outstanding for the
periods. Net income per share basic and diluted for non-redeemable ordinary shares is calculated by dividing the pro rata allocation of
net income to non-redeemable ordinary shares for the year ended December 31, 2023 and 2022 by the weighted average number of non-redeemable
ordinary shares outstanding for the periods. Remeasurement associated with the redeemable shares of Class A ordinary shares is excluded
from earnings per share as the redemption value approximates fair value.
A reconciliation of the net
income per ordinary share is as follows.
| |
For The Year Ended December 31, 2023 | | |
For The Year Ended December 31, 2022 | |
Redeemable Class A Ordinary Shares | |
| | |
| |
Numerator: Net income allocable to Redeemable Class A Ordinary Shares | |
$ | 1,801,291 | | |
$ | 8,514,494 | |
| |
| | | |
| | |
Denominator: Weighted Average Share Outstanding, Redeemable Class A Ordinary Shares | |
| 12,426,115 | | |
| 20,125,000 | |
Basic and diluted net income per share, Class A subject to possible redemption | |
$ | 0.14 | | |
$ | 0.42 | |
| |
| | | |
| | |
Non-Redeemable Ordinary Shares | |
| | | |
| | |
Numerator: Net Income allocable to Non-Redeemable Ordinary Shares | |
$ | 729,331 | | |
$ | 2,128,623 | |
| |
| | | |
| | |
Denominator: Weighted average shares outstanding of non-redeemable ordinary shares, basic and diluted | |
| 5,031,250 | | |
| 5,031,250 | |
Basic and diluted net income per share, non-redeemable ordinary share | |
$ | 0.14 | | |
$ | 0.42 | |
Class A Ordinary Shares Subject to Possible Redemption
All of the Class A ordinary shares sold as part
of the Units in the Initial Public Offering contain a redemption feature which allows for the redemption of such Public Shares in connection
with the Company’s liquidation if there is a shareholder vote or tender offer in connection with the Business Combination and in
connection with certain amendments to the Company’s Articles. In accordance with SEC and its staff’s guidance on redeemable
equity instruments, which has been codified in ASC 480-10-S99, redemption provisions not solely within the control of the Company require
ordinary shares subject to redemption to be classified outside of permanent equity. Therefore, all Class A ordinary shares have been classified
outside of permanent equity.
The Company recognizes changes in redemption value
immediately as they occur and adjusts the carrying value of redeemable ordinary shares to equal the redemption value at the end of each
reporting period. Increases or decreases in the carrying amount of redeemable ordinary shares are affected by charges against additional
paid in capital and accumulated deficit.
The reconciliation of Class A ordinary shares
subject to possible redemption as of December 31, 2023 and 2022 is as follows:
| |
Shares | | |
Amount | |
Class A ordinary shares subject to possible redemption at December 31, 2021 | |
| 20,125,000 | | |
$ | 206,281,250 | |
Remeasurement of Class A ordinary shares to redemption value | |
| — | | |
| 3,269,935 | |
Class A ordinary shares subject to possible redemption at December 31, 2022 | |
| 20,125,000 | | |
$ | 209,551,185 | |
Remeasurement of Class A ordinary shares to redemption value | |
| — | | |
| 6,963,304 | |
Extension contribution due from Sponsor | |
| — | | |
| 480,000 | |
Redemption of Class A ordinary shares | |
| (11,151,163 | ) | |
| (117,744,389 | ) |
Class A ordinary shares subject to possible redemption at December 31, 2023 | |
| 8,973,837 | | |
$ | 99,250,100 | |
Fair Value Measurements
Fair value is defined as the price that would
be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement
date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value.
The hierarchy gives the highest priority to unadjusted
quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs
(Level 3 measurements). These tiers include:
| ● | Level 1, defined as observable inputs such as quoted prices
for identical instruments in active markets; |
| ● | Level 2, defined as inputs other than quoted prices in active
markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices
for identical or similar instruments in markets that are not active; and |
| ● | Level 3, defined as unobservable inputs in which little or
no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques
in which one or more significant inputs or significant value drivers are unobservable. |
In some circumstances, the inputs used to measure
fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is
categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Fair Value of Financial Instruments
As of December 31, 2023 and 2022, the carrying
values of cash, accounts payable, and accrued expenses, which qualify as financial instruments under the FASB ASC 820, “Fair Value
Measurements and Disclosures,” approximate the carrying amounts represented in the consolidated balance sheets.
The fair value of warrants issued in connection
with the Initial Public Offering were initially measured at fair value using a Monte Carlo simulation model for the Public Warrants and
Private Placement Warrants. As of December 31, 2023 and 2022, the fair value of the Public Warrants are valued based on the listed market
price of the Public Warrants since they began trading on December 17, 2021. As of December 31, 2023 and 2022, the fair value of the Private
Placement Warrants were measured by reference to the trading price of the Public Warrants, which is considered to be a Level 2 fair value
measurement.
Derivative Instruments
The Company does not use derivative instruments
to hedge its exposures to cash flow, market, or foreign currency risks. Management evaluates all of the Company’s financial instruments,
including issued warrants to purchase its Class A ordinary shares, to determine if such instruments are derivatives or contain features
that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification of derivative instruments, including whether
such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period.
The Company determined that the conversion option
embedded in its Extension Loan and the Working Capital Loan (as defined below) (together, the “Promissory Notes”) should be
bifurcated and accounted for as a derivative in accordance with ASC 815. However, the exercise price of the underlying warrants was greater
than the closing price of the Company’s Class A ordinary shares as of December 31, 2023, and when the Promissory Notes were drawn
on. The Company believes that the likelihood of the Sponsor’s exercise of the option to convert the Promissory Notes to warrants
is de minimis. As a result, the Company recorded zero liability related to the conversion option on the Promissory Notes. As of December
31, 2023, $960,000 has been drawn on the Extension Loan and $723,322 was outstanding on the Working Capital Loan.
The Company issued 10,062,500 Public warrants to purchase Class A ordinary
shares to investors in the Company’s Initial Public Offering and simultaneously issued 10,156,250 Private Placement Warrants. All
of the Company’s outstanding warrants are recognized as derivative liabilities in accordance with ASC 815-40. Accordingly, we recognize
the warrant instruments as liabilities at fair value and adjust the instruments to fair value at each reporting period. The liabilities
are subject to re- measurement at each balance sheet date until exercised, and any change in fair value is recognized in the consolidated
statements of income.
Non-Redemption Agreements
As of December 31, 2023, in connection with the
58,570 Class A ordinary shares the Company agreed to transfer to the Investors on or promptly after the consummation of the Sio Business
Combination pursuant to the Non-Redemption Agreement, the Company estimated the aggregate fair value of the 58,570 Class A ordinary shares
attributable to the non-redeeming Pyrophyte shareholder to be $482,324 or a weighted average of $8.24 per share, which is estimated by
taking into considerations the estimated probability of the consummation of consummating the Sio Business Combination. The fair value
of the Class A ordinary shares to be issued to the non-redeeming shareholder was determined to be an offering cost in accordance with
Staff Accounting Bulletin Topic 5A. In substance, the Company recognized the offering cost as a capital contribution to induce the shareholder
not to redeem its Class A ordinary shares, with a corresponding charge to additional paid-in capital to recognize the fair value of the
shares transferred as an offering cost.
Income Taxes
The Company accounts for income taxes under ASC
740, “Income Taxes” (“ASC 740”). ASC 740 requires the recognition of deferred tax assets and liabilities for both
the expected impact of differences between the consolidated financial statements and tax basis of assets and liabilities and for the expected
future tax benefit to be derived from tax loss and tax credit carry forwards. ASC 740 additionally requires a valuation allowance to be
established when it is more likely than not that all or a portion of deferred tax assets will not be realized.
ASC 740 also clarifies the accounting for uncertainty
in income taxes recognized in an enterprise’s consolidated financial statements and prescribes a recognition threshold and measurement
process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. For those
benefits to be recognized, a tax position must be more-likely-than-not to be sustained upon examination by taxing authorities. The Company
recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. There were no unrecognized tax benefits
and no amounts accrued for interest and penalties for the year ended December 31, 2023 and 2022. The Company is currently not aware of
any issues under review that could result in significant payments, accruals or material deviation from its position.
The Company is considered an exempted Cayman Islands
Company and is presently not subject to income taxes or income tax filing requirements in the Cayman Islands or the United States. As
such, the Company’s tax provision was zero for the periods presented.
Risk and Uncertainties
Management continues to evaluate the impact of
ongoing geopolitical instability events, including the Russia-Ukraine conflict and the Israel-Hamas conflict, and has concluded that while
it is reasonably possible that the war could have a negative effect on the Company’s financial position, results of its operations
and/or search for a target company, the specific impact is not readily determinable as of the date of these financial statements. The
financial statements do not include any adjustments that might result from the outcome of this uncertainty.
These conflicts are expected to have further global
economic consequences, including but not limited to the possibility of severely diminished liquidity and credit availability, declines
in consumer confidence, declines in economic growth, increases in inflation rates and uncertainty about economic and political stability.
In addition, the United States and other countries have imposed sanctions on Russia which increases the risk that Russia, as a retaliatory
action, may launch cyberattacks against the United States, its government, infrastructure and businesses. Any of the foregoing consequences,
including those we cannot yet predict, may cause our business, financial condition, results of operations and the price of our ordinary
shares to be adversely affected.
Emerging Growth Company
The Company is an “emerging growth company,”
as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”),
and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that
are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting
firm attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation
in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive
compensation and shareholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts
emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that
is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered
under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging
growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth
companies but any such an election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period,
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s consolidated financial statements with another public company that is neither an emerging
growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because
of the potential differences in accounting standards used.
Recent Accounting Pronouncements
In June 2016, the FASB issued ASU No. 2016-13, Credit
Losses - Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires
entities to use a forward-looking approach based on current expected credit losses (“CECL”) to estimate credit losses on
certain types of financial instruments, including trade receivables. This may result in the earlier recognition of allowances for losses. ASU 2016-13 is
effective for the Company beginning January 1, 2023, and the adoption did not have an impact on the consolidated financial statements.
In
December 2023, the FASB issued ASU 2023-09, Income
Taxes (“Topic 740”): Improvements to Income Tax Disclosures (“ASU 2023-09”),
which requires public entities to disclose specific categories in its annual effective tax rate reconciliation and disaggregated information
about significant reconciling items by jurisdiction and by nature. ASU 2023-09 also
requires entities to disclose their income tax payments (net of refunds) to international, federal, and state and local jurisdictions.
This guidance is effective for fiscal years beginning after December 15, 2024, and requires prospective application with the option to
apply it retrospectively. Early adoption is permitted. The Company is currently evaluating the impact of this guidance on the consolidated
financial statements and disclosures.
Note 3 – Initial Public Offering
Pursuant to the Initial Public Offering, the Company
sold 20,125,000 Units at a purchase price of $10.00 per Unit. Each Unit consists of one share of Class A ordinary shares and one-half
of one redeemable warrant (“Public Warrant”). Each whole Public Warrant entitles the holder to purchase one share of Class
A ordinary shares at an exercise price of $11.50 per share.
Note 4 – Related Party Transactions
Class B Founder Shares
On February 24, 2021, the Sponsor paid $25,000,
or approximately $0.004 per share, to cover certain offering costs in consideration for 5,750,000 Class B ordinary shares, par value $0.0001
(the “Founder Shares”). Up to 750,000 Founder Shares were subject to forfeiture by the Sponsor depending on the extent to
which the underwriter’s over-allotment option was exercised. At the close of the Initial Public Offering, the underwriter exercised
its overallotment option in full and these Founder Shares were no longer subjected to forfeiture as of October 29, 2021.
On September 29, 2021, the Sponsor effected a
surrender of 718,750 Class B ordinary shares to the Company for no consideration, resulting in an aggregate of 5,031,250 of Class B ordinary
shares outstanding. Prior to the initial investment in the Company of $25,000 by the Sponsor, we had no assets, tangible or intangible.
The per share purchase price of the Founder Shares was determined by dividing the amount of cash contributed to the Company by the aggregate
number of Founder Shares issued. In connection with the Extension, all 5,031,250 Class B ordinary shares were converted from Class B ordinary
shares into Class A ordinary shares on a one-for-one basis for no consideration.
Private Placement Warrants
Simultaneously with the closing of the Initial
Public Offering, the Company consummated the Private Placement of 10,156,250 Private Placement Warrants at a price of $1.00 per Private
Placement Warrant to the Sponsor, generating proceeds of $10,156,250.
Each warrant is exercisable to purchase one Class
A ordinary share at a price of $11.50 per share. Certain proceeds from the sale of the Private Placement Warrants were added to the proceeds
from the Initial Public Offering held in the Trust Account. If the Company does not complete a Business Combination by the Extended Date,
the proceeds from the sale of the Private Placement Warrants will be used to fund the redemption of the Public Shares (subject to the
requirement of applicable law) and the Private Placement Warrants will expire worthless.
Convertible Promissory Notes
Promissory Note – Extension Loan
In connection with the Extension, the Sponsor
agreed to loan the Company an amount equal to the lesser of (i) $0.04 per public share multiplied by the number of public shares then
outstanding and (ii) $160,000, for each calendar month beginning on April 30, 2023 until the earlier of (i) the completion of a Business
Combination and (ii) the Company’s liquidation (each, a “Contribution”).
In connection with the first Contribution, on
May 4, 2023, the Company issued a convertible promissory note to the Sponsor with a principal amount up to $1.92 million for working capital
expenses (as discussed in Note 1). The convertible promissory note bears no interest and is repayable in full upon the earlier of the
consummation of the Company’s initial Business Combination, or the liquidation of the Company. If the Company does not consummate
an initial Business Combination by the Extended Date, the convertible promissory note will be repaid only from funds held outside of the
Trust Account or will be forfeited, eliminated or otherwise forgiven. Upon maturity, the outstanding principal of the convertible promissory
note may be converted into warrants identical to the Private Placement Warrants, at a price of $1.00 per warrant, at the option of the
Sponsor. As of December 31, 2023, the Sponsor has advanced $960,000 to the Company representing extension contribution through September
30, 2023. As of December 31, 2023, extension contribution of $480,000 is due from Sponsor.
The Company determined that the conversion option
should be bifurcated and accounted for as a derivative in accordance with ASC 815. However, the exercise price of the underlying warrants
was greater than the closing price of the Company’s Class A ordinary shares as of December 31, 2023, and when the convertible promissory
note was drawn on. The Company believes that the likelihood of the Sponsor’s exercise of the option to convert the convertible promissory
note to warrants is de minimis. As a result, the Company recorded zero liability related to the conversion option.
Promissory Note – Working Capital Loan
The Sponsor has committed to loan us up to $1,500,000
for working capital loans (as amended and restated, the “Working Capital Loan”). If the Company completes an initial business
combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. In the
event that an initial business combination does not close, the Company may use a portion of proceeds held outside the Trust Account to
repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working
Capital Loans bear no interest and would either be repaid upon consummation of an initial business combination or, at the Sponsor’s
discretion. In addition, up to $1,500,000 of such Working Capital Loans may be convertible into Private Placement Warrants of the Company
at a price of $1.00 per warrant. As of December 31, 2023 and 2022, the Company had $723,322 and $0 outstanding under the Working Capital
Loans.
Administrative Support Agreement
Commencing on the date of the Initial Public Offering,
the Company has paid the Sponsor $15,000 per month for utilities, secretarial and administrative support services provided
to the members of the Company’s management team, which included payment of $10,000 per month to our former Chief Financial Officer
and Executive Vice President of Business Development. Upon completion of the initial business combination or the Company’s liquidation,
the Company will cease paying these monthly fees. On July 1, 2022 the Company amended the administrative support agreement with the Sponsor
from $15,000 per month to $5,000 per month. The Company incurred $60,000 and $120,000 for the years ended December 31, 2023 and 2022,
respectively, in Sponsor administrative fees.
For the years ended December 31, 2023 and 2022,
the Company reimbursed management $21,205 and $101,870, respectively, for expenses related to acquisition activities.
Due from Related Party
As of December 31, 2023 and 2022, the
Company was due $0 and $49,500, respectively, from the Sponsor for an over payment of reimbursable expenses and administrative
support fees.
Due to Related Party
As of December 31, 2023 and 2022, the Company
has an outstanding balance of $25,000 and $0 respectively due to the Sponsor for administrative support services.
Extension Contribution Due from Sponsor
In connection with the Extension, the Sponsor
is obligated to fund the Trust Account with $160,000 each month until April 30, 2024. As of December 31, 2023, $480,000 representing the
first extension contribution for the seventh, eighth, and ninth months of the Extension is due from Sponsor.
Sponsor Support Agreement
Concurrently with the execution of the Sio Business
Combination Agreement, the Sponsor entered into a letter agreement (the “Sponsor Support Agreement”) with Sio, Sio Newco,
Pyrophyte and the directors and officers (or otherwise a part of the management team) of Pyrophyte, solely for purposes of amending certain
of the terms of the letter agreement signed by them in connection with the Initial Public Offering, pursuant to which, among other things,
the Sponsor agreed to among other things, vote all Class A Ordinary Shares, or any securities convertible into, exercisable or exchangeable
for Class A Ordinary Shares, held by it or acquired after the date of the Sponsor Support Agreement (the “Covered Shares”)
at the meeting of Pyrophyte shareholders to be held in connection with the Sio Business Combination in favor of the adoption and approval
of the Sio Business Combination and each other proposal related to the Sio and not transfer any Covered Shares (other than Pubco Class
A Common Shares issued upon exercise of any Private Placement Warrants held by the Sponsor) until the earlier of (A) one year after the
closing of the Sio Business Combination, (B) the first day the last sale price of Pubco Class A Common Shares equals or exceeds $12.00
per share for any 20 trading days within a 30-day trading period commencing at least 150 days after the Closing or (C) after the closing
of the Sio Business Combination, the date on which Pubco completes a liquidation, amalgamation, share exchange or similar transaction
resulting in the shareholders of Pubco having the right to exchange their shares for consideration.
In addition, under the terms of the Sponsor Support
Agreement, the Sponsor agreed to subject up to 4,025,000 Class A Ordinary Shares (“Restricted Owned Shares”) to certain earn
out restrictions, if and only to the extent such shares are used to obtain any additional PIPE financing or other financing arrangements
in connection with the consummation of the Sio Business Combination; provided that in no event shall the aggregate number of Restricted
Owned Shares equal more than 4,025,000 Class A Ordinary Shares (the “Maximum Restricted Owned Shares”). If, prior to the closing
of the Sio Business Combination, the SPAC Proceeds (as defined in the Sio Business Combination Agreement) are less than $70,000,000, then
the number of Restricted Owned Shares will be adjusted pursuant to the terms of the Sponsor Support Agreement.
Note 5 – Commitments & Contingencies
Registration and Shareholder Rights
The holders of Founder Shares and Private Placement
Warrants that may be issued upon conversion of the Working Capital Loans and convertible promissory note, if any (and any Class A ordinary
share issuable upon the exercise of the Private Placement Warrants issued upon conversion of such loans), are entitled to registration
rights pursuant to a registration rights agreement signed prior to the consummation of the Initial Public Offering. These holders are
entitled to certain demand and “piggyback” registration rights. However, the registration rights agreement provides that we
will not be required to effect or permit any registration or cause any registration statement to become effective until termination of
the applicable lock- up period. The Company will bear the expenses incurred in connection with the filing of any such registration statements.
Underwriting Agreement
The Company granted the underwriter a 45-day option
to purchase up to 2,625,000 additional Units to cover over-allotments at the Initial Public Offering price, less the underwriting discounts
and commissions. The underwriter fully exercised the option on October 29, 2021.
The underwriter is entitled to a cash underwriting
discount of 1.5% of the gross proceeds of the Initial Public Offering, or $2,625,000 in the aggregate, which was paid upon closing
of the Initial Public Offering. In addition, the underwriter is entitled to a deferred fee of 4.0% of the gross proceeds of the Initial
Public Offering. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event
that the Company completes a Business Combination, subject to the terms of the underwriting agreement.
On June 8, 2023, we entered into an engagement
letter with UBS, which was subsequently amended on October 26, 2023, pursuant to which the Company engaged UBS to act as its exclusive
capital markets advisor with respect to the Sio Business Combination. Pursuant to such engagement letter, if the Sio Business Combination
closes, UBS agreed to waive the $8,443,750 of deferred underwriting commission owed to it in connection with the Initial Public Offering
in exchange for the right to receive a transaction fee of $5,000,000, plus an incentive fee of up to $3,443,750, each of which is payable
upon the closing of the Sio Business Combination. In addition, certain members of our management team have agreed to offset a certain
amount of fees that may be due to UBS under this engagement letter.
Investment Advisory Agreement
On November 5, 2021, the Company entered into
an investment advisory agreement with Clean Energy Associates, LLC (“Clean Energy”), pursuant to which Clean Energy will serve
as an investment advisor in connection with the Company’s initial Business Combination. If the Company enters into a letter of intent
with a potential target that has been introduced to it by Clean Energy, it shall pay Clean Energy a cash success fee of $40,000. Clean
Energy shall also be paid a retainer of up to $40,000. This agreement was subsequently terminated. As of and for the
period ended December 31, 2023 and 2022 there were no amounts incurred and accrued for Clean Energy.
Financial Advisory Agreements
On March 18 and March 28, 2022, respectively,
the Company engaged UBS, the underwriter in the Initial Public Offering, as a placement agent and to serve as financial advisor and capital
markets advisor in connection with a specified de-SPAC transaction. Under that arrangement, the Company agreed to pay UBS a cash fee for
such services upon the consummation of such transaction in an amount equal to $3,000,000. The letter of intent related to such potential
de-SPAC transaction expired on July 1, 2022 and, as such, rendered the engagement letter void and no future accrual or expense thereunder
was booked. The engagement letter also provided for up to $25,000 in reimbursable fees to UBS and as of the expiration date of the agreement,
there are no reimbursable fees incurred by the Company.
On June 5, 2023, Sio entered into an engagement
letter with UBS and BMO Capital Markets (“BMO” and together with UBS, the “Placement Agents”), pursuant to which
the Placement Agents agreed to serve as co-placement agents in connection with a proposed PIPE offering of securities of Sio Newco in
connection with the Sio Business Combination. Pursuant to a separate letter agreement entered into on the same day between the Company
and the Placement Agents, the Company agreed that, in the event that the Sio Business Combination is not consummated, it would reimburse
the Placement Agents for its reasonable, documented, out of pocket expenses incurred by such Placement Agent in their role as Placement
Agents up to an aggregate amount of $300,000.
Non-Redemption Agreement
Concurrently with the execution of the Business
Combination Agreement, Pyrophyte and Sio Newco entered into a non-redemption agreement with a Pyrophyte shareholder with respect to 100,000
SPAC Class A Ordinary Shares held by such shareholder (the “Non-Redemption SPAC Shares”), pursuant to which, among other things,
Pyrophyte agreed to issue 58,570 SPAC Class A Ordinary Shares to such shareholder in consideration of such shareholder’s commitment
not to redeem the Non-Redemption SPAC Shares held by it in connection with the approval of the Sio Business Combination by Pyrophyte’s
shareholders.
Note 6 – Derivative Warrant Liabilities
The Company accounted for the 20,218,750 warrants issued in connection
with the Initial Public Offering (the 10,062,500 of Public Warrants and the 10,156,250 of Private Placement Warrants) in accordance with
the guidance contained in ASC 815- 40 Derivatives and Hedging — Contracts in Entity’s Own Equity. Such guidance provides
that, because the warrants do not meet the criteria for equity treatment thereunder, each warrant must be recorded as a liability. Accordingly,
the Company classifies each warrant as a liability at its fair value. This liability is subject to re-measurement at each balance sheet
date. With each such re-measurement, the warrant liability will be adjusted to fair value, with the change in fair value recognized in
the Company’s consolidated statements of income.
Additionally, certain adjustments to the settlement
amount of the Private Placement Warrants are based on a variable that is not an input to the fair value of a “fixed-for-fixed”
option as defined under ASC 815-40, and thus the Private Placement Warrants are not considered indexed to the Company’s own stock
and not eligible for an exception from derivative accounting.
The accounting treatment of derivative financial instruments requires
that the Company record a derivative liability upon issuance of the warrants at the closing of the Initial Public Offering. Accordingly,
the Company classified each warrant as a liability at its fair value. The Public Warrants were allocated a portion of the proceeds from
the issuance of the Units equal to its fair value determined with the assistance of a professional independent valuation firm. The warrant
liability is subject to re-measurement at each balance sheet date. With each such re-measurement, the warrant liability is adjusted to
fair value, with the change in fair value recognized in the Company’s consolidated statements of income. The Company reassesses
the classification of the warrants at each balance sheet date. If the classification changes as a result of events during the period,
the warrants will be reclassified as of the date of the event that causes the reclassification.
Public Warrants may only be exercised for a whole
number of shares. No fractional Public Warrants were issued upon separation of the Units and only whole Public Warrants will trade. The
Public Warrants became exercisable 30 days after the completion of an initial public offering provided that the Company has an effective
registration statement under the Securities Act covering the Class A ordinary share issuable upon exercise of the warrants and a current
prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or
blue sky, laws of the state of residence of the holder (or holders are permitted to exercise their warrants on a cashless basis under
certain circumstances as a result of (i) the Company’s failure to have an effective registration statement by the 60th
business day after the closing of the initial business combination or (ii) a notice of redemption described under “Redemption of
warrants when the price per share of Class A ordinary share equals or exceeds $10.00”). The Company has agreed that as soon as practicable,
but in no event later than 20 business days after the closing of its initial business combination, the Company will use its commercially
reasonable efforts to file with the SEC and have an effective registration statement covering the Class A ordinary share issuable upon
exercise of the warrants and will use its commercially reasonable efforts to cause the same to become effective within 60 business days
after the closing of the Company’s initial business combination and to maintain a current prospectus relating to those Class A ordinary
share until the warrants expire or are redeemed. If the shares issuable upon exercise of the warrants are not registered under the Securities
Act in accordance with the above requirements, the Company will be required to permit holders to exercise their warrants on a cashless
basis. However, no warrant will be exercisable for cash or on a cashless basis, and the Company will not be obligated to issue any shares
to holders seeking to exercise their warrants, unless the issuance of the shares upon such exercise is registered or qualified under the
securities laws of the state of the exercising holder, or an exemption from registration is available. Notwithstanding the above, if the
Company’s Class A ordinary share are at the time of any exercise of a warrant not listed on a national securities exchange such
that they satisfy the definition of a “covered security” under Section 18(b)(1) of the Securities Act, the Company may, at
its option, require holders of Public Warrants who exercise their warrants to do so on a “cashless basis” in accordance with
Section 3(a)(9) of the Securities Act and, in the event the Company so elects, it will not be required to file or maintain in effect a
registration statement, and in the event the Company does not so elect, it will use its commercially reasonable efforts to register or
qualify the shares under applicable blue sky laws to the extent an exemption is not available.
The warrants have an exercise price of $11.50
per share, subject to adjustments, and will expire five years after the completion of a Business Combination or earlier upon redemption
or liquidation. In addition, if (x) the Company issues additional Class A ordinary share or equity-linked securities for capital raising
purposes in connection with the closing of the initial business combination at an issue price or effective issue price of less than $9.20
per share of Class A ordinary share (with such issue price or effective issue price to be determined in good faith by the board of directors
and, in the case of any such issuance to the Sponsor or its affiliates, without taking into account any Founder Shares held by the Sponsor
or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross proceeds from
such issuances represent more than 60% of the total equity proceeds, and interest or dividend thereon, available for the funding of the
initial business combination on the date of the consummation of the initial business combination (net of redemptions) and (z) the volume
weighted average trading price of Class A ordinary share during the 20 trading day period starting on the trading day prior to the day
on which the Company consummates the initial business combination (such price, the “Market Value”) is below $9.20 per share,
the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value and the
Newly Issued Price, and the $10.00 and $18.00 per share redemption trigger prices described under “Redemption of warrants for Class
A ordinary share” and “Redemption of warrants for cash” will be adjusted (to the nearest cent) to be equal to 100% and
180% of the higher of the Market Value and the Newly Issued Price, respectively.
The Private Placement Warrants are identical to
the Public Warrants, except that, so long as they are held by the Sponsor or its permitted transferees, (i) they will not be redeemable
by the Company, (ii) they (including the Class A ordinary share issuable upon exercise of these warrants) may not, subject to certain
limited exceptions, be transferred, assigned or sold by the Sponsor until 30 days after the completion of the initial business combination,
(iii) they may be exercised by the holders on a cashless basis and (iv) are subject to registration rights.
If a tender offer, exchange or redemption offer
shall have been made to and accepted by the holders of the Class A ordinary share and upon completion of such offer, the offeror owns
beneficially more than 50% of the outstanding Class A ordinary share the holder of the warrant shall be entitled to receive the highest
amount of cash, securities or other property to which such holder would actually have been entitled as a shareholder if such warrant had
been exercised, accepted such offer and all of the Class A ordinary share held by such holder had been purchased pursuant to the offer.
If less than 65% of the consideration receivable by the holders of the Class A ordinary share in the applicable event is payable in the
form of common equity in the successor entity that is listed on a national securities exchange or is quoted in an established over-the-counter
market, and if the holder of the warrant properly exercises the warrant within thirty days following the public disclosure of the consummation
of the applicable event by the Company, the warrant price shall be reduced by an amount equal to the difference (but in no event less
than zero) of (i) the warrant price in effect prior to such reduction minus (ii) (A) the Per Share Consideration (as defined in the warrant
agreement) minus (B) the value of the warrant based on the Black-Scholes Warrant Value for a Capped American Call on Bloomberg Financial
Markets.
Redemption of warrants
when the price per share of Class A ordinary share equals or exceeds $18.00: Once the warrants become exercisable, the Company may
redeem the outstanding warrants (except as described herein with respect to the Private Placement Warrants):
| ● | in whole and not in part; |
| ● | at a price of $0.01 per warrant; |
| ● | upon a minimum of 30 days’ prior written notice of
redemption; and |
| ● | if, and only if, the last reported sale price (the “closing
price”) of Class A ordinary share equals or exceeds $18.00 per share (as adjusted for adjustments to the number of shares issuable
upon exercise or the exercise price of a warrant as described under the heading “Description of Securities — Warrants —
Public Warrants — Redemption Procedures — Anti-dilution Adjustments”) for any 20 trading days within a 30-trading day
period ending on the third trading day prior to the date on which we send the notice of redemption to the warrant holders. |
The Company will not redeem the warrants as described
above unless an effective registration statement under the Securities Act covering the Class A ordinary share issuable upon exercise of
the warrants is effective and a current prospectus relating to those Class A ordinary share is available throughout the 30-day redemption
period. Any such exercise would not be on a cashless basis and would require the exercising warrant holder to pay the exercise price for
each warrant being exercised.
Redemption of warrants
when the price per share of Class A ordinary share equals or exceeds $10.00: Once the warrants become exercisable, the Company may
redeem the outstanding warrants:
| ● | in whole and not in part; |
| ● | at a price of $0.10 per warrant upon a minimum of 30 days’
prior written notice of redemption; provided that holders will be able to exercise their warrants on a cashless basis prior to redemption
and receive that number of shares determined by reference to the table set forth under “Description of Securities — Warrants
— Public Warrants” based on the redemption date and the “fair market value” of Class A ordinary share (as defined
below) except as otherwise described in “Description of Securities — Warrants — Public Warrants”; and; |
| ● | if, and only if, the closing price of Class A ordinary share
equals or exceeds $10.00 per public share (as adjusted for adjustments to the number of shares issuable upon exercise or the exercise
price of a warrant as described under the heading “Description of Securities — Warrants — Public Warrants — Redemption
Procedures — Anti-dilution Adjustments”) for any 20 trading days within the 30-trading day period ending three trading days
before we send the notice of redemption to the warrant holders; and |
| ● | if the closing price of the Class A ordinary share for any
20 trading days within a 30-trading day period ending on the third trading day prior to the date on which we send the notice of redemption
to the warrant holders is less than $18.00 per share (as adjusted for adjustments to the number of shares issuable upon exercise or the
exercise price of a warrant as described under the heading “Description of Securities — Warrants — Public Warrants
— Redemption Procedures — Anti-dilution Adjustments”), the Private Placement Warrants must also be concurrently called
for redemption on the same terms as the outstanding public warrants, as described above. |
In no event will the Company be required to net
cash settle any warrant. If the Company is unable to complete a Business Combination by the Extended Date and the Company liquidates the
funds held in the Trust Account, holders of warrants will not receive any of such funds with respect to their warrants, nor will they
receive any distribution from the Company’s assets held outside of the Trust Account with the respect to such warrants. Accordingly,
the warrants may expire worthless.
Note 7 – Shareholders’ Deficit
Preference shares - The Company is authorized
to issue 1,000,000 shares of preference shares, par value $0.0001 per share, with such designations, voting and other rights and preferences
as may be determined from time to time by the Company’s board of directors. As of December 31, 2023 and 2022, there were no preference
shares issued or outstanding.
Class A ordinary shares - The Company is authorized to issue 200,000,000
Class A ordinary shares with a par value of $0.0001 per share. As of December 31, 2023 and 2022, there were 5,031,250 and -0- Class A
ordinary shares issued or outstanding (excluding 8,973,837 and 20,125,000 Class A ordinary shares subject to possible redemption), respectively.
Class B ordinary shares - The Company is authorized to issue 20,000,000
Class B ordinary shares with a par value of $0.0001 per share. On September 29, 2021, the Sponsor surrendered 718,750 Founder Shares to
us for cancelation for no consideration, resulting an aggregate of 5,031,250 Founder Shares outstanding. On April 24, 2023, in connection
with the Company’s extraordinary meeting, passed an amendment to the Company’s Articles allowing Class B shareholders the
right to convert their shares into Class A ordinary shares at the election of the holder. As a result of this amendment, all Class B ordinary
shareholders elected to convert their shares into Class A ordinary shares thus reducing the number of Class B ordinary shares issued and
outstanding to zero. As of December 31, 2023 and 2022, there were -0- and 5,031,250 Class B ordinary shares issued and outstanding, respectively.
Holders of the Class A ordinary shares and holders
of the Class B ordinary shares will vote together as a single class on all matters submitted to a vote of the Company’s shareholders,
except as required by law or stock exchange rule.
Note 8 – Fair Value Measurements
The following table presents information about
the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 by level
within the fair value hierarchy:
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Assets: |
|
|
|
|
|
|
|
|
|
Investments held in Trust Account |
|
$ |
98,870,109 |
|
|
$ |
— |
|
|
$ |
— |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Public Warrants |
|
$ |
— |
|
|
$ |
805,000 |
|
|
$ |
— |
|
Private Placement Warrants |
|
|
— |
|
|
$ |
812,500 |
|
|
|
— |
|
The following table presents information about
the Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 by level
within the fair value hierarchy:
|
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
Assets: |
|
|
|
|
|
|
|
|
|
Investments held in Trust Account |
|
$ |
209,651,193 |
|
|
$ |
— |
|
|
$ |
— |
|
Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Public Warrants |
|
$ |
754,687 |
|
|
$ |
— |
|
|
$ |
— |
|
Private Placement Warrants |
|
|
— |
|
|
|
761,719 |
|
|
|
— |
|
The fair value of the Public Warrants issued in
connection with the Public Offering and Private Placement Warrants were initially measured at fair value using a Monte Carlo simulation
model. The fair value of Public Warrants issued in connection with the Initial Public Offering have been measured based on the listed
market price of such warrants, a Level 1 measurement, since December 17, 2021, which was the date the Public Warrants detached from the
Units. The close price of the Public Warrants on the New York Stock Exchange was used as the primary input to the fair value of the Public
Warrants as of each relevant date subsequent to December 17, 2021. The measurement of the Public Warrants after the detachment of the
Public Warrants from the Units is classified as Level 1 due to the use of an observable market quote in an active market. The subsequent
measurements of the Private Placement Warrants after the detachment of the Public Warrants from the Units are classified as Level 2 due
to the use of an observable market quote for a similar asset in an active market.
The last trading day in the Company’s prior quarters in fiscal
year 2023 does not have significant trading volume and as a result, the public warrants were reclassified from Level 1 to Level 2. The
fair value of the Private Placement Warrants has subsequently been measured by reference to the trading price of the Public Warrants,
which is considered to be a Level 2 fair value measurement.
Note 9 – Subsequent Events
The Company evaluated subsequent events and transactions
that occurred after the balance sheet date up to the date the consolidated financial statements were issued. The Company did not identify
any other subsequent events, except as stated below, that would have required adjustment or disclosure in the consolidated financial statements.
On April 1, 2024, the Company amended and restated
the Working Capital Loan to extend the maturity date thereunder to the earlier of (i) thirty months after the closing of the Public Offering
and (ii) the consummation of a Business Combination. The Company also increased the principal amount from $1,500,000 to $1,840,616.
On April 22, 2024, in connection with the Company
extension arrangement, the Sponsor advanced $960,000 to the Company, which amount reflected the payment in full of the Company’s
remaining commitment to make an aggregate of $1.92 million of cash contributions to the Trust Account in connection with the Extension.
In addition, on April 24, 2024, the Company entered into an amendment
to the Trust Agreement, to permit the Trustee to hold the assets in the Trust Account in an interest-bearing demand deposit account or
cash until the earlier of the consummation of an initial business combination or the Company’s liquidation. The Company then instructed
the Trustee to liquidate the Trust Account and move the proceeds into an interest-bearing demand deposit account.
On April 26, 2024, the Company had an
extraordinary general meeting of its shareholders (the “Second Extension Meeting”) to vote on another amendment to its amended and
restated articles and memorandum of association to extend the deadline by which it has to complete an initial business combination
from April 29, 2024 to April 29, 2025 (the “Second Extension”). In connection with the vote to approve the Extension,
the holders of 2,683,126 public shares exercised their right to redeem their shares for cash at a redemption price of approximately
$11.35 per share, for an aggregate redemption amount of approximately $30.4 million, resulting in 6,290,711 public shares
outstanding. Following the approval, the Company will deposit $90,000 for each calendar month beginning on April 30, 2024 until
April 29, 2025.
On April 26, 2024, in connection with the Second Extension Meeting, the Company issued a promissory note to the Sponsor in the amount
of $1.08 million in connection with the Second Extension Contributions.
On April 26, 2024, the Company amended and restated
the Working Capital Loan to extend the maturity date thereunder to the earlier of (i) forty-two months after the closing of the Public
Offering and (ii) the consummation of a Business Combination.
Exhibit
Number |
|
Description |
2.1† |
|
Business Combination Agreement, dated as of November 13, 2023, by and among Pyrophyte Acquisition Corp., Sio Silica Corporation, Snowbank NewCo Alberta ULC and Sio Silica Incorporated. (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023). |
3.1 |
|
Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 10-Q, filed with the SEC on August 21, 2023). |
3.2* |
|
Amendment No. 1 to the Amended and Restated Memorandum and
Articles of Association. |
3.3 |
|
Amendment
No. 2 to the Amended and Restated Memorandum and Articles of Association (incorporated by reference to Exhibit 3.1 to the
Company’s Current Report on Form 8-K, filed with the SEC on April 29, 2024). |
4.1 |
|
Warrant Agreement, dated October 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K, filed with the SEC on October 29, 2021). |
4.2 |
|
Specimen Ordinary Share Certificate (incorporated by reference to the corresponding exhibit to the Company’s Registration Statement on Form S-l (File No. 333-260041), filed with the SEC on October 14, 2021). |
4.3 |
|
Specimen Warrant Certificate (incorporated by reference to the corresponding exhibit to the Company’s Registration Statement on Form S-l (File No. 333-260041), filed with the SEC on October 14, 2021). |
4.4 |
|
Description of Securities (incorporated by reference to Exhibit 4.5 to the Company’s Form 10-K for the year ended December 31, 2021, filed with the SEC on March 31, 2022). |
10.1 |
|
Letter Agreement, dated October 26, 2021 by and among the Company, its executive officers and directors and Pyrophyte Acquisition LLC (incorporated by reference to Exhibit 10.1 to the company’s Form 8-K, filed with the SEC on October 29, 2021). |
10.2 |
|
Investment Management Trust Agreement, dated October 26, 2021, by and between the Company and Continental Stock Transfer & Trust Company, as trustee (incorporated by reference to Exhibit 10.2 to the company’s Form 8-K, filed with the SEC on October 29, 2021). |
10.3 |
|
Registration Rights Agreement, dated October 26, 2021, by and among the Company, its executive officers and directors and Pyrophyte Acquisition LLC (incorporated by reference to Exhibit 10.3 to the company’s Form 8-K, filed with the SEC on October 29, 2021). |
10.4 |
|
Private Placement Warrants Purchase Agreement, dated October 26, 2021, by and between the Company and Pyrophyte Acquisition LLC (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on October 29, 2021). |
10.5 |
|
Administrative Services Agreement, dated October 26, 2021, by and between the Company and Pyrophyte Acquisition LLC (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on October 29, 2021). |
10.6* |
|
Amendment to Administrative Services Agreement, dated July 1, 2022, by and between the Company and Pyrophyte Acquisition LLC. |
10.7 |
|
Securities Subscription Agreement between Pyrophyte Acquisition LLC and the Registrant (incorporated by reference to Exhibit 10.7 to the Company’s Registration Statement on Form S-1 (File No. 333-260041), filed with the SEC on October 5, 2021). |
10.8 |
|
Form of Indemnity Agreement (incorporated by reference to Exhibit 10.5 to the Company’s Registration Statement on Form S-1 (File No. 333-260041), filed with the SEC on October 14, 2021). |
10.9 |
|
Form of Subscription Agreement with Non-Insider PIPE Investors (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023). |
10.10 |
|
Form of Subscription Agreement with Insider PIPE Investors (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023). |
10.11 |
|
Form of Non-Redemption Agreement (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023). |
10.12 |
|
Form of Lock-Up Agreement. (incorporated by reference to Exhibit 10.4 to the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023). |
10.13 |
|
Sponsor Support Agreement, dated as of November 13, 2023, by and among Pyrophyte Acquisition LLC, Pyrophyte Acquisition Corp., Sio Silica Corporation, Sio Silica Incorporated and the directors and officers of Pyrophyte Acquisition Corp (incorporated by reference to Exhibit 10.5 to the Company’s Current Report on Form 8-K, filed with the SEC on November 13, 2023). |
10.14 |
|
Promissory Note for Working Capital Loan, dated October 14, 2021, issued to Pyrophyte Acquisition LLC, (incorporated by reference to Exhibit 10.9 to the Company’s Registration Statement on Form S-1 (File No. 333-260041), filed with the SEC on October 14, 2021). |
10.15* |
|
Amended and Restated Convertible Promissory Note, dated April 1, 2024, between Pyrophyte Acquisition Corp. and Pyrophyte Acquisition LLC. |
10.16 |
|
Second Amended and Restated Convertible Promissory Note, dated April 26, 2024, issued to Pyrophyte Acquisition LLC (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K, filed with the SEC on April 29, 2024). |
10.17 |
|
Promissory Note, dated April 26, 2024, issued to Pyrophyte Acquisition LLC (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, filed with the SEC on April 29, 2024). |
10.18* |
|
Amendment No. 1 to Investment Management Trust Agreement, dated as of April 24, 2024, by and between Pyrophyte Acquisition Corp. and Continental Stock Transfer & Trust Company. |
24.1* |
|
Power of Attorney (included in the signature page of this Annual Report). |
31.1* |
|
Certification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
31.2* |
|
Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a) and 15d - 14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
32.1* |
|
Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
32.2* |
|
Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
97.1* |
|
Policy relating to recovery of erroneously awarded compensation, as required by applicable listing standards adopted pursuant to 17 CFR 240.10D-1. |
101.INS* |
|
Inline XBRL Instance Document |
101.SCH* |
|
Inline XBRL Taxonomy Extension Schema Document |
101.CAL* |
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF* |
|
Inline XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB* |
|
Inline XBRL Taxonomy Extension Label Linkbase Document |
101.PRE* |
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
104 |
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 10.1) |
| † | Certain
of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5).
The Company agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon
its request. |
SIGNATURES
Pursuant to the requirements of Section 13 or
15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Date: May 24, 2024 |
PYROPHYTE ACQUISITION CORP. |
|
|
|
By: |
/s/ Sten Gustafson |
|
Name: |
Sten Gustafson |
|
Title: |
Chief Financial Officer |
POWER OF ATTORNEY
The undersigned of Pyrophyte Acquisition Corp.
hereby constitute and appoint each of Bernard J. Duroc-Danner and Sten Gustafson, with the power to act without the others and with full
power of substitution and resubstitution, our hue and lawful attorney-in-fact and agent with full power to execute in our name and behalf
in the capacities indicated below any and all amendments to this report and to file the same, with all exhibits and other documents relating
thereto and hereby ratify and confirm all that such attorney-in-fact, or such attorney-in-fact’s substitute, may lawfully do or
cause to be done by virtue hereof.
Pursuant to the requirements of the Securities
and Exchange Act of 1934, this report has been signed below by the following persons in the capacities and on the dates indicated below.
Name |
|
Title |
|
Date |
|
|
|
|
|
/s/ Bernard J. Duroc-Danner |
|
Chief Executive Officer and Chairman |
|
May 24, 2024 |
Bernard J. Duroc-Danner |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Sten Gustafson |
|
Chief Financial Officer and Director |
|
May 24, 2024 |
Sten Gustafson |
|
(Principal Financial Officer) |
|
|
|
|
|
|
|
/s/ Brian Guido Hassin |
|
Director |
|
May 24, 2024 |
Brian Guido Hassin |
|
|
|
|
|
|
|
|
|
/s/ Per Hornung Pedersen |
|
Director |
|
May 24, 2024 |
Per Hornung Pedersen |
|
|
|
|
|
|
|
|
|
/s/ Adam Pierce |
|
Director |
|
May 24, 2024 |
Adam Pierce |
|
|
|
|
00-0000000
12701075
20125000
0.14
0.42
5031250
5031250
0.14
0.42
0.14
0.42
5031250
5031250
0.14
0.42
false
FY
0001848756
0001848756
2023-01-01
2023-12-31
0001848756
phyt:UnitsEachConsistingOfOneClassAOrdinaryShare00001ParValueAndOnehalfOfOneRedeemableWarrantMember
2023-01-01
2023-12-31
0001848756
phyt:ClassAOrdinarySharesParValue00001PerShareMember
2023-01-01
2023-12-31
0001848756
phyt:RedeemableWarrantsEachWarrantExercisableForOneClassAOrdinaryShareEachAtAnExercisePriceOf1150PerShareMember
2023-01-01
2023-12-31
0001848756
2023-06-30
0001848756
2024-05-23
0001848756
2023-12-31
0001848756
2022-12-31
0001848756
phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember
2023-12-31
0001848756
phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember
2022-12-31
0001848756
us-gaap:CommonClassAMember
2023-12-31
0001848756
us-gaap:CommonClassAMember
2022-12-31
0001848756
us-gaap:CommonClassBMember
2023-12-31
0001848756
us-gaap:CommonClassBMember
2022-12-31
0001848756
2022-01-01
2022-12-31
0001848756
phyt:CommonClassaSubjectToRedemptionMember
2023-01-01
2023-12-31
0001848756
phyt:CommonClassaSubjectToRedemptionMember
2022-01-01
2022-12-31
0001848756
phyt:NonRedeemableClassBOrdinarySharesMember
2023-01-01
2023-12-31
0001848756
phyt:NonRedeemableClassBOrdinarySharesMember
2022-01-01
2022-12-31
0001848756
us-gaap:CommonClassAMember
phyt:OrdinarySharesSubjectToPossibleRedemptionMember
2022-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-12-31
0001848756
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-12-31
0001848756
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001848756
us-gaap:RetainedEarningsMember
2022-12-31
0001848756
us-gaap:CommonClassAMember
phyt:OrdinarySharesSubjectToPossibleRedemptionMember
2023-01-01
2023-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-01-01
2023-12-31
0001848756
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-01-01
2023-12-31
0001848756
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-12-31
0001848756
us-gaap:RetainedEarningsMember
2023-01-01
2023-12-31
0001848756
us-gaap:CommonClassAMember
phyt:OrdinarySharesSubjectToPossibleRedemptionMember
2023-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2023-12-31
0001848756
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2023-12-31
0001848756
us-gaap:AdditionalPaidInCapitalMember
2023-12-31
0001848756
us-gaap:RetainedEarningsMember
2023-12-31
0001848756
us-gaap:CommonClassAMember
phyt:OrdinarySharesSubjectToPossibleRedemptionMember
2021-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2021-12-31
0001848756
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2021-12-31
0001848756
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001848756
us-gaap:RetainedEarningsMember
2021-12-31
0001848756
2021-12-31
0001848756
us-gaap:CommonClassAMember
phyt:OrdinarySharesSubjectToPossibleRedemptionMember
2022-01-01
2022-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0001848756
us-gaap:CommonClassBMember
us-gaap:CommonStockMember
2022-01-01
2022-12-31
0001848756
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-12-31
0001848756
us-gaap:RetainedEarningsMember
2022-01-01
2022-12-31
0001848756
us-gaap:IPOMember
2021-10-29
0001848756
us-gaap:OverAllotmentOptionMember
2021-10-01
2021-10-29
0001848756
us-gaap:OverAllotmentOptionMember
2021-10-29
0001848756
2021-10-01
2021-10-29
0001848756
2021-10-29
0001848756
us-gaap:PrivatePlacementMember
2023-12-31
0001848756
us-gaap:PrivatePlacementMember
2023-01-01
2023-12-31
0001848756
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2023-12-31
0001848756
us-gaap:IPOMember
2023-12-31
0001848756
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2023-01-01
2023-12-31
0001848756
2023-04-30
2023-04-30
0001848756
phyt:ExtensionMeetingMember
2023-04-30
0001848756
phyt:ExtensionMeetingMember
phyt:SponsorMember
2023-04-30
0001848756
us-gaap:WarrantMember
2023-12-31
0001848756
us-gaap:CommonClassAMember
2023-01-01
2023-12-31
0001848756
phyt:ExtensionMeetingMember
us-gaap:CommonClassAMember
phyt:SponsorMember
2023-12-31
0001848756
phyt:ExtensionMeetingMember
2023-12-31
0001848756
us-gaap:CommonClassBMember
2023-04-28
0001848756
srt:BoardOfDirectorsChairmanMember
2023-12-31
0001848756
us-gaap:WarrantMember
us-gaap:CommonClassAMember
2023-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:PrivatePlacementMember
2023-12-31
0001848756
phyt:RedeemableClassAOrdinarySharesMember
2023-01-01
2023-12-31
0001848756
phyt:RedeemableClassAOrdinarySharesMember
2022-01-01
2022-12-31
0001848756
phyt:ClassASubjectToPossibleRedemptionMember
2023-01-01
2023-12-31
0001848756
phyt:ClassASubjectToPossibleRedemptionMember
2022-01-01
2022-12-31
0001848756
phyt:NonRedeemableClassAOrdinarySharesMember
2023-01-01
2023-12-31
0001848756
phyt:NonRedeemableClassAOrdinarySharesMember
2022-01-01
2022-12-31
0001848756
phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember
2021-12-31
0001848756
phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember
2022-01-01
2022-12-31
0001848756
phyt:ClassAOrdinarySharesSubjectToPossibleRedemptionMember
2023-01-01
2023-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:IPOMember
2023-01-01
2023-12-31
0001848756
us-gaap:CommonClassAMember
us-gaap:IPOMember
2023-12-31
0001848756
phyt:PublicWarrantsMember
us-gaap:CommonClassAMember
2023-12-31
0001848756
phyt:ClassBFounderSharesMember
2021-02-01
2021-02-24
0001848756
phyt:ClassBFounderSharesMember
2021-02-24
0001848756
2021-02-01
2021-02-24
0001848756
phyt:ClassBFounderSharesMember
2021-09-01
2021-09-29
0001848756
phyt:ClassBFounderSharesMember
2021-09-29
0001848756
us-gaap:CommonClassAMember
us-gaap:PrivatePlacementMember
2023-01-01
2023-12-31
0001848756
phyt:PromissoryNoteExtensionLoanMember
2023-01-01
2023-12-31
0001848756
phyt:PromissoryNoteExtensionLoanMember
2023-04-30
2023-04-30
0001848756
phyt:SponsorMember
2023-05-04
0001848756
phyt:PromissoryNoteExtensionLoanMember
2023-05-04
2023-05-04
0001848756
phyt:SponsorMember
2023-01-01
2023-12-31
0001848756
us-gaap:IPOMember
2023-01-01
2023-12-31
0001848756
phyt:SponsorMember
2022-07-01
2022-07-01
0001848756
2022-07-01
2022-07-01
0001848756
phyt:AdministrativeSupportAgreementMember
2023-01-01
2023-12-31
0001848756
phyt:AdministrativeSupportAgreementMember
2022-01-01
2022-12-31
0001848756
phyt:ExtensionContributionDueFromSponsorMember
2023-12-31
0001848756
us-gaap:CommonStockMember
2023-12-31
0001848756
2023-10-01
2023-10-26
0001848756
2023-10-26
0001848756
2021-11-05
0001848756
2021-11-01
2021-11-05
0001848756
2022-03-28
0001848756
2022-03-01
2022-03-28
0001848756
2023-06-05
2023-06-05
0001848756
phyt:PublicWarrantsMember
2023-12-31
0001848756
us-gaap:CommonClassAMember
phyt:RedemptionOfWarrantsMember
2023-01-01
2023-12-31
0001848756
us-gaap:WarrantMember
2023-01-01
2023-12-31
0001848756
srt:MinimumMember
2023-01-01
2023-12-31
0001848756
srt:MaximumMember
2023-01-01
2023-12-31
0001848756
phyt:OwnershipMember
us-gaap:CommonClassAMember
2023-01-01
2023-12-31
0001848756
us-gaap:WarrantMember
2023-12-31
0001848756
phyt:RedemptionOfWarrantsMember
2023-12-31
0001848756
phyt:RedemptionOfWarrantsMember
2023-01-01
2023-12-31
0001848756
us-gaap:CommonClassBMember
2023-09-30
0001848756
us-gaap:CommonClassBMember
2021-09-01
2021-09-29
0001848756
us-gaap:CommonClassBMember
2021-09-29
0001848756
us-gaap:ConvertibleCommonStockMember
2022-12-31
0001848756
us-gaap:FairValueInputsLevel1Member
2023-12-31
0001848756
us-gaap:FairValueInputsLevel2Member
2023-12-31
0001848756
us-gaap:FairValueInputsLevel3Member
2023-12-31
0001848756
us-gaap:FairValueInputsLevel1Member
us-gaap:WarrantMember
2023-12-31
0001848756
us-gaap:FairValueInputsLevel2Member
us-gaap:WarrantMember
2023-12-31
0001848756
us-gaap:FairValueInputsLevel3Member
us-gaap:WarrantMember
2023-12-31
0001848756
us-gaap:FairValueInputsLevel1Member
us-gaap:PrivatePlacementMember
2023-12-31
0001848756
us-gaap:FairValueInputsLevel2Member
us-gaap:PrivatePlacementMember
2023-12-31
0001848756
us-gaap:FairValueInputsLevel3Member
us-gaap:PrivatePlacementMember
2023-12-31
0001848756
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001848756
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001848756
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001848756
us-gaap:FairValueInputsLevel1Member
us-gaap:WarrantMember
2022-12-31
0001848756
us-gaap:FairValueInputsLevel2Member
us-gaap:WarrantMember
2022-12-31
0001848756
us-gaap:FairValueInputsLevel3Member
us-gaap:WarrantMember
2022-12-31
0001848756
us-gaap:FairValueInputsLevel1Member
us-gaap:PrivatePlacementMember
2022-12-31
0001848756
us-gaap:FairValueInputsLevel2Member
us-gaap:PrivatePlacementMember
2022-12-31
0001848756
us-gaap:FairValueInputsLevel3Member
us-gaap:PrivatePlacementMember
2022-12-31
0001848756
srt:MinimumMember
srt:ScenarioForecastMember
2024-04-01
2024-04-01
0001848756
srt:MaximumMember
srt:ScenarioForecastMember
2024-04-01
2024-04-01
0001848756
srt:ScenarioForecastMember
2024-04-22
0001848756
srt:ScenarioForecastMember
phyt:PublicSharesMember
2024-04-26
2024-04-26
0001848756
srt:ScenarioForecastMember
phyt:PublicSharesMember
2024-04-26
0001848756
srt:ScenarioForecastMember
2024-04-26
0001848756
phyt:SponsorMember
2024-04-26
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
Pyrophyte Acquisition Corp. (ROC # 371601) (the
“Company”)
“RESOLVED as a special resolution THAT, effective immediately,
the Amended and Restated Memorandum and Articles of Association of the company be amended by:
“Class B Shares shall automatically
convert into Class A Shares on a one-for-one basis (the “Initial Conversion Ratio”) automatically on the day of the closing
of a Business Combination or on such earlier date at the election of the
holder of such Class B Shares.”
subject in each case to its obligations
under Cayman Islands law to provide for claims of creditors and other requirements of Applicable Law.”
“Any Member holding Public
Shares who is not a Founder, officer of the Company or Director may, in connection with any vote on a Business Combination, elect to have
their Public Shares redeemed for cash (the “IPO Redemption”),
provided that no such Member acting together with any affiliate of his or any other person with whom he is acting in concert or as a partnership,
limited partnership, syndicate, or other group for the purposes of acquiring, holding, or disposing of Shares may exercise this redemption
right with respect to more than 15 per cent of the Public Shares in the aggregate without the prior consent of the Company. If so demanded,
the Company shall pay any such redeeming Member, regardless of whether he is voting for or against such proposed Business Combination,
a per-Share redemption price payable in cash, equal to the aggregate amount then on deposit in the Trust Fund calculated as of two business
days prior to the consummation of the Business Combination, including interest (which interest shall be net of taxes payable), divided
by the number of then issued Public Shares (such redemption price being referred to herein as the “Redemption
Price”), but only in the event that the applicable proposed Business Combination is approved and consummated. The
Company shall not redeem Public Shares that would cause the Company’s net tangible assets to be less than US$5,000,001 following
such redemptions (the “Redemption Limitation”).”.
each holder of Public Shares who is not the
Sponsor, a Founder, Officer or Director shall be provided with the opportunity to redeem their Public Shares upon the approval or
effectiveness of any such amendment at a per-Share price, payable in cash, equal to the aggregate amount then on deposit in the
Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay
its taxes, divided by the number of then outstanding Public Shares. The Company’s ability to provide such redemption
in this Article is subject to the Redemption Limitation.”
As of July 1, 2022, the prior arrangement of having
Pyrophyte Acquisition Corp. (“Pyrophyte”) provide Pyrophyte Acquisition LLC (“Sponsor”) a monthly payment of $15,000
is hereby amended to reduce this monthly amount paid by Pyrophyte to Sponsor to $5,000 per month.
THIS AMENDED & RESTATED CONVERTIBLE PROMISSORY NOTE (THIS “AMENDED
& RESTATED NOTE”) AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED (THE “SECURITIES ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES ARE SUBJECT TO RESTRICTIONS
ON TRANSFERABILITY AND RESALE. THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED EXCEPT AS
PERMITTED UNDER THE SECURITIES ACT AND THE APPLICABLE STATE SECURITIES LAWS, PURSUANT TO REGISTRATION OR EXEMPTION THEREFROM. INVESTORS
SHOULD BE AWARE THAT THEY MAY BE REQUIRED TO BEAR THE FINANCIAL RISKS OF THIS INVESTMENT FOR AN INDEFINITE PERIOD OF TIME. THE COMPANY
AND THE SECURITIES INTO WHICH IT MAY BE CONVERTED MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE
TO THE COMPANY TO THE EFFECT THAT ANY SALE OR OTHER DISPOSITION IS IN COMPLIANCE WITH THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES
LAWS.
WHEREAS, on October 14, 2021,
the undersigned Pyrophyte Acquisition Corp., a Cayman Islands exempted company (the “Maker”), issued that certain
Promissory Note (the “Original Promissory Note”) to Pyrophyte Acquisition LLC, a Delaware limited liability
company, or its registered assigns or successors in interest (the “Payee”); and
WHEREAS, the Maker and Payee
desire to amend and restate in its entirety the Original Promissory Note, retroactive as of April 29, 2023, on the terms and conditions
provided in this note (the “Amended and Restated Note”).
NOW, THEREFORE, in consideration
of the mutual covenants contained herein and other good and valuable consideration, the existence and sufficiency of which is expressly
recognized by each of the parties hereto, the parties agree as follows:
FOR VALUE RECEIVED and subject
to the terms and conditions set forth herein, Maker, promises to pay to the order of Payee or its registered assigns or successors in
interest, or order, the principal balance as set forth on Schedule A hereto in lawful money of the United States of America; which
schedule shall be updated from time to time by the parties hereto to reflect all advances and readvances outstanding under this Amended
& Restated Note; provided that at no time shall the aggregate of all advances and readvances outstanding under this Amended
& Restated Note exceed one million eight hundred forty thousand six hundred sixteen dollars ($1,840,616). Any advance hereunder shall
be made by the Payee upon receipt of a written request of the Maker commencing twelve (12) months after the closing of Maker’s initial
public offering (the “IPO”), related to ongoing expenses reasonably related to the business of the Maker and
the consummation of the Business Combination (as defined below), and shall be set forth on Schedule A. Any advance hereunder shall
only be made by the Payee as, and to the extent, expenses are incurred or are reasonably expected to be incurred and the amounts of such
advance shall be used to pay or repay such expenses. All payments on this Amended & Restated Note shall be made by check or wire transfer
of immediately available funds or as otherwise determined by the Maker to such account as the Payee may from time to time designate by
written notice in accordance with the provisions of this Amended & Restated Note.
Subject to the terms and conditions set forth in the Amended &
Restated Note to which this schedule is attached to, the principal balance due under the Amended & Restated Note shall be set forth
in the table below and shall be updated from time to time to reflect all advances and readvances outstanding under the Amended & Restated
Note.
THIS AMENDMENT NO. 1 TO THE
INVESTMENT MANAGEMENT TRUST AGREEMENT (this “Amendment”) is made as of April 24, 2024, by and between Pyrophyte
Acquisition Corp., a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust
Company, a New York corporation (the “Trustee”). Capitalized terms contained in this Amendment, but not specifically
defined in this Amendment, shall have the meanings ascribed to such terms in the Original Agreement (as defined below).
1. Amendments
to Trust Agreement
(a) Sections 1(c) of the Original Agreement are
hereby amended and restated to read in their entirety as follows:
1. Agreements
and Covenants of Trustee. The Trustee hereby agrees and covenants to:
(c) In a timely manner,
upon the written instruction of the Company, i) hold funds uninvested, ii) hold funds in an interest-bearing bank demand deposit
account, or iii) invest and reinvest the Property in solely United States government securities within the meaning of Section
2(a)(16) of the Investment Company Act of 1940, as amended, having a maturity of 185 days or less, or in money market funds meeting
the conditions of paragraphs (d)(1), (d)(2), (d)(3) and (d)(4) of Rule 2a-7 promulgated under the Investment Company Act of 1940, as
amended (or any successor rule), which invest only in direct U.S. government treasury obligations, as determined by the Company; the
Trustee may not invest in any other securities or assets, it being understood that the Trust Account will earn no interest while
account funds are uninvested awaiting the Company’s instructions hereunder and while invested or uninvested, the Trustee may
earn bank credits or other consideration.
2. Miscellaneous
Provisions.
IN WITNESS WHEREOF,
the parties hereto have caused this Amendment to be duly executed as of the date first above written.
I, Bernard J. Duroc-Danner, certify that:
I, Sten L. Gustafson certify that:
In connection with the Annual Report of Pyrophyte
Acquisition Corp.. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Bernard J. Duroc-Danner, Chief Executive Officer and Director of the Company,
certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best
of my knowledge:
In connection with the Annual Report of Pyrophyte
Acquisition Corp.. (the “Company”) on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange
Commission on the date hereof (the “Report”), I, Sten L. Gustafson, Chief Financial Officer and Director of the Company, certify,
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
A. OVERVIEW
In accordance with the applicable
rules of the New York Stock Exchange Listed Company Manual (the “NYSE Rules”), Section 10D and Rule 10D-1 of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (“Rule 10D-1”),
the Board of Directors (the “Board”) of Pyrophyte Acquisition Corp. (the “Company”)
has adopted this Policy (the “Policy”) to provide for the recovery of erroneously awarded Incentive-based Compensation
from Executive Officers. All capitalized terms used and not otherwise defined herein shall have the meanings set forth in Section H, below.
B. RECOVERY OF ERRONEOUSLY
AWARDED COMPENSATION
C. DISCLOSURE
REQUIREMENTS
The Company shall file all
disclosures with respect to this Policy required by applicable U.S. Securities and Exchange Commission (“SEC”)
filings and rules.
D. PROHIBITION OF INDEMNIFICATION
The Company shall not be permitted
to insure or indemnify any Executive Officer against (i) the loss of any Erroneously Awarded Compensation that is repaid, returned or
recovered pursuant to the terms of this Policy, or (ii) any claims relating to the Company’s enforcement of its rights under this
Policy. Further, the Company shall not enter into any agreement that exempts any Incentive-based Compensation that is granted, paid or
awarded to an Executive Officer from the application of this Policy or that waives the Company’s right to recovery of any Erroneously
Awarded Compensation, and this Policy shall supersede any such agreement (whether entered into before, on or after the Effective Date
of this Policy).
E. ADMINISTRATION AND INTERPRETATION
This Policy shall be administered
by the Committee, and any determinations made by the Committee shall be final and binding on all affected individuals.
The Committee is authorized
to interpret and construe this Policy and to make all determinations necessary, appropriate, or advisable for the administration of this
Policy and for the Company’s compliance with NYSE Rules, Section 10D, Rule 10D-1 and any other applicable law, regulation, rule
or interpretation of the SEC or NYSE promulgated or issued in connection therewith.
F. AMENDMENT; TERMINATION
The Committee may amend this
Policy from time to time in its discretion and shall amend this Policy as it deems necessary. Notwithstanding anything in this Section
F to the contrary, no amendment or termination of this Policy shall be effective if such amendment or termination would (after taking
into account any actions taken by the Company contemporaneously with such amendment or termination) cause the Company to violate any federal
securities laws, SEC rule or NYSE rule.
G. OTHER RECOVERY RIGHTS
This Policy shall be binding
and enforceable against all Executive Officers and, to the extent required by applicable law or guidance from the SEC or NYSE, their beneficiaries,
heirs, executors, administrators or other legal representatives. The Committee intends that this Policy will be applied to the fullest
extent required by applicable law. Any employment agreement, equity award agreement, compensatory plan or any other agreement or arrangement
with an Executive Officer shall be deemed to include, as a condition to the grant of any benefit thereunder, an agreement by the Executive
Officer to abide by the terms of this Policy. Any right of recovery under this Policy is in addition to, and not in lieu of, any other
remedies or rights of recovery that may be available to the Company under applicable law, regulation or rule or pursuant to the terms
of any policy of the Company or any provision in any employment agreement, equity award agreement, compensatory plan, agreement or other
arrangement.
H. DEFINITIONS
For purposes of this Policy, the following capitalized
terms shall have the meanings set forth below.
Effective as of December 1, 2023.